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Summary:
This thesis presents data obtained from genetic analysis of TGFB1 
knockout neonates (Shull et al., 1992, Kulkarni et al., 1993) bred onto different 
genetic backgrounds. TGFB1(-/-) embryos were initially reported to develop to 
term normally and die by 3 weeks due to multisystemic inflammation (Shull et 
al., 1992; Kulkarni et al., 1993). Therefore, it was suggested that TGFB1 was 
not vital during embryogenesis. However, an independent group (Dickson et 
al., 1995) demonstrated the implication of TGFB1 in an early stage of 
embryogenesis. It was shown that 50% of the TGFB1(-/-) embryos died in 
uterus due to defects in yolk sac vasculogenesis and haematopoiesis, whereas 
the rest did not succumb to the yolk sac phenotype but developed to term 
normally and died by 3 weeks post-partum as described previously (Kulkarni et 
al 1993). It has also been shown that maternal TGFB1 can cross the placenta 
(Letterio et al., 1994). TGFB1 was detected in TGFB1(-/-) embryos born to 
TGFB1(+/-) females, whereas in those born to null females, TGFB1 was not 
detected. Thus, it has been suggested that Tgfbl gene knockout was not 
equivalent to a protein knockout and the maternally acquired protein could 
rescue TGFB1(-/-) foetuses and embryos.
The work accomplished in this project set out to determine the reason for 
the existence of at least two different phenotypes; yolk sac insufficiency and 
survival to birth, among TGFB1(-/-) conceptuses. During this study, the 
involvement of several possible genetic and/or non-genetic modifying factors in 
the different expressivity of the TGFB1(-/-) phenotype was examined. The 
phenotype of TGFB1(-/-) was studied by breeding the Tgfbl null allele onto two 
inbred strains; NIH/Ola and C57BI/6J/Ola. Also TGFB1(-/+) heterozygous 
crosses between various combinations of NIH/Ola and C57BI/6J/Ola enabled 
study of the possible implications of maternal factors in the different 
expressivity of the TGFB1(-/-) phenotype. It was estimated that one locus with 
a codominant pattern of inheritance was responsible for the different 
expressivity. Due to the codominant behaviour of the modifying gene(s), the 
F2(NIH/Ola x C57BI/6J/Ola) intercross animals were considered to be the most
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informative animals for genetic linkage analysis. 50 polymorphic DNA markers 
were utilised to initiate a genome-wide search by screening 50 TGFB1(-/-) 
neonates from an F1 intercross. More than 90% of the genome was screened 
for modifying gene(s) during this study. Four regions of the genome showed 
suggestive linkage (P<0.05) in the first screen. To confirm the linkages, 30 
extra null animals were screened with the interested markers. A small region of 
mouse chromosome 5 harbouring a genetic modifier met the criterion of 
definitive linkage (P<10‘5).
During this project, the feasibility of mapping genetic factors involved in 
determining early embryonic lethality without need to access the embryos was 
demonstrated.
Fibroblast growth factor receptor type 3 (Fgfr3) and Fibroblast growth 
factor inducible gene 13 (Fin13), which mapped in the vicinity of the modifying 
gene, were considered as candidate genes. The expression of these genes 
were assessed in 9.5 d.pc. embryos and yolk sacs bred onto either NIH/Ola or 
C57BI/6J/Ola strains by application of RT-PCR. Also expression of 
Transforming growth factor beta I {Tgfbl) gene was examined in 9.5 d.pc both 
yolk sac and embryo bred onto either of the strains. By application of 
heteroduplex analysis (HA) and direct DNA sequencing, the possibility of 
genetic polymorphism within Fin13 between the two mouse strains was 
investigated over the coding region.
The latter part of the thesis presents data about the genetical mapping 
of Transforming Growth Factor Beta type II receptor {Tgfbr2) and Plasminogen 
activator inhibitor type I {PlanHI) on the mouse genome. Following the 
mapping Tgfbr2 on the mouse genome, two uncloned mouse mutants which 
mapped in the vicinity of the Tgfbr2 location were examined, by Southern 
blotting, for the possibility of a large deletion in Tgfbr2 gene in either of these 
mutants.
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Part I:
1: Introduction
1:1.1 Transforming Growth Factor B (TGFB):
TGFB is emerging as the prototype of a superfamily of polypeptides 
involved in control of development of various cells and tissues. The complexity 
of the superfamily is large (Table 1.1), and may even be greater than now 
known due to the existence of additional members of more distantly related 
molecules and by the potential formation of heterodimers between Tgfb gene 
products co-expressed in the same cell. The existence of the TGFB1/TGFB2 
heterodimer has been confirmed in porcine platelets (Cheifetz et al., 1987). 
Family members, found in a wide variety of species from Drosophila to man, are 
related through an approximately 112-amino acid carboxyl terminal domain with 
varying degrees of sequence identity (Floffmann, 1991). Each member has a 
set of seven cysteine residues in common.
The study of the mechanism of action of activated growth and 
differentiation factors has frequently been complicated by the presence of a 
high level of complexity at three levels: the factors themselves (isoforms), the 
receptors, and the cellular responses. Thus, the factors may be found to be 
members of a large family of structurally and functionally homologous 
polypeptides, to bind to multiple types of cell surface receptors and to elicit an 
array of apparently unrelated cellular responses. In TGFB1 complexity is found 
in all three levels.
In the first part of the introduction the biochemistry and biology of TGFB1 will 
be discussed with particular emphasis on other members/genes which might 
potentially modify the activity of TGFB1 in vivo.
1:1.2 Transforming Growth Factor beta I (TGFB1):
Type I TGFB is an important cellular regulatory molecular which is 
secreted from producer cells as small and large latent high molecular weight
l
Individual
genes/ligands
Location in 
Mouse 
Chromosome
(cM)
Refrences
(et al.,)
Mammalian TGF-B1 7 (6.5) Fujji 1986
Mammalian TGF-B2 1 (101) Barton 1988
Mammalian TGF-B3 12(41) Barton 1988
Xenopus TGF-B5
Mammalian Activin-pA
Mammalian Activin-pB
Mammalian Activin-pC
Drosophila Dpp
Mammalian BMP2 2(75) Dickinson 1990
Mammalian BMP4 14(14) Dickinson 1990
Drosophila 60A
Mammalian BMP5 9(42) Green 1961
Mammalian BMP6 (Vgr-1) 13(18) Dickinson 1990
Mammalian BMP7 (Op-1) 2 (=100) Marker 1995
Mammalian BMP8 (Op-2) 4(59) Marker 1995
Xenopus Vg-1
Mammalian GDF-1 UN
Mammalian GDF-3 (Vgr-2) 6(58) Jones 1992
Mammalian Nodal 10(29) Zhou 1993
Xenopus Xnr1
Xenopus Xnr2
Xenopus Xnr3
Mammalian BMP3 (Osteogenin) 5 (55) Dickinson 1990
Mammalian GDF-10
Mammalian GDF-5 (CDMP-1) 2(90) Storm 1994
Mammalian GDF-6 (CDMP-2) 4(90) Storm 1994
Mammalian GDF-7 12 (Proximal) Storm 1994
Mammalian MIS
Mammalian Inhibin-a 1 (41.6) Male 1991
Mammalian GDF-9 UN
Mammalian GDNF
Chicken Dorsalin
Drosophila Screw
Table 1.1: The Transforming Growth Factor Beta (TGF-B) Superfamily 
(Massague and Weis-Garcia., 1996).
Type I TGFB is an important cellular regulatory molecular which is 
secreted from producer cells as small and large latent high molecular weight 
complexes (Miyazono et al., 1993). Although receptors for TGFB are found in 
almost all cell types (Gentry et al., 1987), these receptors do not recognise 
latent TGFB1. An understanding of structure, processing , and activation of 
latent TGFB1 in greater detail should provide clues to its mechanism of action 
and function. Large latent TGFB1 complex purified from human platelets 
(Miyazono et al., 1988; Wakefield et al., 1988; Okada et al., 1989) is composed 
of at least three components, identified (figure 1.1) as TGFB1 (small bioactive 
peptide), the NH2-terminal part of the TGFB1 precursor known as latent- 
associated peptide (LAP), and another gene product, latent TGFB binding 
protein (LTBP). Latent TGFB which is composed of only the mature TGFB and 
BLAP, is denoted small latent TGFB complex , whereas that associated with 
LTBP is denoted large latent TGFB complex.
1:1.2.1 TGFB latency and LTBPs:
LTBP is linked to LAP by a disulphide bond and creates a high 
molecular weight form of LTGFB with a molecular mass of 210,000 kD (Daniel 
et al., 1993). LTBP is not directly needed for the latency of TGFB, but it 
appears to have several important functions. It plays roles in the assembly and 
secretion of LTGFB complex from certain cell types (Miyazono et al., 1991). In 
human fibroblasts and fibrosarcoma cells, LTBP1 binds to extracellular matrix 
after secretion and is released from the matrix by proteolytic digestion (Taipale 
et al., 1994, 1995). In addition, LTBP1 is important for the activation of LTGFB 
in co-culture of endothelial cells and smooth muscle cells (Flaumenhaft et al., 
1993). LTBP has a variable size depending upon the cell type. The difference 
in the sizes may be, in part, due to proteolytic processing of the protein 
(Miyazono et al., 1991). In addition, two different transcript sizes of LTBP1 
mRNA have been observed, which suggests use of different polyadenylation 
sites, different promoters or the presence of alternative splice variants (Kanzaki 
et al., 1990; Tsuji et al., 1990). So far three LTBPs (LTBP1-3) have been 
identified. The overall structure of LTBP2 is very similar to that of LTBP1.
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Figure 1:1 The structure of Precursor and Latent Transforming Growth factor-B 
(LTGFB).
LAP: Latent Associated Protein., LTBP: Latent TGF-B Binding protein.
EGF-like: Epidermal Growth Factor-like.
Similar to LTBP1, LTBP2 has been shown to form complex with the TGFB1 
precursor (Moren et al., 1994). The third member in the LTBP family, LTBP3, 
cloned from the mouse, is expressed widely in cells during murine development 
and can form a complex with the TGFB1 precursor in MC 3T3-E1 osteoblasts 
(Yin et al., 1995).
A single LTBP1 locus appears to exist in the human genome that has 
been mapped to chromosome 2, region p12-q22 (Stenman et al,. 1994). LTBP2 
has been localised to human chromosome band 11 q12 and mouse 
chromosome band 19B (Li et al., 1995).
I: 1.3 Biological activation of LTGFB:
Biological activation of TGFB occurs by dissociation of the mature TGFB 
from the rest of the complex, which can be achieved in vitro by physical or 
chemical treatment such as heating or exposure to low pH (Brown, et al, 1990). 
The activation of LTGFB normally seen in co-cultures of endothelial cells and 
either smooth muscle cells or percytes (Sato et al., 1989; Antonelli-Olridge et 
al., 1989), has been suggested to require cell-cell contact and involves plasmin 
and urokinase.
Analysis of the carbohydrate chains of the TGFB precursor revealed that 
two of the three carbohydrate chains contain mannose 6-phosphate (Man-6-P) 
which is not seen in mature TGFB (Purchio et al., 1988). Enzymatic removal of 
the carbohydrate-containing LAP produces active TGFB from LTGFB complex 
(Miyazono and Heldin, 1989). LTGFB isolated from platelets binds to the 
plasma membrane form of the cation-independent Man-6-P/insulin like growth 
factor receptor type II (IGFII R) (Purchio et al., 1988; Kovacina et al., 1989) 
indicating the possible involvement of IGFII-R in activation of LTGFB.
1 :1.3.1 IGFII R/ Mannose-6-Phosphate:
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IGFII-R is involved in targeting Man-6-P containing proteins to 
lysosomes. It also plays a role in the binding and internalisation of insulin-like 
growth factor II (IGFII) at the cell surface which leads to degradation of the 
growth factor by the lysosomes (Cohick & Clemmons, 1993). IGFII is a potent 
growth stimulant (Lau et al,. 1994; Oka et al., 1985) which binds to both IGFI-R 
and IGFII-R, but with higher affinity to IGFI-R. Binding of IGFII by IGFI-R 
promotes cellular proliferation and suppresses apoptosis (Baserga, 1994; 
1995; Harrington et al., 1994). In contrast, binding of IGFII to IGFII-R results in 
internalisation and subsequent degradation of the ligand, making it unable to 
activate IGFI-R. Thus, IGFII-R, by antagonising the growth stimulatory effect of 
IGFII, effectively operates as a growth suppresser gene. Furthermore, recent 
studies in human breast cancer cells (MCF-7) by showing that cellular 
proliferation and receptor tyrosine kinase-dependent is reduced in the 
presence of IGFII-R, support the role of IGFII-R as a tumour suppresser (Ellis 
et al., 1996).
It has been demonstrated that induction of cell surface IGFII-R caused 
an increased binding of LTGFB to adipocytes. Moreover, activation of LTGFB 
is inhibited by mannose 6-phosphate or anti-IGF2/mannose 6-phosphate 
receptor antibodies. Therefore, IGFII-R indirectly exerts growth suppressive 
effects by activation of TGFB which is a potent growth suppressor protein. 
(Kovacina et al., 1989; Prchio et al., 1987; Kojima et al., 1993; Dennis and 
Rifkin, 1991; Kornfeld 1992).
High levels of IGFII and IGFII-R are seen in the developing rat embryo but both 
decline postnatally suggesting that may have a role in embryonic growth and 
development (Kornfeld., 1992).
The IGF2R gene has been localised to the long arm of human 
chromosome 6, region 6q25-» 6q27 and mouse chromosome 17, region A-C 
(Laureys et al., 1988). Igf2r has been shown to be paternally-imprinted in the 
mouse (Barlowet al., 1991).
1:1.3.2 Plasminogen activator inhibitor type I (PAI1):
PAI1 is a member of the serine protease inhibitor, or serpin, superfamily 
of proteins (Huber& Carrell., 1989). It is a key regulator of plasmin-mediated 
proteolytic cascades, which contributes to both fibrinolysis and matrix 
degradation.
Proteolytic activation of latent TGFB by plasmin has been demonstrated 
(Lyons et al., 1990). Plasmin is produced proteolytically from plasminogen by 
tissue plasminogen activator (tPA) at the cell surface (Kirschenlohr et al., 
1993). PAI1 blocks the activation of latent TGFB by competitively inhibiting 
tPA.
PAI1 has been implicated in a number of vascular diseases. During 
atherosclerosis, it has been proposed that PAI1 indirectly enhances human 
vascular smooth muscle cell (SMC) proliferation by inhibiting plasmin-mediated 
activation of TGFB, a potent inhibitor of SMC proliferation (Grainger et al., 
1993 and 1994). Elevated levels of PAM in transgenic mice contribute to the 
development of venous, but not arterial occlusions (Erickson et al., 1990). 
Conversely, complete deficiency of PAM in human was associated with 
abnormal bleeding (Fay et al., 1992) and mice deficient in PAM, display an 
enhanced hyperfibrinolytic state (Carmeliet et al., 1993).
1:1.4 TGFB binding components:
TGFB and other members of the TGFB family initiate a signalling 
pathway through binding to transmembrane receptors with serine / threonine 
kinase activity (Massague et al., 1994; 1992; Attissano et al., 1994; Lin and 
Lodish, 1993; Miyasono et al., 1993). The TGFB receptors, which were 
identified through affinity-labelling assays, include the so called type I, type II, 
and type III receptors; proteins of -  53 kDa, 70-85 kDa, and 200-400 kDa, 
respectively (Massague, 1987).
Some mutant mink lung epithelial cells (MvlLu), selected through loss of TGFB 
responsiveness, no longer express type I receptor; others, similarly selected,
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lose expression of both the type I and II receptors. However, all of these 
variants continue to express the type III receptor (Boyd et al., 1989, Laiho et 
al., 1990; 1991). This has led to the proposal the type III receptor may not be 
involved directly in signal transduction but mediates ligand access to the 
signalling receptors (Massague et al., 1990).
I: 1.4.1 Transforming Growth factor beta type I (TBRI) and type II receptors 
(TBRII):
The transforming growth factor B (TGFB) type II receptor (TBRII) is a 
constitutively phosphorylated serine-threonine kinase receptor for the ligands 
TGFB1, TGFB2, and TGFB3 (Wrana et al., 1994). This ligand/receptor system 
is important in negative growth regulation and has profound effects on cellular 
phenotype and extracellular matrix deposition (Cui et al., 1996). TBRII is active 
as an oligoheteromeric complex with the TGFB type I receptor (TBRI). Binding 
of TGFB to the constitutively phosphorylated TBRII results in recruitment of 
TBRI (figure 1.2), which itself is unable to bind TGFB. After this type l-type II 
receptor complex has been formed, TBRII phosphorylates TBRI in its GS 
(serine / glycine rich) domain. The GS domain preceding the kinase domain is 
the distinguishable feature of TBRI (Wrana et al., 1994; 1996). The kinase 
activity of TBRI, as well as its phosphorylation by TBRII, are required for all the 
downstream responses induced by TGFB. Although the role of this receptor 
trans-phosphorylation is not currently understood, phosphorylation of the type I 
receptor could activate its own kinase activity or the phosphorylated residues 
could serve as substrate binding sites.
TBRII is essential in mediating the negative growth response of cells to TGFB 
(Laiho et al., 1990), and its level of expression dictates the magnitude of this 
biological response in vivo (Cui et al., 1995). Somatic cell mutations in TBRII 
have been found in human colon carcinomas (Markowitz et al., 1995). TBRII 
deficiency embryos die by 13.5 dpc. due to yolk sac hematopoiesis and 
vasculogenesis deficiency (Oshima et al., 1996). The histological features of 
the Tgfbr2(-/-) yolk sac were almost identical with those in the TGFB1(-/-)
6
1- Ligand binding by 2- Recruitment of the 
the type I I  receptor. type I receptor.
3- Type I receptor transphosphorylation, 
activation of downstream components.
II
Smad 4
I  
I
I  ( I
Smad 2 or 3
i
 ► I
I I
I I
Signal
I
Cell-cycle arrest 
Mesoderm induction
Figure 1.2 Mechanism of activation of the TGFB receptors. The TGFB type II 
receptor is the primary ligand (TGFB-indicated with black diamond) binding 
receptors, while the TGFB type I receptor, once recruited to the ligand-bound 
type II receptor, serve as the first substrate for the type II and initiates down 
stream responses.
embryos dying around 10.5 dpc. (Dickson et al., 1995) indicating that TGFB1 
and TBRII are essential for hematopoeisis in vivo.
The search for TGFB receptor substrates has been approached using 
the yeast two hybrid system and complementary DNA (cDNA) from neonatal rat 
heart. The rapamycin binding protein, FKBP12, interacted with TBRI used as a 
“bait”. Flowever, no interaction between FKBP12 and the cytoplasmic domain of 
TBRII or activin type II receptor was observed (Wang et al., 1994). The binding 
of FKBP12 to the TBRI is potentially interesting because of its involvement in 
another growth inhibitory pathway induced by rapamycin (Chung et al., 1992; 
Jayaraman et al., 1993). The FKBP12-rapamycin complex, similarly to TGFB, 
inhibits G1 phase progression in various mammalian cell types as well as yeast 
(Schreiber 1992). It could be hypothesised that certain components of the 
TGFB and rapamycin signalling pathways might be the same or similar 
proteins.
The first major milestone in identifying the downstream components that 
turn TGFB receptor signals into specific effects on gene expression has been 
reached with the identification of the Smad proteins as TGFB signal 
transducers.
The discovery of Smad proteins in vertebrates as downstream components of 
TGFB signalling pathway stems from identifying of Mad (mothers against dpp) 
gene in Drosophila, dpp (decapentaplegic) encodes a fly homologue of BMP2, 
and BMP4 from vertebrates (Sekelsky et al., 1995) and its function is required 
for the embryo development and for the development of eyes and wings 
(Newfeld et al., 1996). It was found that mutation in Mad gene exacerbate the 
phenotype of weak dpp allele (Sekelsky et al., 1995). After this finding, several 
MAD homologues, now referred to as Smad proteins, were reported from 
vertebrates (Hoodies et al., 1996; Liu et al., 1996; Baker & Harland, 1996). It 
was noticed that mutations in Mad block the signalling ability of a constitutively 
active form of the DPP type I receptor encoded by tkv (thick vein) gene. This 
indicated that MAD functions downstream of the receptor (Hoodies et al., 
1996). Further evidence to support that Smads function downstream of TGFB
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receptors has been obtained by observing that introduction of Smads from 
human and mouse into frog early embryo mimics the effects of activated TGFB- 
family receptors on mesoderm development (Graff et al., 1996; Liu et al., 1996). 
Moreover it was found that Smads are phosphorylated (Hoodies et al., 1996; 
Baker & Harland, 1996) and accumulate in the nucleus (Hoodies et al., 1996; 
Liu et al., 1996) in response to TGFB-family agonists. These findings argue 
that Smad proteins are mediators of TGFB receptors’ signals. Upon 
phosphorylation by activated receptors (Macias-Silva et al., 1996), Smads form 
complexes (Zhang et al., 1996; Wiersdorff et al., 1996) (figure 1.2), move into 
the nucleus, associate with DNA-binding proteins (Chen et al., 1996) and 
activate gene transcription.
The human, mouse and frog Smads 1 through 6 have been cloned. Smads 4 
and 2 are located at 18q21, and they are the target of mutations in cancer 
(Riggins et al 1996; Yingling et al., 1996; Eppert et al., 1996).
Although both type I and type II TGFB receptors are required for TGFB- 
induced growth inhibition and extracellular matrix protein synthesis in Mv1 Lu 
cells (Massague et al., 1990), there could be divergent signalling pathways for 
the two sets of responses and association of TBRII functions with TGFB's anti- 
proliferation activity (Derynck et al., 1994; Chen et al., 1993). Using the 
cytoplasmic domain of TBRII as a “bait”, the protein called transforming growth 
factor receptor interacting protein (TRIP1) was isolated. No interaction between 
this protein and activin type II or type I receptors was observed. 
Phosphorylation of TRIP1 on serine and threonine by the receptor kinase, and 
its co-expression with TBRII receptor during development, suggest a signalling 
role for TRIP1 (Chen et al., 1995).
Type I receptors so far identified include TSR-R (ALK1), ActRI (ALK2), 
BMPR-IA (ALK3), ActR-IB (ALK4), TBRI (ALK5), and BMPR-IB (ALK6) 
(Attisano et al., 1993; ten Dijick et al., 1994; Frolik et al., 1984; Carcamo et al.,
1994). The activin receptor-like kinase 1 (ALK1) which is a type I cell surface 
receptor for the TGFB ligands is highly expressed in endothelial cells and other
8
highly vascularized tissues (such as lung and placenta) (Attisano et al., 1993). 
The ALK1 protein can associate with the TGFB or activin type II receptors in 
vitro, with the complex binding TGFB and activin respectively (Attisano et al., 
1993; ten Dijke et al., 1994(b); Miyazono et al., 1994). However, its ligand in 
vivo remains to be revealed (ten Dijke et al., 1994(a)).
Type II receptors include ActRII, ActRIIB, TBRII, and BMPRII (Mathews 
& Vale, 1991; lin et al., 1992; Attisano et al., 1992; Estevez et al., 1993).
Using somatic cell hybrids and fluorescence in situ hybridisation, 
TGFBRII has been mapped to human chromosome 3p22 (Mathew et al., 1994). 
Human ALK1, ALK2, ALK3, ALK4, ALK5, and ALK6 have been assigned to 
chromosomes 12q11-q14, 2q22-q37, 6, 12q11-q14, 9, and 4 respectively 
(Johnson et al., 1995; Roijeretal., 1997).
I: 1.4.2 TGFB type III receptor (betaglycan):
The type III receptor for TGFB, known as betaglycan has a biological 
function distinct from that of the type I and II receptors. This receptor is 
heterogeneous in nature and typically runs on SDS-polyacrylamide gels as a 
broad band with an average mass of 280 to 330 kDa (Massague 1985). One of 
the most remarkable characteristics of betaglycan is that it is an integral 
membrane proteoglycan consisting of approximately 200 kDa of 
glycosaminoglycan (GAG) chain, in which the relative proportion GAG varies in 
different cell types. The GAGs are not required for functional expression of the 
receptor on the cell surface (Cheifetz & Massague 1989) nor for binding to 
TGFB (Cheifetz & Massague 1986; Cheifetz & Massague 1988).
As discussed before (1.3.1), TBRIII may not be involved directly in signal 
transduction but serve some other functions such as concentrating ligand 
before presentation to bona fide signal-transducing receptors (Massague et al., 
1990). The type III receptor shows comparable affinities for all TGFB isotopes. 
It is also the most abundant cell surface TGFB receptor in many cell lines
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(Massague 1995, Massague & Like., 1985; Cheifetz et al., 1986.; Fanger et al
1986). Johnson et al (1995) have assigned human betaglycan to 1p32-p33.
1:1.4.3 Endoglin (Eng):
Endoglin is a homodimeric integral membrane glycoprotein composed of 
disulphide-linked subunits of 95 kDa (Gougos & Letarte, 1988, 1990). The 
transmembrane domain and the relatively short (43 amino acids) cytoplasmic 
tail of this protein (Lopez-Casillas et al., 1991; Wang et al., 1991) were 
remarkably similar to the corresponding regions in betaglycan (71% amino acid 
sequence similarity with 63% identity) (Gougos & Letarte., 1990). The 
extracellular regions of these two proteins show limited amino acid sequence 
homology (Gougos & Letarte., 1990; Lopez-Casillas et al., 1991; Bork et al.,
1992). Endoglin has been shown to bind TGFB1 and TGFB3 with high affinity, 
while betaglycan binds all three isoforms (Cheifetz et al., 1992). Moreover, 
TGFB2 was shown to be less potent than TGFB1 and TGFB3 on certain cell 
types, including hematopoietic cells and endothelial cells (Ohata et al., 1987; 
Jennings et al., 1988; Cheifetz et al., 1990; Hiai & kaji., 1992) which could be 
due to absence (or less) of affinity between TGFB2 and endoglin.
On human vascular endothelial cells of capillaries, arterioles and 
venules in all tissues examined (Gougos et al., 1990) endoglin is the most 
abundant transforming growth factor B binding protein (Cheifetz et al., 1992). In 
the presence of TGFB ligand, endoglin can associate with the signalling 
receptors TBRI and TBRII, and is thought to potentiate response to the growth 
factor (Yamashit et al., 1994). The human autosomal dominant condition 
hereditary haemorrhagic telangiectasia type I which shares many cellular and 
histological similarities to the yolk sac phenotype of TGFB1(-/-) knockout mice, 
is caused by mutations in endoglin (McAllister et al., 1994).
ENG has been assigned to human chromosome 9 using a human x 
hamster somatic cell hybrid mapping panel, and regional localisation to 
9q34->qter was determined by fluorescence in situ hybridisation to metaphase
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chromosomes (Fernandez-Ruiz et al., 1993). The murine Eng maps to 
chromosome 2 to a region syntenic with human chromosome 9q34-»qter 
(Qureshi et al., 1995)
1:1.5 TGFB isoforms and their functions:
Three TGFB isoforms (TGFB1-3) have been identified in mammals. The 
biologically active TGFB isoforms are homodimers, and each monomer of each 
isoform has nine conserved cysteine residues. The bioactive peptide of TGFB 
among these isoforms is also highly conserved (approximately 70% amino acid 
content)(Roberts & Sporn, 1990). In the mouse, TGFB1 is encoded by the gene 
Tgfbl, TGFB2 by Tgfb2, and TGFB3 by Tgfb3. Conservation is also evident at 
the genomic level. The Tgfbl gene has seven exons and this structure is 
largely conserved in other Tgfb genes. Murine Tgfb type I, 2, and 3 have been 
assigned to chromosomes 7 (6.5cM) (Fujji et al., 1986), 1 (101cM), and 12 
(41 cM) respectively (Baton et al., 1988).
1:1.5.1 TGFB and Reproduction: 
1:1.5.1.1 Testicular function:
TGFB1 is one of the chemotrophic factors involved in the migration of 
primordial germ cells to the genital ridge and the initiation of gonad 
development (Godin and Wylie, 1991). Expression of all TGFB isoforms has 
been observed in embryonic and/or adult testis (Derynck et al., 1988; Miller et 
al., 1989 a, b; Watrin et al., 1991). Two TGFB1 transcripts; 2.4 and 1.8 kb 
TGFB1 mRNAs, are found. Both TGFB1 mRNAs have been observed in testis 
and most tissues. However, a 1.8 kb TGFB1 transcript is reported to 
predominate in the testis and it appears to be germ cell-specific. It has been 
observed in all germ cell populations examined, including meiotic prophase 
spermatocytes, early spermatids, and residual bodies (Wartin et al., 1991). 
Also, all three TGFB isoforms are produced by Sertoli and peritubular cells, 
and appear among proteins secreted by them (Skinner and Moses, 1989). 
TGFBs are involved in autocrine and paracrine regulation of testis function and
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germ cell development and differentiation. TGFB1 promotes production of 
proteins and stimulates clustering and colony formation by peritubular cells in 
vitro (Skinner and Moses, 1989). TGFB1 from Sertoli cells acts in a paracrine 
fashion to modulate steroidogenesis in Leydig cells (Avallet et al., 1987; Lin et 
al., 1987; Fauser and Hsueh, 1988; Morera et al., 1988). All these results imply 
the possible involvement of TGFBs in the process of spermatogenesis. TGFB1 
has been localised on human spermatozoa at neutral pH (by 
immunocytochemical studies) which suggests that TGFB1 could have some 
roles in human gametes (i.e. transmission or viability of spermatozoa). The 
TGFB1 immunostaining pattern at an acidic pH was similar to that at neutral 
pH, but at a higher intensity. Thus, it was suggested that an in vivo activation of 
latent TGFB1 in seminal plasma may take place in the acidic environment of 
the vagina (Chui et al., 1996).
I: 1.5.1.2 Ovarian function:
TGFB1 and TGFB2 are produced in ovarian tissue. TGFB1 appears in 
all tissues (Derynck et al., 1988; Thompson et al., 1989; Akhurst et al., 1990a; 
Ksander et al., 1990; Mulheron and Schomberg, 1990; Roy et al., 1992), but 
TGFB2 is lacking in oocytes (Chegini and Flanders, 1992; Roy et al., 1992; 
Teerds and Dorrington, 1992). TGFB may act in an autocrine/paracrine manner 
to regulate ovarian functions. Folliculogenesis, oocyte maturation, and 
differentiation of granulosa, thecal, and luteal cells are processes dependent 
on a complex interaction of gonadotropins, steroid hormones, and growth 
factors, the latter including TGFB (Chegini and Flanders, 1992). TGFB is also 
involved in modulating follicle stimulating hormone secretion from the pituitary 
(Knecht et al., 1986; 1987; Ying et al., 1986b).
I: 1.5.2 TGFB and uterine function:
Localisation studies suggest that TGFB1 is involved in uterine function, 
including implantation, decidualization, and placentation (Altman et al., 1990; 
Tamada et al., 1990; Dungy et al., 1991; Das et al., 1992; Lea et al., 1992;
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Manova et al.} 1992). TGFB1 appears in luminal and glandular epithelium 
before implantation (Tamada et al., 1990), and in the deciduum after 
implantation (Akhurst et al., 1990b; Tamada et al., 1990; Manova et al., 1992). 
TGFB2 also appears in luminal and glandular epithelium, and in myometrium 
and vascular smooth muscle, before implantation. Postimplantation, it is 
present in myometrium, epithelium, and deciduum (Das et al., 1992). TGFB3 is 
expressed only in the myometrium and vascular smooth muscle throughout the 
pre-implantation period (Das et al., 1992). An immunosuppressive factor 
closely related to TGFB2 is released from decidual tissue after implantation, 
and helps prevent maternal rejection of the foetus (Altman et al., 1990). These 
studies suggest the possible involvement of maternal sources of TGFBs in 
embryonic development during pre- and post-implantation stages.
1:1.5.3 TGFB1 and embryo development: 
1:1.5.3.1 Preimplantation stage:
Both gene product localisation and functional studies indicate an 
important role for TGFB1 in preimplantation embryos. Present at the single cell 
stage, it may almost disappear at the two-cell stage, but reappears in four-cell 
and later embryos. It may be involved in regulation of differentiation during 
preimplantation development, in transformation of the morula to the blastocyst, 
or blastocyst maturation. Production of TGFB1 continues into postimplantation 
development, the different isoforms showing both overlapping and distinct 
expression patterns throughout (Paria et al., 1992; Slager et al., 1991).
In addition to expression studies, functional studies also support a role 
for TGFB1 in preimplantation development. In vitro culture of individual two-cell 
embryos results in impaired development to the blastocyst stage, with fewer 
numbers of cells per blastocysts and fewer numbers of embryos developing 
into blastocysts relative to that observed when embryos are cultured in groups. 
Addition of TGFB1 to the culture medium significantly enhances the percentage 
of embryos that develop into blastocysts, although it does not increase the 
number of cells per blastocyst (Paria and Dey 1990) suggesting the important
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function of TGFB1 in transformation of the morula to the blastocyst, and in 
blastocyst maturation.
I: 1.5.3.2 Postimplantation stage:
TGFBs are also implicated in postimplantation development. The three 
TGFB isoforms exhibit both overlapping and distinct patterns of expression 
throughout development. Expression has been observed mainly in areas 
undergoing morphogenesis.
Expression of TGFB1 mRNA in the early murine embryo has been 
associated with both vasculogenesis and angiogenesis. High level mRNA 
expression of TGFB1 is seen in the forming yolk-sac blood islands, in the 
cardiac mesoderm prior to the differentiation of endothelial cells, and in 
endothelial cells per se (Akhurst et al., 1990b). It has been suggested that an 
important function of TGFBs in the early events of vasculogenesis and 
angiogenesis could be the augmentation of bFGF activity, either by increasing 
synthesis of this growth factor (Plouet and Gospodarowicz, 1989), or by the 
induction of glycosaminoglycan (GAGs) which are essential for the binding of 
bFGF to its receptor (Nugent and Edelman., 1992). Expression of TGFB 
transcripts and proteins are seen during cardiac and skeletal myogenesis 
(Pelton et al., 1991; Dickson et al., 1993) though they appear to be localized to 
nonmyogenic cells (Akhurst et al., 1990b; Millan et al., 1991; Dickson et al.,
1993). TGFBs are implicated in inductive tissue interactions that result in the 
formation of mesenchymal cardiac cushion tissue, which contributes to valve 
and septum formation (Akhurst et al., 1990).
During formation of both bone and cartilage, TGFBs are expressed in 
different subsets of cells (Pelton et al., 1990; Millan et al., 1991). The positive 
effects of TGFBs on proliferation and differentiation of cells from the 
chondrocyte and osteocyte lineages could be compatible with their function as 
inducers of bone and cartilage formation (Akhurst, 1994). Interleukin-10 
suppresses osteogenic differentiation of mouse bone marrow by suppressing
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synthesis of TGFB1, which is essential for commitment of bone marrow cells to 
osteogenesis (van Vlasselaer et al., 1994). Exogenous TGFB added to long 
term mouse bone marrow cultures inhibits cell growth, and neutralisation of the 
added factor accelerates growth (Waegell et al., 1994).
The three mammalian TGFB isoforms are also expressed in palatal 
epithelium and mesenchyme during formation of the secondary palate 
(Fitzpatrick et al., 1990), in the lung during branching morphogenesis (Heine et 
al., 1990), in the tooth epithelium and mesenchyme during odontogenesis; 
(Vaahtokari et al., 1991), in the cells and tissues of the developing central and 
peripheral nervous system (Flanderz et al., 1991), and in the mammary gland 
epithelium during ductal development(Robinson et al., 1991). Observing the 
expression of all three TGFB isoforms during postimplantation as well as 
preimplantation development emphasises the importance of their functions 
throughout the embryogenesis.
15
Part II:
II: 1.1: Genetic analysis of complex traits:
II: 1.1.1 Simple traits and Complex traits:
The term “simple trait” refers to any phenotype which exhibits a pattern 
of classical Mendelian recessive or dominant inheritance, attributable to a 
single gene locus, which overrides other genetic or non-genetic factors. That is 
, there is a simple correspondence between genotype and phenotype. This 
perfect co-segregation of a trait with the gene, makes linkage analysis and 
positional cloning very straightforward. In contrast to simple Mendelian traits, 
complex traits do not override the effects of other genetic and non-genetic 
factors. Due to factors other than the gene itself, typically other loci and often 
the environment, correspondence between phenotype and genotype breaks 
down. This problem can be exacerbated by non-additive (epistatic) interactions 
between factors. In human such complex traits include susceptibilities to neural 
tube defects (Laurence 1990), autoimmune disease (Vyse & Todd, 1996), 
diabetes (Deng et al., 1995), and cancers (Ponder, 1990).
Some human conditions were initially classified as simple traits. 
However, these conditions show markedly different clinical manifestations 
among individuals carrying the identical causative locus. For example, sickle 
cell anaemia has been classified as a recessive, simple trait, however, 
individuals carrying identical alleles at the beta-globin locus show different 
clinical manifestations ranging from early childhood mortality to a virtually 
unrecognised condition even at age 50 (Huisman, 1979; Steinberg and Hebbel, 
1983). Therefore, there must be other modifying factors, genetic or non- 
genetic, that influence on the phenotypic expressivity of sickle cell anaemia.
The indication of a complex trait can be categorised as follows (Lander & 
Schork, 1994):
1 - Polygenic traits, 2- Genetic heterogeneity, and 3- Incomplete penetrance.
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II: 1.1.2 Polygenic traits:
The term “polygenic trait” refers to any phenotype influenced by 
different genetic loci. Polygenic traits can be classified as: quantitative traits 
(e.g. height of an individual), or qualitative traits (e.g. individuals grouped into 
discrete traits such as death from myocardial infarction).
In polygenic traits, the presence of epistatic (non-additive) effects among the 
involved loci complicates the process of genetic mapping especially in outbred 
populations such as humans.
II: 1.1.3 Genetic heterogeneity:
The term “genetic heterogeneity” refers to cases in which mutations in 
any one of several genes results in the same or similar phenotype. Genetic 
heterogeneity can occur when several genes are required for a common 
biochemical pathway or cellular structure.
It must be born in mind that “genetic heterogeneity” differs from “allelic 
heterogeneity” in which different mutations at a single locus result in different 
manifestations of the disease. Allelic heterogeneity does not usually hamper 
the genetic mapping process. Cystic Fibrosis (CF) is an example of “allelic 
heterogeneity”. CF is a common autosomal recessive disorder diagnosed by 
obstructive lung disease, elevated sweat electrolyte level, and exocrine 
pancreatic insufficiency (Welsh et al., 1995). The clinical manifestation of CF is 
heterogeneous which could be partly due to the diverse spectrum of mutations 
in the CF transmembrane conductance regulator (CFTR) gene (Rommens et 
al., 1989; Riordan etal., 1989).
Genetic heterogeneity poses problems in approaching genetic mapping 
because the inheritance pattern of chromosomal regions harbouring the 
disease genes in affected families may differ. Hereditary non-polyposis colon 
cancer, for instance, appears to be due to defects in DNA mismatch repair 
genes (Strand et al., 1993; Fishel et al., 1993; Leach et al., 1993; Parsons et
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al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994). These genes have 
been highly conserved throughout evolution; five human genes homologous to 
those responsible for mismatch repair in unicellular organisms have been 
discovered (Strand et al., 1993; Fishel et al., 1993; Leach et al., 1993; Parsons 
et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994, Fujii & Shimada 
1989; Palombo et al., 1994). This disease is caused by mutations in any of the 
genes involved in DNA mismatch repair (Liu et al., 1994).
II: 1.1.4 Incomplete penetrance and phenotype:
The penetrance of some loci is not complete, and as a consequence, 
some carriers manifest the phenotypes whereas others may not. This 
incomplete penetrance could be due to interference of some factors such as 
age, sex, environment, infection, and other genes with the penetrance of the 
locus (or loci).
In autoimmune type I diabetes mellitus, which is an organ-specific 
autoimmune disease, the identical twins of affected individuals have only 36% 
risk of developing the disease (Olmoss et al., 1988), demonstrating the 
importance of the environmental factors in developing the disease. The risk to 
siblings of type I diabetic individuals is about 6% (Thomson et al., 1988) 
whereas that of European descent population as a whole is 0.2-0.3%. 
Although, penetrance of the disease genes is determined by unknown 
environmental factors, genetic factors are essential (Cordell &Todd, 1995).
II: 1.2 Animal models for human genetic disorders:
Animal models such as mouse and rat can be utilised for mapping genes 
of relevance to human genetic disease due to the fact that experimental 
crosses override many factors which hamper genetic mapping in human 
families. In nearly all cases of linkage analysis in animal models, for example in 
the mouse, the parental combinations of alleles, the so-called phase of linkage 
-will be known with absolute certainty. However, in the analysis of human
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pedigrees the phase of linkage is often not known with certainty. As a 
consequence, human geneticists are forced to employ more sophisticated 
statistical tools that evaluate results in the light of the probabilities associated 
with each possible phase relationship for each parent in a pedigree (Elston & 
Stewart 1971). The experimental crosses, with providing the opportunity to 
study hundreds of meioses from a single set of parents, override the problem of 
genetic heterogeneity. Also far more complex genetic interactions such as 
susceptibility to cancer (Nagase et al., 1995), drug sensitivity, resistance to 
infections, and aggressive behaviour (Festing, 1979) can be probed in 
experimental crosses than is possible for human families.
The mouse has been chosen as an animal model for genetic analysis 
mainly due to its short gestation period and relatively large litter size, the ability 
to perform controlled matings, and most importantly due to the availability of 
inbred strains showing a wide range of natural strain variations (Copeland et 
al., 1993). Moreover as cloning and mapping of both the mouse and human 
genomes began, two important evolutionary facts became clear. First, nearly all 
human genes have homologies in the mouse and vice versa. Second, not only 
are the genes themselves conserved, but so is their order- to a certain extent- 
along the chromosome. In 1984, Nadeau and Taylor used linkage data 
obtained from 83 loci that had been mapped in both species to estimate the 
average length of conserved autosomal segments as 8.2 cM, in the mouse 
(Nadeau, 1984). The practical implication of conserved chromosomal segments 
is that the mapping of a gene in one species can provide a clue to the location 
of the equivalent gene in other species by interpreting synteny information. 
There are many examples of smaller genomic segments that have popped out 
or into larger syntenic regions. Thus, even if a human gene maps between two 
human loci with demonstrated synteny in the mouse, there is still a small 
chance that it will have moved to another location in the mouse genome. 
Nevertheless, over 80% of the autosomal genomes of mice and humans have 
now been matched up at the subchromosomal level (Copeland et al., 1993). 
Thus, with map information for a gene in humans, it will often be possible to 
predict a corresponding mouse chromosomal segment of -10  cM in length as a 
likely location to test first for linkage with nearby DNA markers.
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The mouse models such as the non-obese diabetic (NOD) mouse for 
autoimmune type I diabetes mellitus in humans (Makino et al., 1980), the 
Splotch (Sp) mouse for Waardenburg syndrome type I in humans (Baldwin et 
al., 1992; Tassabehji et al., 1992), the Extra-toes (Xt) mouse for Greg’s 
cephalopolysyndactyly, a rare multi-system syndrome in humans (Hui and 
Joyner, 1993), the curly-tail (ct) mutant mouse for neural tube defects in 
humans (Embury et al, 1979) have been reported. These natural mutant 
animals were selected as models for human genetic disease on the basis of 
similarities in pathology, associated anomalies, inheritance and the influence of 
potential teratogens. Moreover, in laboratory animal models such as mouse, 
some complex traits are induced by chemicals and diets (e.g. Nagase et al.,
1995). The different manifestation of the complex traits in different strains is 
due to influence of natural strain variation. Applying a genetic mapping 
approach enables genetic determination of these strain variations. The method 
of genetic mapping, by which one compares the inheritance pattern of a trait (or 
disease) with the inheritance patterns of chromosomal regions, allows one to 
locate a gene without knowledge about the function of the gene. Genetic 
mapping of trait-causing genes to chromosomal locations dates back to the 
work of Haldane in 1915. Haldane found evidence for coupling between 
mutations of the albino (c) and pink-eyed dilution (p) loci, which we now know 
to lie 15 cM apart on chromosome 7.
Because disease-causing mutations may occur at many steps in a 
biochemical pathway, animal models may not point to those genes most 
frequently mutated in human disease. However, animal studies should identify 
key genes acting in the same biochemical pathway or physiological system. 
Moreover, the genetic model underlying the disease, in terms of number of 
genes involved and interaction effects between loci, may present similarities 
between the two species.
Typical experimental crosses consist of crossing one inbred strain, 
which has a high risk of developing a disease (or trait), with another inbred 
strain, which has very low or no risk. The F1 generation is typically unaffected
20
(e.g. Nagase et al., 1995), which could be interpreted for involvement of one 
recessive locus or several loci with recessive outcome. However, studying a 
large number of F1 animals could show small percentage of affected animals.
II: 1.2.1 F1 backcross or F1 intercross animals:
Upon beginning a new linkage study there is a choice whether to screen 
F1 backcross or F1 intercross animals. Both the F1 backcross and intercross 
approaches have advantages and disadvantages. However, it is important to 
bear in mind that males from F1 interspecific hybrids in some mouse strains are 
infertile ruling out the intercross approach. The sterility of males in these 
strains follow Haldane’s (1922) rule which states, when in the F1 offspring one 
sex is absent, rare or sterile, that sex is the heterozygous sex. Therefore, in 
these crosses the only practical approach for genetic mapping purposes is to 
create a backcross generation by backcrossing F1 females to the male from a 
high-risk parental strain.
The primary advantages of the backcross approach are all based on the 
fact that each offspring from the backcross can be viewed as representing an 
isolated meiotic event. Therefore, the analysis of backcross data is very 
straightforward. However, in practice this approach can not be used to map loci 
defined only by recessive phenotypes that interfere with viability or absolute 
fecundity in both males and females, which could be mapped by applying an F1 
intercross approach. Moreover, the F1 intercross approach as a consequence 
of the fact that informative meiotic events will occur in both parents will lead to 
essentially twice as much recombination information on a per animal basis 
compared to the backcross approach. Therefore, it leads to obtain high- 
resolution mapping of the locus of interest relative to closely linked markers 
which is the first requirement for the process of positional cloning.
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Besides conventional crosses, i.e. backcross and intercross, there is 
another very powerful mouse cross known as “recombinant inbred strains” 
utilised for genetic mapping purposes.
II: 1.2.2 Recombinant inbred (Rl) strains:
Like all inbred strains, Rl strains are fixed to homozygosity at essentially 
all loci. However, in Rl strains there are two choices for the origin of allele that 
can be present at each locus. The construction of a set of Rl strains is quite 
simple in theory. It begins with an outcross between two well established highly 
inbred strains of mice, such as B6 and DBA. These are considered the 
progenitor strains. The F1 progeny from this cross are all identical and thus, in 
genetic terms, they are all interchangeable. F1 hybrid animals are bred to each 
other to produce a large set of F2 animals which are riot identical. At this 
stage, pairs of F2 animals are chosen at random to serve as the founders for 
new inbred strains of mice. The offspring from each F2 founder pair are 
maintained separately from all other offspring, and just two are chosen 
randomly for brother-sister mating to produce the next generation. The same 
process is repeated at each subsequent generation until at least 20 sequential 
rounds of strict brother-sister matings have been completed and a new inbred 
strain with special properties is established. Each of the new inbred strains 
produced according to this breeding scheme is called a “recombinant inbred” 
strain.
Establishment of recombinant inbred (Rl) strains by Bailey and Taylor at 
the Jackson Laboratory (Bailey, 1971; 1981; Taylor., 1978) was the first 
important conceptual breakthrough aimed at reducing the time, effort, and mice 
required to map single loci. Rl strains are powerful mapping tools for systemic 
linkage studies, offering two major advantages over conventional crosses: first, 
genotype information is cumulative, thus, researchers need not type many 
reference markers, and second, identical genotypes can be phenotyped 
multiple times, therefore improving the reliability of quantitative measurements. 
On the basis of these advantages, Rl strains have launched major efforts to 
map complex traits including: chemically induced-lung tumorigenesis,
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(Gariboldi et al., 1993), thymocyte apoptosis induced by radiation, and 
genetically induced-dactylaplasia (Johnson et al., 1995). However, there are 
two drawbacks of utilising Rl strains; first, there are only two choices for the 
allele that can be present at each locus, second, because there is only a 
limited number of opportunities for recombination to occur between the two sets 
of progenitor chromosomes before homozygosity sets in, complete 
homogenisation of the genome can not take place.
II: 1.3 Markers for linkage analysis:
Linkage analysis can only be performed on loci that are polymorphic with 
two or more distinguishable alleles. As discussed before, the initial choice of 
the mouse as an experimental genetic system was due to the collection of rare 
genetic variants presents in hand. However, even this variation was restricted 
in its scope and usefulness for geneticists. This was because of the severe 
limitation in the number of informative markers. Although over 50 independent 
phenotypic markers (loci) were identified with effects on coat colour (Silver, 
1979), it was impossible to follow more than a handful at any one time since 
mutant alleles at any one locus would act to obscure the expression of mutant 
alleles at other loci. An alternative approach was to utilise restriction fragment 
length polymorphism (RFLPs). A RFLP is defined by the existence of 
alternative alleles associated with restriction fragments that differ in size from 
each other. RFLPs are visualised by digesting DNA from different individuals 
with a restriction enzyme, followed by gel electrophoresis to separate 
fragments according to size, then blotting and hybridisation to a labelled probe 
that identifies the locus under investigation. In the mouse, the RFLP approach 
proved to be extremely powerful in interspecies crosses (Avner et al., 1988). 
Using interspecific crosses, which show high polymorphism, detailed genetic 
maps have been constructed showing the position of hundreds of genes 
(Kingsley et al., 1989).
Notwithstanding the great utility of RFLPs, they still have several major 
limitations: 1-The rate of polymorphism is considerably lower among inbred 
laboratory strains. 2-Typing RFLPs is time-consuming and difficult to automate.
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Additionally, although interspecies crosses are quite useful, there are many 
circumstances in which it is preferable to use crosses between two inbred 
laboratory strains of the same species. Applications include mapping of 
mutations whose phenotypes are affected by genetic background, mapping of 
modifier genes and mapping of polygenic factors underlying physiological 
differences between strains.
An alternative source of DNA polymorphism is based on variation in the 
length of simple sequence repeats (SSRs). Because these variable number of 
tandem repeat (VNTR) polymorphisms exhibit high heterozygosity within the 
population, they are especially useful in linkage studies to track a specific gene 
as well as identifying the genes/loci responsible for genetic diseases. Variation 
in the number of repeats within a block of tandem repeats appears to be a 
universal feature of eukaryote DNA, regardless of the length of the repeat unit 
(Weber & May, 1989). There are two classes of variable number of tandem 
repeats one of which consists of larger tandem repeats called minisatellites. 
These show marked variability in the number of repeats and about 70% of 
human individuals are heterozygous for any one marker. Unfortunately these 
hypervariable VNTR loci tend to be biased in their distribution with a tendency 
to localise in telomeric bands. Minisatellites are not so useful for following 
specific genes in families or populations, although they have been applied in 
several genetic analyse, such as determining family relationships, as well as 
identifying the origin of tissue samples in forensic medicine. Developing the 
polymerase chain reaction (PCR) has provided a rapid means of detection of 
these VNTRs in linkage studies. This application of the PCR to type 
polymorphic DNA markers consumes less DNA and is faster than for routine 
genotyping of a block of markers, and PCR is even capable of amplifying DNA 
from a single template molecule (Saiki et al., 1988).
The second type of variable number of tandem repeats is the 
microsatellite repeat. These consist of around 10-50 copies of a motifs of 1 to 6 
bp in size which occur, on average, every 6 kb. Dinucleotide repeats specially 
CA and GA, are particularly frequent with an estimated total of 50,000 
dispersed through the genome. The availability of dense genetic linkage maps
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of mammalian genomes makes feasible a wide range of studies, including 
positional cloning of monogenic traits, genetic dissection of polygenic traits, 
construction of genome-wide physical maps, rapid marker-assisted construction 
of congenic strains, and evolutionary comparisons (Copeland et al., 1993).
II: 1.4 Congenic mice:
In order to assess the contributions made by single locus to polygenic 
disease, congenic strains have been bred in which chromosomal regions from 
the resistant strain have been introgressed onto the backgrounds of sensitive 
to disease strains (Snell, 1948). This is done by successive backcrosses and 
selection for genotype; using markers that conservatively span the trait locus 
region. If the resultant strain pair retains a phenotypic difference, then crosses 
can be fine mapped as a simple locus.
The relative contributions of the major histocompatibility complex (MHC) 
and non-MHC genes to susceptibility to type I diabetes were analysed by the 
use of experimental crosses and congenic mouse strains (Hattori et al., 1986; 
Prochazka et al., 1987; Wicker et al., 1987; 1989; Livingston et al., 1991). A 
congenic strain NOD.B10-H-2b (NOD.H-2b), in which the H-29 of the NOD was 
replaced with the H-2 region from the diabetes-resistant C57BI/10SnJ (B10) 
strain, did not develop insulitis or diabetes demonstrating that the NOD MHC 
was essential for beta-cell destruction. However, the non-MHC genes in the 
NOD strain, in the absence of the NOD MHC, significantly contribute to the 
development of autoimmunity (Wicker et al., 1992).
II: 1.5 Assignment of the function of cloned genes by application of 
animal models:
The classic approach to identify the function of a cloned gene is to 
inactivate the gene and to study the biological consequence of lack-of-function 
of the gene. However, due to the fact that biology is full of interactions of gene 
products with each other and with the environment, some of the proteins could
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show functional redundancy. Although, this could be misleading in assignment 
of the actual function of some genes, it can be employed to identify some 
possible hidden interactions between loci.
The function of a gene , in principle, can be inactivated at several levels. It can 
be approached either by manipulation of the gene by homologous 
recombination (Knockout approach) or by applying dominant negative 
mutations or antisense oligonculeotides approach.
II: 1.5.1 Knockout technology:
The general term of “knockout” relates to artificially generated null 
mutations of an endogenous gene. Such mouse mutants, which are devoid of a 
particular protein, are created by a process called homologous recombination 
or targeted disruption. The process involves the inactivation of an endogenous 
gene by insertion of cloned sequences. This takes place in embryonic stem 
(ES) cells which are then used to produce transgenic animals. ES cells are 
non-transformed totipotent cells derived from the inner cell masses of normal 
late blastocysts, which give rise to all organs of the growing foetus including 
germ line.
The knockout technique has been successful in generating loss-of- 
function mutations (null mutations) in transgenic mice, lacking expression of 
particular genes. Therefore, it has been possible to investigate the 
physiological consequence associated with the selective elimination of a 
particular protein in transgenic animals. The application of this technology led 
to generation of animal models for some genetic disorders in human such as 
cystic fibrosis (Snouwaert et al., 1992; Ratliff et al., 1992; O’Neal et al., 1993; 
Dorin et al., 1992) and inflammatory disorders (Kulkarni et al., 1995).
The introduction of this technology also led to the discovery of a number 
of null mutations which result in an embryo lethal phenotype (Gridley et al.,
1987). Even though the mouse embryo is relatively accessible for study, it has 
often proven difficult to draw definite conclusions about the cause of death in
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particular mutants. These mutants have been divided into three groups in terms 
of the stage of lethality (Copp, 1995) as follows:
1) Embryo lethality during the pre-implantation.
2) Embryo lethality at organogenesis.
3) Embryo lethality in the foetal period.
Many mutations causing pre-implantational death appear to disrupt basic 
cellular functions such as RNA metabolism (Michaud et al., 1993; DeGregori et 
al., 1994), transmethylations (Miller et al., 1994), transcription regulation of 
gene expression (Spyropoulos & Capecchi, 1994) and movement of 
chromosomes from the mitotic spindle (Magnuson & Epstein 1984).
At the organogenesis stage the embryo is critically dependent on the 
formation and maintenance of a functioning yolk sac circulation. It has been 
noted that in GATA-2, Rbtn2, and some of the Tgfbl knockout mice (Tsi et al., 
1994; Warren et al., 1994; Dickson et al., 1995) the yolk sac contains no blood 
and embryos die due to hematopoiesis deficiency. Other lethalities at 
organogenesis stage are due to failure to establish a chorioallantoic placenta 
(Yang etal., 1993).
Death in the early foetal period is mainly due to failure of either 
cardiovascular circulation or liver hematopoiesis, or of both. For example; Sp or 
Nf1 knockout embryos die between 12-15 dpc due to cardiovascular failure 
(Franze 1989; Jacks et al., 1994) or Rb, c-myc, and keratin 8 knockout 
embryos die in the early foetal period mainly due to failure of liver 
hematopoiesis (Lee et al., 1992; Jacks et la., 1992, Baribault et al., 1993; 
Mucenski et al., 1991).
To study other functional aspects of these developmentally vital genes 
that would occur at later stages of development can be approached by 
employing “the tissue-specific knockout” technique (Barinaga, 1994). The 
tissue-specific knockout technology allows to investigate the lack-of-function of 
particular genes after passing the early critical period when the genes are
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needed. This method enables the expression of a transgene to be controlled, 
using both the ere and FLP recombinases (Kilby et al, 1993).
ere is the recombinase of the bacteriophage P1, a virus that infects the 
bacterium Escherchia Coli, and recognises a site called LoxP. During the 
infection, ere lines up LoxP sites of phage DNA and removes DNA between 
them, leaving one LoxP site behind. FLP is from a yeast plasmid, and 
recognises FRT sites. Applying conventional homologous recombination 
techniques, enables to insert a transgene containing loxP or FRT sites into ES 
cells, which are then used to create transgenic mice. Another transgenic line is 
generated which expresses ere or FLP. Once the ere and lox, or FLP and FRT 
lines are mated, activation of the recombinase results in excision of the 
segment of DNA between the recombinase recognition sites. Applying this 
technique enables to switch genes on or off. If the sites are introduced at either 
end of the whole construct including promoter, expression of ere results in 
excising the entire coding sequence and transgene would switch off, whereas 
in absence of ere, the transgene would be expressed normally.
Using traditional knockouts to study the function of DNA polymerase p, 
Gue et al., (1994) found that eliminating the gene in all the cells of the mouse’s 
body would result in lethality at an early stage of development. Therefore, it 
would not be possible to investigate other aspects of the gene's function that 
would occur at later stages. To overcome this problem, the DNA polymerase 
gene in ES cells were flanked LoxP sites (Figure 1.3). Mice that have this 
engineered gene were perfectly normal, because they were able to make an 
active DNA polymerase p. To achieve cell-type specific inactivation, these 
transgenic mice were crossed with the transgenic mice in which the ere gene 
was expressed only in developing T cells. Surviving of the T cells of offspring 
indicated that polymerase was not absolutely needed throughout T cell 
development.
11:1.5.1.1 Transforming Growth Factor beta 3 (Tgfb3) knockout mice:
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The Tgfb3 gene was mutated in ES cells by homologous recombination. 
The chimaeric mice produced by using Tgfb3 mutated ES cells were mated with 
three different genetic backgrounds, i.e. CF-1, C57BI/6, and 129/Sv. TGFB3(+/- 
) offspring showed no phenotypic difference compared to that of wild type 
offspring (Proetzel et al., 1995). To generate TGFB3(-/-) mutants, intercrosses 
between heterozygous animals were set up. TGFB3(-/-) pups developed to 
term but died shortly after birth. Embryonic analysis at different stages of 
development (10.5 dpc-19.5 dpc) showed no statistically significant difference 
in the expected Mendelian ratio of 1:2:1 for wild type, heterozygous, and null 
embryos respectively. This indicated the presence of little or no prenatal 
lethality of TGFB3(-/-) mutants. Neonates lacking TGFB3 could not 
successfully suckle, and in their stomachs milk was not observed. These 
animals began gasping for air and subsequently became cyanotic and 
dehydrated just before death. All pups homozygous for TGFB3(-/-), suffered 
from cleft palate. In some of the TGFB3(-/-) neonates, the palatal cleft 
proceeded into the most anterior part of the palate, whereas in the rest the 
anterior segment appeared to be fused. Such variation in expressivity of the 
cleft palate phenotype observed among null pups has been suggested to be 
due to the effect of genetic background. The most severe cleft palate 
phenotypes were observed on the C57BI/6 background. About 50% of the 
TGFB3(-/-) pups bred onto the C57BI/6 genetic background exhibited a 
complete cleft palate, whereas only a very small percentage (2%) of TGFB3(-/-) 
pups bred onto the 129/Sv genetic background had a complete cleft palate.
Analysis of the lungs of TGFB3(-/-) mutants revealed a developmental 
delay, detectable as early as day E12.5. The number of epithelial tubules and 
primitive peripheral branches was reduced by 50% in TGFB3(-/-) mutants 
compared to that of wild type littermate controls. In neonates, the airway and 
terminal air spaces were grossly abnormal.
Analysis of other organs such as cartilage, bone, brain, skeleton and heart of 
TGFB3(-/-) embryos and neonates did not reveal any gross malformations. The 
lack of gross abnormality in other tissues could be due to compensation by 
other TGFB isoforms; i.e. TGFB1 and B2. However, expression studies on
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TGFB3(-/-) embryos did not exhibit any significant difference in TGFB1 and B2 
transcripts excluding the possible upregulation of these TGFB isoforms in the 
absence of TGFB3.
U: 1.5.1.2 Transforming Growth Factor beta type II receptor (Tgfbr2) 
knockout mice:
In order to breed Tgfbr2 knockout mice, one allele of the gene was 
targeted in the ES cell line D3a2 by applying a homologous recombination 
approach. Targeted ES cells were injected into the blastocoel of C57BI/6J 
embryos. Chimaeric males were mated with C57BI/6J females (Oshima et al.,
1996).
Tgfbr2(+/-) animals were developmentally normal and fertile. Tgfbr2(-/-) 
mutants were generated by heterozygous intercrossing. No Tgfbr2(-/-) animals 
developed to term, indicating that TBRII was vital during embryogenesis. 
Embryonic analysis revealed that Tgfbr2(-/-) embryos died by 13.5 dpc due to 
defects in hematopoiesis and vascular development. These findings indicate 
that signalling through TBRII was essential for hematopoiesis and 
vasculogenesis in the yolk sac. This phenotype has also been observed in 
some of the TGFB1(-/-) embryos dying in utero around 10.5 dpc (Dickson et al.,
1995). Therefore, it could be suggested that TGFB1 signalling through TBRII is 
important for hematopoiesis and vasculogenesis in the yolk sac.
II: 1.5.1.3 Transforming Growth Factor beta 1 (T g fb l) knockout mice:
Although there are some overlaps, the expression of each Tgfb gene is 
spatially and temporally distinct (Gatherer et al., 1990), so in order to 
investigate the role of TGFB1 and to differentiate its function during 
embryogenesis from other TGFBs (in mammals), gene “knockout” technology 
was employed. ES cell lines derived from 129/Sv blastocysts were subjected to 
homologous recombination to insert a NEO gene lacking a polyadenylation 
signal into the Tgfbl gene (Figure 1.4). The targeted ES cells were selected 
with neomycin and injected into C57BI/6J/Ola blastocysts. These chimeric
NEO
A)
Smal Smal
Exon 6 Exon 7
Smal Smal
B)
Exon 6 Exon 7
Smal
c) —  -j H r
Smal
+ H  NEO ~W 
Exon 6 Exon 7
Figure 1.4 Targeted disruption of the murine Tgfbl gene in ES cells by 
homologous recombination.
A) Targeting construct consisting of a Tgfbl 4.0 kb Smal genomic fragment 
containing exon 6 and a portion of exon 7 of the Tgfbl gene. A NEO gene 
lacking the polyadenylation signal was inserted into the BamH1 site in exon 6 
of Tgfbl, 102 nucleotides from the N terminal of the mature peptide.
B) The map of the wild type Tgfb l gene locuse.
C) Predicted structure of the disrupted Tgfbl allele.
blastocysts were incubated in a foster mother. The injected ES cells contributed 
to the germ cell lineage in the chimeric animals were allowed to pass the 
changes in the mouse genome to the next generation. Although there is no 
phenotypically obvious difference between a TGFB1(-/+) animal and a normal 
one (wild type), PCR techniques enable the mice carrying the mutated Tgfbl 
allele to be distinguished from wild type animals (Shull et al., 1992). 
Homozygotes for TGFB1(-/-) generated from intercrosses between TGFB1(-/+) 
animals were first described as developmentally normal animals, but they die at 
about 20 days postnatal with a severe inflammatory disease (Sull et al., 1992). 
An independent study of targeted disruption of Tgfbl exhibits the same 
inflammatory condition leading to organ failure and death by 3 weeks (Kulkarni 
et al., 1993).
Mild inflammatory infiltrates of the heart were seen as early as 5 days of 
age, with rapid spread to all organs by 14 days old. Inflammation became 
moderate to severe by 10 to 14 days (Boivin et al., 1995). Hyperproliferation of 
lymphoid cells was observed in TGFB1 deficient mice (Christ et al., 1994). 
Daily injection of synthetic fibronectin peptides reduced inflammatory cell 
infiltration of heart and lungs and modified the lethal wasting syndrome (Hines 
et al., 1994). Increased levels of major histocompatiblity class I and class II 
mRNA were found in TGFB1(-/-) mice, and may contribute to the 
inflammation/wasting disease of these mice. Therefore, TGFB1 deficient mice 
have been proposed as a model for human inflammatory disorders, such as 
autoimmune disease, transplant rejection, and graft versus host reactions 
(Shull et al., 1992).
Detailed analysis of the neonatal TGFB1 genotype ratios (+/+: +/- : -/-) 
from TGFB1(+/-) intercrosses demonstrated that only 50% of the TGFB1(-/-) 
embryos developed to term, while the rest died in utero due to defects in yolk 
sac vasculogenesis and hematopoiesis (Dickson et al., 1995). It has been 
suggested that dichotomy in TGFB1(-/-) lethal phenotypes is due to maternal 
TGFB1 rescue of some, but not all, TGFB1(-/-) embryos (Letterio et al., 1994).
II: 1.6 Phenotypic variations in Knockouts:
II: 1.6.1 Cystic fibrosis:
Cystic fibrosis (CF) is characterized by obstructive lung disease, 
elevated sweat electrolyte levels and exocrine pancreatic insufficiency (Welsh 
et al., 1995). The clinical variations observed in CF patients could be partly 
explained by the allelic heterogenity of the CFTR gene. However, the variation 
also occurs among patients of the same CFTR genotype, indicating the 
involvement of some other modifying factors (Rozmahel et al., 1996). To reveal 
more about CF disease, animal models have been generated by disrupting 
exon 1 of the mouse Cftr gene (Rozmahel et al., 1996). Different expressivity of 
the CF phenotype was observed among homozygous Cftr knockouts bred onto 
a mixed genetic background of 129/Sv and CD1 strains. The majority of the F2 
homozygous Cftr knockout mice exhibited severe intestinal obstruction leading 
to death within the first week of life. However, ~30% of the F2 knockouts 
survived well past 6 weeks of age. The other group of animals, classified in 
terms of severity between these two classes, died by 5 weeks of age. Genetic 
analysis of animals has shown that genetic background plays an important role 
in the different expressivity of the phenotype among Cftr knockout animals. A 
genome wide search to identify modifier genes, conducted on F2 animals 
revealed a modifier gene located in the proximal region of mouse chromosome 
7. The prolonged survival phenotype was contributed by a genetic locus from 
the CD1 background. Whereas most of the Cftr knockout animals dying within 
the first week inherited this region homozygous for 129/129 strain (Rozmahel et 
al., 1995).
II: 1.6.2 Epidermal Growth factor Receptor (EGFR):
The EGFR, which is a member of a family of tyrosine kinase receptors, 
is expressed on the trophectoderm of the blastocyst (Sibilia & Wagner., 1995). 
Due to its expression pattern, it has been suggested that EGFR may be 
important for embryo development. A gene targeting approach was utilised to 
examine the physiological functions of EGFR in vivo (Sibilia & Wagner., 1995;
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Threadgill et al., 1995). Different expressivity of Egfr knockout phenotype in 
different genetic backgrounds has been observed. When the Egfr knockout 
allele was bred onto CF-1 genetic background, degeneration of the inner cell 
mass in null conceptuses led to death in the pre-implantation stage. The Egfr 
knockout allele bred onto a CD-1 genetic background developed to term and 
died by 3 weeks. The phenotypes observed in this group included 
abnormalities in skin, kidney, brain, liver, and gastrointestinal tract. EGFR(-/-) 
embryos bred onto a 129/Sv genetic background died at mid-gestation due to 
placental defects (Sibilia & Wagner., 1995; Threadgill et al., 1995). Different 
expressivity of the Egfr null phenotype in different genetic backgrounds 
indicates the involvement of some genetic factors modifying the phenotype. It 
remains to identify the modifier genes.
II: 1.6.3 Transforming Growth Factor beta 3:
As discussed in the previous section (1.6.1) TGFB3(-/-) animals 
exhibited the cleft palate phenotype with variable severity. The most severe 
cleft palate phenotypes were observed on the C57B1/6 background, whereas 
on the 129/Sv genetic background the phenotype was much less severe. 
Therefore, it has been suggested that the variation in the expressivity of cleft 
palate phenotype observed among null pups could be due to the effect of some 
modifier genetic factors.
II: 1.7 The aim of the project: 
II: 1.7.1 Deleterious effect of TGFB1(-/-) mutant in different genetic 
backgrounds.
The major aim of the project was to investigate the possible factor(s) 
involved in different expressivity of the TGFB1(-/-) phenotype reported in 
TGFB1(-/-) animals bred onto a mixed genetic background. As discussed 
above, targeted disruption of the Tgfbl gene does not necessarily lead to 
embryonic lethality (Shull et al., 1992; Kulkarni et al., 1993). On a mixed 
genetic background approximately 50% of TGFB1(-/-) conceptuses died
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prenatally due to defects in yolk sac vasculogenesis and hematopoiesis 
(Dickson et al., 1995) whereas the other half were developmentally normal but 
died around three weeks post-partum as a consequence of massive 
multisystemic inflammation (Shull et al., 1992; Kulkarni et al., 1993). It has 
been suggested that dichotomy in TGFB1(-/-) lethal phenotype is due to 
maternal TGFB1 rescue of some, but not all, TGFB1(-/-) embryos (Letterio et 
al., 1994).
The project was mainly carried out to reveal whether there were any modifying 
factors discriminating between TGFB1(-/-) embryos dying from the yolk sac 
defect and those developing normally to term.
II: 1.7.2 Determining the effect of modifying factor(s) on expressivity of 
TGFB1(-/-) phenotypes during embryogenesis.
The absolute requirement to identify modifying factors by genetic 
analysis of inbred strains is to determine an unambiguous phenotype as a 
strain specific phenotype. To determine whether TGFB1(-/-) lethality was strain 
specific, the Tgfbl null allele was to be bred onto pure genetic backgrounds of 
either NIH/Olac or C57BI/6J/Olac. The deleterious effect of the TGFB1(-/-) 
genotype was observed to be dependent mainly on genetic background. The 
second approach was to elucidate the nature of these differences in genetic 
background, which lead to variable expressivity. To achieve this, it was 
necessary to consider all potential factors which could have influenced the 
deleterious effect of the TGFB1(-/-) mutant. These factors could be classified 
as follows: 1) Non-embryonic factors, such as circulating maternal TGFB1 or 
the maternal immune system 2) Embryonic factors such as embryonic genetic 
background or 3) The combination of maternal and embryonic factors (additive 
or non-additive effect).
The results of this project would reveal hidden interactions of TGFB1 and 
other genetic and/or non-genetic factor(s) which could be important during 
development of the embryo and the other biological functions in which TGFB1 
is implicated.
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II: 1.7.3 Strategy:
To address the problem of different expressivity of TGFB1(-/-) 
phenotype in two different genetic backgrounds, various crosses between 
NIH/Ola and C57BI/6J/Ola were to be set up to find out whether there was 
strain-specific expressivity of the TGFB1(-/-) phenotype and to then estimate 
the crude number and the inheritance pattern of genetic loci responsible for the 
different expressivity. It was estimated that one locus with a codominant pattern 
of inheritance was responsible for different expressivity of the TGFB1(-/-) 
phenotype.
The goal of the first stage in mapping modifying gene(s) was to link the 
locus (loci) to a defined sub-chromosomal interval. This approach was 
accomplished by typing a relatively small set of markers on a relatively small 
number of phenotypically typed animals. Due to the codominant behaviour of 
the modifying gene(s), the F2(NIH/Ola x C57BI/6J/Ola) intercross animals were 
considered to be the most informative animals for genetic linkage analysis. 50 
polymorphic DNA markers were utilised to initiate a genome-wide search by 
screening 50 TGFB1(-/-) neonates from an F1 intercross. More than 90% of the 
genome was screened for modifying gene(s) during this study. Four regions of 
the genome showed suggestive linkage (P<0.05) in the first screen. To confirm 
the linkages, 30 extra null animals were screened with the interested markers. 
To study on some candidate genes which were not mapped on the mouse 
genome, Southern blotting technique was utilised to map these candidate 
genes. Also some other candidate genes mapped in the vicinity of the region 
meeting the criterion of definitive linkage were examined by applying reverse 
transcriptase PCR to study their expression in both yolk sacs and embryos (9.5 
dpc) from both NIH/Ola and C57BI/6J/Ola strains. To study the possibility of 
polymorphism in cDNA of one of the candidate genes (Fin13), heteroduplex 
analysis and sequencing techniques were employed.
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2: Materials and Methods
During this project, two different mouse strains; NIH/Ola and 
C57BI/6J/Ola were utilised. To breed the Tgfbl null allele onto either NIH/Ola 
or C57BI/6J/Ola genetic backgrounds, TGFB1(-/+) animals, which were mixture 
of three genetic backgrounds of 12.5% 129/Sv, 37.5% C57BI/6J/Ola, and 50% 
NIH/Ola strains were utilised (Dickson et al., 1995). These animals were bred 
through four generations by Mrs. Frances Cousins onto either inbred NIH/Ola 
or inbred C57BI/6J/Ola obtained from Harlan Olac Ltd., UK. In each generation, 
animals were genotyped for Tgfbl by performing polymerase chain reaction 
(PCR).
TGFB1(-/-) neonates used in this study were obtained from heterozygous x 
heterozygous matings [TGFB1(+/-) x TGFB1 (+/-)] of various combination of 
NIH/Ola and C57BI/6J/Ola genetic backgrounds. Neonates were killed by 
cervical dislocation prior to DNA extraction.
2.1 Mouse Husbandry:
For each line, the male mice were mated with females to obtain embryos 
9.5 days post coitum (dpc). Mice were housed in a conventional room (light 
5am - 7pm). For these animals, noon on the day the copulation plug was found 
was taken as 0.5 dpc.
Two different lines of mice were used in this study; NIH/Ola and C57BI/6J/Ola.
2.2 DNA extraction from tail tip biopsy:
1cm of tail was cut from a mouse (under general anaesthesia) or a 
neonate (killed prior to tail tipping) and placed in a 1.5ml autoclaved eppendorf 
tube which contained 0.7ml lysis buffer [100mM Tris-HCI pH 8.5, 5mM EDTA,
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0.2% sodium dodecyl sulphate (SDS), 200mM NaCI, and 0.1 mg/ml of freshly 
added Proteinase K]. The tube was incubated at 55-60°C in a water bath with 
agitation. Following complete lysis, the rack of tubes was shaken vigorously. 
The tube was then centrifuged in an eppendorf microcentrifuge at 14,000 rpm 
for 10 min. The supernatant was poured into a fresh 1.5ml autoclaved tube, 
and 0.7ml isopropanol added to the tube and mixed gently by inversion until 
precipitation was completed. The DNA was recovered by lifting the aggregated 
precipitate from the solution using a disposable yellow tip. Excess liquid was 
dabbed off and the DNA was dispersed in a sterile microfuge tube containing 
the required volume of 1 x TE buffer (10mM Tris-HCI, 1mM EDTA, pH8.0).
2.3 Screening animals for T g fb l:
2.3.1 Screening animals for Tgfb l by polymerase chain reaction (PCR):
Three primer sets [Table 2.1 (95-98, TGFO, and PGK-1)] were utilised to 
amplify the Tgfbl wild type and Neo (null) alleles (Figure 2.1). These primers 
(prepared within the Department) required a deprotection stage, to remove the 
oligonucleotide from the columns [0.2^m (standard) purchased from 
Cruachem)], 2ml of ammonia solution was pushed through the column using a 
small syringe and the eluant pooled. The tube was incubated overnight at 
55°C, and then the ammonia allowed to evaporate off in a fume hood. The 
concentration of the remaining primer solution was determined (ng/pl) by 
Spectrophotometer (Gene Quant II, Pharmacia Biotech) using Optical Density 
(260) (O D 26o x diluted times x 33) and the required concentration was obtained 
by dilution in TE buffer (10mM Tris-HCI, 1mM EDTA, pH 8.0). To amplify the 
Tgfbl wild type allele, 1pM from each of two primer sets (95-98), and to amplify 
the Tgfbl null allele, 1.3^iM from each of primer sets (TGF-0 and PGK-1) were 
added to the PCR solution containing 1x PCR buffer [(Cambio); 1.0M Tris-HCI 
pH 9.0 at 25°C, 0.4M ammonium sulphate], 0.6mM dNTPs, 1.5mM Mg2+, 150-
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Figure 2.1: Targeted disruption of murine Tgfbl gene in ES cells by 
homologous recombination.
Schematic representations of: a) the targeting vector, b) normal allele of Tgfbl, 
and c) targeted Tgfbl.
Solid boxes indicate Tgfbl exons, open boxes show introns and the 
promoterless region. Neo and TK (hatched boxes) when expressed confer drug 
resistance and sensitivity, respectively, thereby enabling selection of 
transformed cells.
A 0.56 kb sequence was deleted between Asp 718 (A) sites and the Neo 
cassette inserted.
The location of primers used for amplification of normal and targeted alleles are 
shown by arrows.
S; Sac/, H; Hindlll, B; Bglll, A; Asp.
200ng of genomic DNA, and 1 Unit Tf1 Thermostable DNA polymerase 
(Cambio) in a final volume of 25pl. The PCR reaction mixture was overlaid with 
50pl mineral oil to prevent evaporation of solution during the PCR procedure. 
The PCR was performed under the following conditions for 30 cycles; 94°C 
(denaturing) for 1 min, 63°C (annealing) for 1.5 min, and 72°C (extension) for 2 
min and it was terminated with 1 cycle 72°C (extension) for 10 min. By applying 
this protocol, animals were genotyped for both Tgfbl wild type and null alleles 
in a single combined PCR.
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Table 2.1 : The sequences of different primer sets utilised for amplification of
specific fragments of different genes screened during this project.
Name 5’.......3’ Sequence o f Set P rim e r P roduct
Leng th
A nnea ling
Tm .
FIN-A
FIN-B
723 ACAAACCAGAGGATGAAG 740 
1048 GGATGACAATAACCGAAG 1031 326 bp 54° C
TGF-A 706 CGC CAT CTA TGA GAA AAC 723 - -
TGF-B 1031 TCGCACAAGAGCAGT GAG 1014 326 bp 55°C
IGFR-A 1700 ACT GTC CTG AAG ATG CTG C 1718 - -
IGFR-B 2982 TTT CCG ATG CCT AAG ACC 2999 1300 bp 57°C
IGFR-C 6699 GCC CAA TGA CCA GCA TTT C 6717 - -
IGFR-D 7453 TCT CAC CCT CCC TTT CCT TC 7434 755 bp 61°C
FGFR-A 2046 GTA TTC ACA GAG ACT TGG C 2064 - -
FGFR-B 2254 GAC ACC AAA AGA CCA AAC 2237 209 bp 53°C
FGFR-C 299 AGT GCT TGT GTG TGC TGA GGT 319 - -
FGFR-D 418 AAC TTG TCC ACT CTT CCC CAG 438 139 bp 55°C
GDH-A
GDH-B
TGA GTA TGT CGT GGA GTC TAC 
GGC CAT GTA GGC CAT GAG GTC 720 bp 55°C
96 CGT GCG CCT GTC GCT TTC TG - -
97 GCG GAC TC TAT GCT AAA G - -
98 GGT CAC CCG CGT GCT AAT GG - -
95 GCG AGT AAG CCC ACT AGA G 625 bp 63°C
TGFO AGG GAG CTG GTG AAA CGG AA - -
PGK-1 TCC ATC TGC ACG AGA CTA GT 375 bp 63°C
FIN(A,B)> Fibroblast growth factor Inducible 13 (cDNA, EMBL Access No. Mmu42383); 
TGF(A,B), Transforming Growth Factor beta 1 (cDNA, EMBL Access No. M13177); 
IGFR(A,B,C,D), Insulin Like Growth Factor II Receptor(cDNA, EMBL Access No. 
MMU04710); FGFR(A,B), Fibroblast Growth Factor Receptor type lll(cDNA, EMBL 
Access No. MusMFR3); FGFR(C.D), A Microsatellite located on the intron 4 of FGFR3 
gene (EMBL Access No. Musfgfr05.gbn); GDH(A,B), GAPDH (cDNA); 95-98, 
Transforming Growth Factor beta 1 (Genomic DNA) Wild type allele; TGFO, PGK-1, 
Transforming Growth Factor beta 1 (Genomic DNA) Null allele.
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Table 2.2: The sequences of different primer sets utilised for the sequencing of
the FIN13 gene during this project.
Name 5’ .........3 ’ Sequence o f Set P rim e r P roduct
Leng th
A nnea ling
Tm .
FN1A
FN1C
FN1B
11 CGAGATAAAGACAAAGTAGCAG 32 
359 TCT TCA GCC TCT GAC AAG CT 378 
563 TCATCTCTTCATCATCATCC 544
(nested)
553 58°C
FN2A
FN2C
FN2B
539 GAAGAGGATGATGATGAAGAG 559 
711 TCT CCT ATG ACC ACA AAC 719 
1055 CCACAATGGATGACAATAAC1036
(nested)
517 56°C
FN3A
FN3C
FN3B
959 AATGTGATGAGCAAGCCAG 976 
1101 GTACAGGGTGTGACAACATGAC1122 
1481 TGAGCCCAAGGAGAGTAAG1463
(nested)
523 59°C
2.3.2 Detecting PCR products:
The PCR products were resolved by agarose gel electrophoresis. 10pl 
of the PCR product was mixed with 2y,\ of (6x) loading buffer [0.25% 
bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll (type 400; Pharmacia) 
in water] and loaded into the wells of a 1.5% agarose gel dissolved in either 1 x 
Tris-acetate/EDTA electrophoresis (TAE) buffer [0.04M Tris-acetate, 0.001 M 
EDTA, pH8.0] or 1 x Tris-borate/EDTA electrophoresis (TBE) buffer [0.045M 
Tris-borate, 0.001 M EDTA, pH8.0] containing 0.5pg/ml ethidium bromide. The 
gel was run in 1 x TAE or TBE buffer, at 100-120 Voltage for 30 min. The DNA 
bands were visualised under ultraviolet light and photographed by UVP 
Imagestore 5000.
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2.4 Screening animals for microsatellites:
2.4.1 PCR protocol for screening microsatellites:
The PCR was performed in a final volume of 22jj.I containing; 3.5mM 
Mg2+, 0.27mM dNTPs (dTTP, dATP, dCTP, dGTP), 1 x PCR buffer (Cambio), 1 
Unit Taq polymerase enzyme (Cambio), 1pM from each of primer sets (150 
primer sets used in this project were either from professor John Todd (Oxford) 
or professor Allan Balmain (Glasgow) or purchased from Genetic Research, or 
synthesised on an Applied Biosystems 391 DNA synthesiser within the 
Department), and 150-200ng of genomic DNA. The PCR reaction mixture was 
overlaid with 50jil mineral oil. The PCR was carried out under the following 
conditions with slight modifications for different primer sets: 94°C (denaturing) 
for 1 min; 55-60°C (annealing) for 1.5 min; 72°C (extension) for 1min. There 
were 30 amplification cycles and PCR was terminated with 1 cycle extension 
(72°C) for 10 min.
2.4.2 Detecting PCR products :
To screen the markers for polymorphisms between NIH/Ola and 
C57BI/6J/Ola strains, the PCR products were run on a 3-3.5% low-melting- 
point agarose (NuSivEVER GTG, 50082, FMC BioProducts). However, most of 
the polymorphisms were only detectable on a non-denaturing polyacrylamide 
gel [19/1 (40%) acrylamide/N-N’-methylenebisacrylamide, 1 x TAE buffer, 
0.7ml from 10% Ammonium persulphate,)] electrophoresis.
2.4.2.1 Casting 8% non-denaturing polyacrylamide gel:
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Polymerisation was initiated by the addition of 35pl of N,N,N’,N’- 
tetramethylethylenediamine(TEMED) to 100ml of 8% polyacrylamide solution. 
After polymerisation, which took about 1.5h, the comb was removed and the 
wells washed out with buffer and 10jal of the PCR product was mixed with (6x) 
loading buffer [0.25% bromophenol blue, 0.25% xylene cyanol FF, 15% Ficoll 
(type 400; Pharmacia) in water] and loaded into the wells. Electrophoresis 
occurred at 100V for 12h in 1 x TAE buffer.
2.4.2.2 Visualisation of DNA bands run on non-denaturing polyacrylamide 
gel electrophoresis:
DNA bands were visualised by applying a silver staining protocol. The 
gel was fixed for 10 min in fixation solution (10% ethanol, 0.5% Acetic Acid) 
then stained in 0.1% silver nitrate for 15 min with gentle shaking. To wash off 
extra silver nitrate, the gel was rinsed with two changes of distilled water. The 
gel was developed for 20 min with gentle shaking in 1.5% NaOH, and 0.1% 
Formaldehyde. DNA bands were stained light brown during this step. Staining 
was fixed for 10 min in 0.75% Na2C03 and the gel was wrapped in a plastic 
sheet and stored in a dark place.
2.5 DNA purification for probe prepration & subcloning:
2.5.1 Purification of PCR product:
To purify DNA band, the Geneclean Kit (1001-400, Bio 101 Inc) was 
used according to manufacturer’s protocol. To remove unincorporated 
nucleotides and primers from PCR solution, 3 volumes of 6M Nal and 20^1 of 
Glassmilk were added to the solution and incubated in room temperature with 
gentle shaking. The solution was briefly centrifuged at full speed for 15 sec to 
pellet the Glassmilk which was washed 3x with 400jj,I New Wash (2.5% New
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Wash, 50% Ethanol, 47.5% dH20, stored at -20°C). The Glassmilk was 
pelleted by brief centrifugation, the supernatant was removed and the pellet 
was dissolved in a required volume of TE buffer and incubated at 55°C in a 
water bath for 15 min. DNA was recovered by centrifugation in a 
microcentrifuge at full speed for 1 min and the supernatant containing the 
recovered DNA was transferred to a sterile microfuge tube and stored at -20°C 
until used. 1pl of DNA was tested on 1% agarose gel to check the efficiency of 
the recovery.
Alternatively to purify a PCR product, an equal volume of 3M ammonium 
acetate and 2 volumes of isopropanol alcohol was added to the PCR solution. 
The tube was quenched on ice for 10 min and DNA was precipitated by 
centrifugation at full speed for 10 min. The pellet was washed with 70% ethanol 
and dissolved in a required volume of TE buffer.
2.5.2 Purification of specific DNA band:
To purify a specific DNA band produced by either PCR or restriction 
enzyme digestion, the solution was run on 1% low-melting-point agarose 
(NuSivEVER GTG, FMC BioRroducts) dissolved in TAE buffer. The specific 
DNA band was excised under UV (ultraviolet) light and placed in an eppendorf 
tube containing 3 volumes of 6M Nal. The tube was incubated for 5 min at 55°C 
on a water bath with agitation to dissolve the agarose gel covering the DNA 
band. 20pl of the Glassmilk was added to the tube and the purification 
continued as described before.
2.6 Southern blotting:
2.6.1 Digestion of genomic DNA:
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7 to 10|ag of genomic DNA was digested using the appropriate restriction 
endonuclease in a total volume of 40|xl containing 1 x appropriate enzyme 
buffer (Gibco BRL) and 40 units of the specific enzyme (Gibco BRL). The 
digests were incubated for 12-16 h in a water bath set at the recommended 
temperature.
2.6.2 Agarose gel electrophoresis:
The DNA digests were resolved using a 20cm 0.8% agarose gel (FMC 
bioproducts) prepared in 1 x TAE buffer and containing 0.5pg/ml ethidium 
bromide. Samples were prepared by adding 8pl of (6x) agarose gel loading 
buffer to the 40pl digest. Samples were then loaded alongside 1 kb size ladder 
in the gel and electrophoresed at 2 Volts/cm for 18 h. After electrophoresis the 
gel was visualised and photographed alongside a scale for reference under UV 
light. The gel was treated with depuration solution (0.25M HCI) for 10-15 min, 
rinsed in tap water, and then in denaturation solution (0.5M NaOH, 1.5M NaCI) 
for 30 min. After rinsing the gel in tap water, the gel was neutralised in 
neutralisation solution (3M NaCI, 0.5M Tris-HCI, pH7.4) for 30 min.
2.6.3 Southern blotting:
The apparatus was set up as described for Northern blotting (2.12.2).
2.6.4 Probe labelling:
The probe was radioactively labelled using the random primed DNA 
labelling kit (1004 760, Boehringer Mannheim, ) according to the manufacturer 
protocol. 80-1 OOng of the probe was added to a mix of 2pl each of dATP, 
dGTP, and dTTP, 4pl of the reaction mix. The mixture was boiled for 5 min and
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quenched on ice, then 5pl (50pCi) of a-32P dCTP (Amersham), 2pl of Klenow 
enzyme, and up to 40pl dH20 were added and mixed by pipetting. The tube was 
then incubated at 37°C for one h and then the reaction was stopped by addition 
of 2(0.1 of 0.5M EDTA. To separate un-incorporated nucleotides from probe, Nick 
Columns Sephadex G-50 (Pharmacia Biotech) was utilised. The column was 
washed through with 2ml TE buffer. Then the sample was loaded and was 
washed through by adding 400pl TE buffer. A second 400pl aliquot of TE buffer 
was loaded and the elutant pooled. 2 pi of the solution was removed to 
determine the specific activity of the probe using a Texas Instruments 
scintillation counter. If the counting was found to be less than 108cpm/pg, the 
probe was discarded (the required counting was 3 x 107cpm/each 
hybridisation). Immediately before use, the probe was boiled at 100°C for 10 
min to denature the DNA, then quenched on ice.
2.6.5 Southern blot Hybridisation:
QUIKHYBr Hybridisation solution (201220, Stratagene) was utilised as a 
pre-hybridisation and hybridisation solution according to the manufacturer’s 
protocol. The Hybond N filter and a fine mesh were soaked in tap water before 
rolling together and placing in a hybridisation bottle with 10-15mls of the QuickR 
hybridisation solution. The bottle was incubated at 65°C for 15 min in an oven. 
The radioactive probe and salmon sperm DNA in a final concentration of 
100pg/ml, were mixed and boiled for 10 min. The tube was quenched on ice for 
5 min and added at 3 x 107cpm (per each hybridisation) to the QuickR 
hybridisation solution. The hybridisation was continued at 65°C for 1 h.
2.6.6 Washing the filter after hybridisation:
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After hybridisation, the hybridisation buffer was discarded and the filter 
was rinsed in 2 x SSC [Standard Saline Citrate (20 x SSC: 3M NaCI, 300mM 
Na citrate, pH7.4)], 0.1% SDS while inside the bottle. The filter was washed 
once by adding 10ml of 2 x SSC, 0.1% SDS to the bottle and returning it to the 
65°C oven for 5-10 min. The filter was then taken out from the bottle and 
placed in a plastic tray with 0.5 x SSC, 0.1% SDS and washed by shaking at 
65°C for a further 5 min. The filter was monitored using a series 900 mini­
monitor and if a signal greater than 10-15cpm was detected, it was then 
washed at increasing stringency (65°C, 0.25 x SSC, 0.1% SDS) taking care not 
to over wash it.
2.6.7 Autoradiography:
The filter was exposed to a Kodak X-Omat autoradiographic film plus 
intensifying screens, and placed at -70°C. The time period before the film was 
developed depended on the signal counted by last monitoring.
2.6.8 Developing the X-Ray film:
The film was developed by using Fuji X-Ray Film Processor.
2.7 Chemical Cleavage of Mismatches (CCM):
To study the possibility of strain specific polymorphisms within the PCR 
products from Igf2r cDNA, the CCM method described by Cotton et al (1988) 
was used with some modifications. In this technique, DNA from one of the 
strains was allowed to form a duplex with a radiolabelled DNA from other strain 
(probe). Where mutations (polymorphism) were present, mismatches were
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chemically modified and cleaved leading to detection of different-sized 
radioactive fragments. The protocol involved the following steps:
2.7.1 Preparation of test DNA
2.7.1.1 RT-PCRand DNA-PCR
Two RT-PCR segments (1.3 kb + 0.755 kb) amplified from the Igf2r 
cDNA (7.448 kb coding sequence, EMBL Access No. MMU04710) using two 
sets of primers (Table 2.1) and the method mentioned in 2.10.2. The PCR 
amplification was accomplished in a 50^1 reaction mix using standard PCR 
protocol (2.10.2) with 30 cycles and a final 5 min extension step at 72°C.
2.7.1.2 Identification of PCR products
10jil aliquots from the PCR products were electrophoresed on 1% 
agarose gels in 1 x TAE buffer with 0.5ng/ml ethidium bromide. They were 
visualised with a UV transilluminator to confirm the size of the band. The 
remaining 40jxl PCR products were cleaned (2.5) for use in CCM.
2.7.1.3 Preparation of labelled probes:
A probe is a PCR product obtained from one of the strain’s DNA taken 
as a control (NIH/Ola or C57BI/6J/Ola). Internal labelling of the PCR was 
carried out by direct incorporation 2pCi [a-32P] dCTP in the PCR reaction mix. 
PCR was carried out in 50pl reaction mix using standard PCR conditions as for 
the non-radiolabelled one. The labelled probe was purified (2.5) and its specific 
activity was determined (approximately 107cpm/pg).
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Alternatively, 5’ end labelling of the probe was performed by mixing 
100ng of the probe DNA (after Geneclean™ purification), 10jiCi [y-32P] ATP, 1 x 
One-Phor-AII buffer plus (10x .Pharmacia Biotech, 100mM Tris-acetate, 
100mM Magnesium acetate, 500mM potassium acetate), 10 Units of T4 
polynucleotide kinase FPLC pure (Pharmacia Biotech) and up to 10pl ddH20. 
The mixture was incubated at 37°C for 45 min then stored at -20°C until used.
2.7.2 Formation of hybrids (heteroduplexes):
To minimise the formation of probe homoduplexes, hybridisation 
between probe and target was set up in which the target DNA was present in
10 to 20 fold molar excess over probe DNA. Approximately 5ng of probe DNA 
per target sample per modification reaction was required. 9 volumes of the 
solution containing [1 x hybrid buffer (0.3M NaCI, 0.1M Tris-HCI, pH8.0) and 
the appropriate quantity («10 ng/test DNA sample) of labelled probe in T0.iE 
buffer (10mM Tris-HCI, pH7.4, 0.1 mM EDTA)] was added to one volume of test 
DNA ( 100-150ng) in a sterile eppendorf tube (1.5ml), topped with 50pil mineral
011 and then placed in a boiling water bath for 5 min. Immediately, after boiling, 
the tube was incubated at 65°C in a water bath for 5-16 h to allow hybrid 
formation to occur. The tube was then quenched on ice and the aqueous phase 
(containing the hybrids) was divided equally between two siliconized eppendorf 
tubes containing 3|j.l of 20mg/ml glycogen (Boehringer-Mannheim) and 750jj.I of 
the stop/precipitation mix (63mM Na acetate, 20jiM EDTA, 80% ethanol). The 
tube was vortexed for 1 min prior to incubation on dry-ice for 10 min. By 
centrifugating the solution at 14000 rpm for 10 min, DNA was pelleted which 
was then washed in 70% ethanol, air dried and resuspended in 7jil T0 .1E buffer. 
The samples were used the same day.
2.7.3 Mismatch analysis
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2.7.3.1 Chemical modification using Hydroxylamine and Osmium 
tetroxide.
20|xl of 6.5M hydroxylamine hydrochloride (Sigma) [(Hydroxylamine; 
1.39g, ddH20  1.6ml , Diethylamine (BDH, 10341) (approx. 1.5ml) until pH 6 , 
stored at 4°C up to one week)] was added to 7jil hybrid (2.7.2), mixed well and 
incubated at 37°C for 2 h. 18pl of freshly made solution of osmium tetroxide 
(Aldrich, 25,175-5) and pyridine (BDH, AnalaR 10225 4L) [ 6.75pl pyridine, 
1.5pl of 4% osmium tetroxide, and 154|il T0.iE buffer, prepared on ice] was 
added to the 7pl hybrid (2.7.2), mixed well and incubated at 37°C for 2 h. 
Modification reactions were stopped and precipitated by adding 750pl 
stop/precipitation solution to each tube, mixed well and quenched on dry ice 
for 10 min. DNAs were pelleted by centrifugation at 14000 rpm for 10 min, then 
washed in 70% ethanol and air dried.
2.7.3.2 Piperidine cleavage of the chemically modified mismatches:
The air-dried pellets (2.7.3.1) were resuspended in 50pl of 1M freshly 
made piperidine (Fluka, 80640) by vortexing, and incubated at 90°C in a water 
bath for 30 min. The tubes were quenched on ice and precipitated by addition 
of 750pl stop/precipitation solution as described before. The pellets were then 
washed in 70% ethanol, air dried, resuspended in 10pl formamide loading 
buffer (95% deionized formamide, 10mM EDTA, 10mg/ml bromophenol blue 
and 10mg/ml xylene cyanol) and denatured by heating at 95°C for 5 min prior 
to run in 6% denaturing polyacrylamide gel (1 x TEA buffer, 6% polyacylamide, 
7M urea (25.2 gr/60 ml of 6% polyacrylamide solution), amonium persulfate 
0.7%, TEMED) cast in a sequencing gel apparatus. The gel was 
electrophoresed at 2000 volts for appropriate time (depending on the size of 
DNA band examined). Then it was transferred onto a 3 MM Whatman paper,
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covered with Saran nylon, dried in a vacuum gel dryer, and exposed to Kodak 
X-Omat AR film using a cassette with intensifying screens for 12 to 16 h at - 
40°C.
2.8 Heteroduplex Analysis:
Several mutation scanning methods have been developed. Heteroduplex 
analysis is used to detect mismatches between double-stranded DNA 
containing one wild type strand and a complementary strand with an altered 
nucleotide sequence. Heteroduplex analysis is simple to perform; does not 
require complex chemical or temperature gradient; and bands can be generally 
be detected without radioactive labels. During this protocol, PCR products of a 
test sample and a wild type control are mixed, heated to denature the double­
stranded DNA (dsDNA), and allowed to reanneal at a lower temperature. If the 
primary sequence of the sample and control differ, 50% of the reannealing 
dsDNA will be heteroduplex DNA.
2.8.1 Denaturing double stranded DNA fragments:
Two PCR products (amplified by utilising either of three set primers 
presented in the table 2.2) from Fin13 gene originated from NIH/Ola and 
C57BI/6J/Ola strains were mixed in 1:1 ratio. The mixture was overlaid by 
mineral oil and denatured by heating at 95°C for 5 min.
2.8.2 Re-annealing:
The denatured mixture (2.8.1) was allowed to cool down from 95°C to 
35°C over a period of 30 min.
2.8.3 MDE gel preparation & electrophoresis condition:
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The MDE (Mutation Detection Enhancement) gel (Flowgen) was utilised 
to detect the possible heteroduplex DNA bands. 1x MDE gel (1x MDE, 0.6x 
TBE, Urea 15g/100ml of solution, 0.7% ammonium persulphate, TEMED) was 
prepared and electrophoresed (20 V/cm) in non-denaturing conditions.
2.8.4 Silver staining:
DNA bands were visualised by applying the silver staining protocol as 
described previously (2.4.2.2).
2.9 Sequencing:
2.9.1 Sequencing cDNA
Direct sequencing of the Fin13 cDNA was carried out using the dideoxy 
chain terminating method (Sanger et a!., 1977) using the Sequenase™ Version 
2.0 sequencing kit (Amersham).
2.9.1.1 RT-PCR
RT-PCR was carried out to amplify Fin13 cDNA by utilising the primer 
sets (table 2.2) as described in section 2.12.
2.9.1.2 Asymmetric PCR:
Single-stranded templates required for sequencing were generated by 
asymmetric PCR. 10^1 of the gel-eluted double-stranded PCR product was 
used as a template for asymmetric PCR, where one primer was 50 to 100 times 
less concentrated than the other (2jaM) in a total volume of 50pl. The other
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components were the same as for symmetric PCR but the number of cycles 
was increased to 40 to 45 cycles as there is a linear increase in the amount of 
PCR products due to the limiting concentration of one primer. The asymmetric 
PCR product yield was monitored by agarose gel electrophoresis as described 
previously (2.3.2).
The asymmetric PCR products were purified by adding an equal volume of 4M 
ammonium acetate and 2 volumes of isopropanol. The mixture was incubated 
at room temprature for 10 min, centrifuged at full speed for 10 min in a 
microcentrifuge, washed in 70% ethanol and resuspended in 7pl of dH20.
2.9.1.3 Sequencing reaction protocol:
Sequencing was performed according to the manifacturer’s instructions. 
7\xI of the single-stranded template was mixed with 2pl of 5x Sequenase™ 
reaction buffer (to give a final concentration of 40mM Tris-HCI pH 7.5, 20mM 
MgCI2, 50mM NaCI) and 1pmol of the appropriate sequencing primer (the 
primer diluted 50 to 100 times during asymmetric PCR).
2.9.1.3.1 Denaturing double-stranded templates & annelaing:
The mixture (2.9.1.3) was denatured by incubating at 65°C for 2 min and 
then allowed to cool slowly to less than 35°C over a period of 30 min.
2.9.1.3.2 Labeling reaction:
The mixture was then immediately placed on ice and to it was added 1 pi 
of 0.1 M DTT, 2pl of a 1:5 dilution of labelling mix (7.5pM of each dNTP except 
dATP), 0.5jj.I of [a-35S]dATP (1000 Ci/mmol), 1^ 1 of Mn buffer (0.15M sodium 
isocitrate, 0.1M MnCI2) if sequences close to the primer are to be read, and 2pl
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(1.5 units) of a 1:8 dilution of T7 DNA polymerase [25pl of Sequenase™ 
Version 2.0, 13 units/fxl; diulted with 25pl of inorganic pyrophosphatase (5 
units/ml in 10mM Tris-HCI pH 7.5, 0.1 mM EDTA, 50% glycrol) and 150pl of 
glycrol enzyme diultion buffer (20mM Tris-HCI pH 7.5, 2mM DTT, 0.1 mM 
EDTA, 50% glycerol)]. The mixture was incubated at room temprature for 2 to 5 
min.
2.9.1.3.3 Termination reaction:
While cooling (during section 2.9.1.3.1), four tubes (for each of the 
termination mixtuers) for each sample were labelled, 2.5^1 of each termination 
mixture (contating 80pM of each dNTP and 8pM of each ddNTP) was 
transferred to the appropriate tube and pre-warmed at 42°C. 3.5pl of labeling 
mixture from section 2.9.1.3.3 was added to each termination mix at 42°C and 
incubated at 42°C for a further 5 min after which 4pl of formamide-dye stop 
solution (95% formamide, 2mM EDTA, 0.05% bromophenol blue, 0.05% xylene 
cyanol FF) was added to terminate the reaction. The reaction could be stored 
at -20°C until required.
2.9.1.4 Denaturing gel electrophoresis:
2.9.1.4.1 Gel electrophoresis reagents and running conditions:
Because the Sequenase™ enzyme was diluted in glycerol-containing 
buffer, the buffer used in the polyacrylamide gel should be a glycerol tolerant 
gel buffer (20x TTE: 216g Tris base, 72g taurine, 4g Na2EDTA.2H20  and made 
up to 1 lit.). The gel used to run the sequencing reactions was an 8% 
denaturing polyacrylamide gel (8% polyacrylamide, 1x TTE buffer, 7M (( 
25.2g/100ml» Urea, 0.7% ammonium persulphate, TEMED). The gel was pre­
warmed to 50°C before samples denatured for 5min at 75°C to be loaded. The
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gel was electrophoresed at 50°C for 2 to 4 hours, after which it was transferred 
onto a 3MM paper, dried in a vaccum gel drier (Bio-Rad) at 80°C for at least 
30min and exposed for 16 to 24 hours to KODAK X-Omat AR film in a cassette 
using intensifying screens at -20°C.
2.9.2 Sequencing plasmid (insertion):
To sequence the PCR product inserted in a vector (described in section 
2.10.2), the plasmid was extracted as described in section 2.10.1.4.
2.9.2.1 Denaturing:
4|ig of plasmid disolved in 20jil dH20  was denatured by adding 2|il of 
denaturing solution (2M NaOH, 2mM EDTA) and incubated 5 min at room 
temperature.
2.9.2.2 Neutralisation:
The reaction from 2.9.2.1 was neutralised by adding 3jil 3M sodium 
acetate (pH 5.5) and 7jil dH20.
In order to precipitate DNA, 75pl of 100% ethanol was added and the mixture 
was incubated on dry ice for 5 min. The DNA was precipitated by centrifugation 
in a microcentrifuge for 5 min at a full speed. The supernatant was discarded 
and the pellet was washed with 70% ethanol, then dried and dissolved in 7pl 
dH20.
2.9.2.3 Annealing, labeling & termination:
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The annealing, labelling and termination procedure was carried out as
described previuosly (2.9.1).
2.10 Subcloning:
During this project two fragments were subcloned. A small fragment of 
Fgfr3 probe already cloned on a plasmid was subcloned for the purpose of 
expression studies. Also a RT-PCR product (523bp, 959-1481) from Fin13 
gene was subcloned into a plasmid for the purpose of expression studies.
2.10.1 Subcloning plasmid:
2.10.1.1 Ligation:
The plasmid DNA (MomFgfr3,Ornitz et al., 1992) and the pBluescript 
SK(+/-) phagemid were separately linearized by digestion with two different 
restriction enzymes (Hindlll and Xhol) and run on 1% agarose gel alongside a 
marker. The appropriate bands were excised, purified (as described previously, 
2.5) and dissolved in an appropriate volume of TE buffer to give 20-50ng/pl.
The ligation was initiated by addition of insert DNA and vector DNA in a 9:1 
(weight: weight) excess to vector DNA, to ligation buffer (Gibco-BRL, 250mM 
Tris-HCI pH7.6, 50mM MgCI2, 5mM ATP, 5mM DTT, 25%(w/v) polyethylene 
glycol-8000) and 1pl of T4 DNA ligase (Gibco-BRL) to give a final volume of 
10^1. The solution was incubated at 16°C for 12-16 h. Control ligations; ligation 
mixture without insert DNA, ligation mixture without plasmid, and ligation 
mixture without enzyme were also carried out simultaneously.
Half of the ligation mixture was used for transformation.
2.10.1.2 Preparation of competent bacterial cells:
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DH5a bacteria cells (Gibco BRL) were used to generate competent 
bacterial cells during this project. The bacterial cells were inoculated from a 
glycerol stock into a 5ml of L Broth [1% bacto-tryptone (0123-17-3, DIFCO), 1% 
NaCI, 0.5% bacto-yeast extract (0127-17-9, DIFCO), pH7.0 adjusted by NaOH, 
autoclaved) and incubated at 37°C for 12-16 h with shaking (200 rpm). 1ml of 
the over/night culture was inoculated into 100ml LB medium and incubated for 
3 hours at 37°C with shaking (200 rpm).The cells were pelleted in a 30-ml 
sterile tube by centrifugation at 1500 rpm for 10 min at 4°C, resuspended in 1 ml 
filtered CaCI2 (100mM), and quenched on ice for 15 min. The solution was 
recentrifuged at 1500 rpm for 10 min at 4°C, the supernatant was removed and 
the pellet was resuspended in 1ml filtered CaCI2 (100mM). These cells 
(competent cells) were used for transformation and could be stored at -70°C 
until required.
2.10.1.3 Transformation:
Transformation was initiated by adding 10pl of plasmid DNA (0.5pg/pl) to 
a sterile (1.5ml) eppendorf tube containing 100pl of competent bacteria cells. 
The bacterial cells were incubated on ice for 30 min, heat-shocked at 42°C for 
90 sec, and quenched on ice for 30 min. 0.5 ml sterile L broth was added to the 
tube prior to incubate at 37°C for 50 min with shaking (200 rpm). 10-20pl of the 
solution was plated out onto L-agar plate (1% bacto tryptone, 1% NaCI, 0.5% 
bacto yeast extract, 1.5% agar, pH7.0), containing 20pg/ml appropriate 
antibiotic. 0.02% of X-gal (Gibco BRL, 5-bromo-4-chloro-3-indoyl-p-D- 
galactoside dissolved in dimethylformamide) was also added onto L-agar 
media when pBluescript SK(+/-) was used as a vector. The colonies of bacteria 
harbouring pBluescript SK(+/-) plasmid, produce blue colour in the presence of 
X-gal, whereas pBluescript SK disrupted by a insert DNA, was unable to 
produce blue coloured colonies.
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The plates were incubated at 37°C for 16 h in an inverted position.
2.10.1.4 Harvesting and lysis of Bacteria:
A single appropriate bacterial colony was transferred into 2ml of LB 
medium containing the appropriate antibiotic in 15-ml sterile tube and 
incubated at 37°C for 12-16 h with vigorous shaking. By centrifugating the 
solution at 12000 rpm for 30 sec at 4°C the bacterial cells were pelleted and 
were then resuspended in 300pl ice-cold STET (0.1M NaCI, 10mM Tris-HCI, 
1mM EDTA, pH8.0) and re-centrifuged for 15 min at 4000 rpm at 4°C. The 
pellet was resuspended in 40jil of ice-cold solution I (50mM Glucose, 10mM 
EDTA, 25mM Tris pH8.0, autoclaved, 10mg/ml freshly added of lysosome) 
followed by an addition of 120pl of freshly prepared solution II (0.2M NaOH, 1% 
SDS). The tube was gently inverted for several times and incubated for 5-10 
min at room temperature (R/T). 70jil of ice-cold solution III (3 M KOAC) was 
added to the tube prior to incubatation on ice for 10 min. The solution was 
centrifuged at 4000 rpm for 15 min at 4°C and the supernatant containing the 
plasmid DNA was filtered through gauze, mixed with 60% volume of 
isopropanol and stored at R/T for 10 min. By centrifugation for 15 min at 5000 
rpm at R/T, the DNA was pelleted which was then washed with 70% ethanol, 
and dissolved in an appropriate volume of 1 x TE buffer (pH 8) containing 
20jig/ml of DNase-free pancreatic RNase (R-4875, Sigma) (Pancreatic RNase 
was dissolved at a concentration of 10mg/ml in 10mM Tris-HCI (pH7.5), 15mM 
NaCI, and heated to 100°C for 15 min and allowed to cool slowly to room 
temperature and stored at -20°C). The plasmid DNA was stored at -20°C until 
required.
2.10.1.5 Confriming the insertion:
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To confirm that the desired fragment was inserted, the vector was cut 
with appropriate restriction enzymes and run on an agarose gel to observe the 
expected bands. Also this approach enabled to find out the direction of 
insertion in vector for the expression purposes.
2.10.2 Subcloning PCR product:
In all PCRs set up during this project, Tf1 thermostable DNA polymerase 
(Cambio) was utilised which resulted in adding an extra A in 3’ end of PCR 
products. Therefore, in order to clone PCR product, the pGEM easy vector 
system (Promega, A1360) was utilised. The vector supplied in this kit contained 
a 3’ terminal thymidine in both ends which could ligate with the PCR products 
but not with each other.
2.10.2.1 PCR product:
The RT-PCR product (523 bp; 959-1481) amplified from Fin13 gene by 
utilizing FN3 (A & B) set primers (table 2.2) was run on 1% low melting agarose 
gel. The expected fragment was cut and cleaned as previously described 
(2.5.2).
2.10.2.2 Ligation:
The appropriate amount of PCR product (25ng) was added to the 
ligation reaction [50ng vector, 1 x T4 DNA Ligase buffer, T4 DNA Ligase (3 
Weiss units/pl)]. The reaction was mixed by pipetting and incubated at 4°C 
overnight.
2.10.2.3 Transfromation & Harvesting and lysis of Bacteria:
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Transformation & harvesting and lysis of bacteria was carried out as
described previously (2 .10 .1 .3 -4 )
2.10.2.4 Confirming the insertion by applying PCR and sequencing:
In order to confirm the insertion in the vector, a PCR reaction (as 
described in 2.12.2) was set up and 3pl of the plasmid was used as a template. 
The expected size band (523bp) was observed.
Also applying the sequencing technique described in (2.10.2) confirmed that 
the expected PCR product was inserted.
2.11 RNA Analysis:
2.11.1 Collection of embryos for RNA extraction:
All tips, eppendorfs, and solutions (except those containing Tris, or 
organic solvents) were treated with 0.1% diethylpyrocarbonate (DEPC) for at 
least 12 hours at 37°C before sterilisation to prevent the degradation of the 
RNA by RNase (DEPC suspected to be a carcinogen and should be handled 
with care).
Pregnant females from timed matings were killed by cervical dislocation, 
and a vertical incision made through the body wall, enabling the uterus to be 
removed. Decidua were dissected from the uterus, placed 3-4 per dishes 
containing ice-cold, m i 11 i pore-f i Itered Phosphate Buffered Saline (PBS) (130mM 
NaCI, 7mM Na2HP04, 3mM NaH2P04l pH7.2) and visualised using an Olympus 
SZH stereo microscope. The embryos were removed from their decidua using 
sterile watchmakers forceps. The RNA was extracted separately from the yolk 
sac and embryo. When dissected free of contaminating material, the tissues
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were placed in sterile eppendorfs and snap-frozen in liquid nitrogen, then 
stored at -70°C until required.
2.11.2 Extraction of RNA from embryos and yolk sacs:
To extract the total RNA from 9.5 dpc embryos and yolk sacs, two 
methods were utilised as follow:
1) The method described by Chomczynski and Sacchi (1987) with slight 
modifications.
2) The method described by TRIzol™ Reagent manufacturer (Life 
Technologies).
2.11.2.1 The acid quanidinium thiocyanate phenol/chloroform extraction:
Before proceeding with RNA extraction, embryo and yolk sac were 
thawed on ice. 550jj.I of solution D [4mM guanidinium thiocyanate (50980, 
Fluka Biochemika), 25mM Sodium citrate pH7.0, 0.5% lauryl sarkosyl (Sigma) 
and freshly added 0.1 mM p-mercaptoethanol (sigma)] was added to each tube 
and the disaggregation of the tissue aided by pipetting. 25jil 2M Sodium citrate 
pH4.0, 200jil water-saturated phenol, and 55jj.I chloroform were added 
separately with gentle mixing after each reagent. Once all three solutions were 
added, the tubes were vortexed for 10 sec before incubation on ice for 15 min. 
The samples were then microcentrifuged for 20 min at 14000 rpm at 4°C in a 
microcentrifuge. The top aqueous layer was transferred to a fresh 1.5ml 
eppendorf and 700jil of isopropanol added. The solution was gently mixed and 
placed at -20°C for at least 1 h to precipitate the RNA. The RNA was pelleted 
by microcentrifugation at 14000 rpm for 20 min at 4C°, and the supernatant was 
dabbed off. The pellet was redissolved in 100|il solution D, and an equal 
volume of isopropanol added before a further precipitation at -20°C for at least
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an hour. The tubes were centrifuged for 10 min at 14000 rpm at 4°C to pellet 
the RNA, which was then washed 2 x in 70% ethanol, air-dried and 
resuspended in 5-1 Opil of DEPC-treated water and stored at -70°C until 
required.
2.11.2.2 TRIzol™ Reagent extraction:
TRIzol™ Reagent (15596-026, Life Technologies) is a ready-to-use 
reagent for isolation of total RNA from cells and tissues. The reagent, a mono- 
phasic solution of phenol and guanidine isothiocyanate, is used as a 
modification to the single-step RNA isolation method developed by 
Chomczynski and Sacchi (1987). Before proceeding with RNA extraction, 
embryo and yolk sac were thawed on ice. To homogenize tissue samples, 1ml 
of TRIzol™ reagent was added per 50-1 OOmg of tissue and the disaggregation 
of the tissue aided by pipetting. The homogenised samples were incubated for 
5 min at room temperature (R/T) to permit the complete dissociation of 
nucleoprotein complexes. 20% of the initial used volume of TRIzol™ reagent, 
chloroform was added to the tubes. The tubes were vigorously shaked for 15 
sec prior to incubate at R/T for 2-3 min. The tubes were centrifuged in a 
microcentrifuge at not more than 12000 g for 10 min at 4°C to pellet the RNA 
which was washed once with 75% ethanol then dissolved in 5-20pl of DEPC- 
treated water and stored at -70°C until required.
2.11.3 Determination of RNA concentration:
To determine the concentration of the RNA samples, an optical density 
(OD) reading at 260nm, using a dual beam spectrophotometer, was utilised. An 
O.D. reading of 1 corresponds to 40pg/ml of the RNA. The integrity of the RNA
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was assessed by comparing the ratio of O.D. at 260/280nm. A good quality 
preparation should give a value of 2.
2.11.4 Qualitative assessment of the RNA:
The quality of the RNA was detected by running 1pl of the RNA on 1% 
denaturing agarose gel containing 16.6% formaldehyde and 1 x MOPS (10 x 
MOPS; 200mM MOPS Sodium salt, 50mM Sodium Acetate, 10mM EDTA, 
pH7.0). 50% formamide, 2.2M formaldehyde, and 1 x MOPS was added to 5[i\ 
of RNA (1|il RNA + 4(il ddH20) to a total volume of 10jil, and incubated at 55- 
60°C for 10 min before quenching on ice. 1jil of loading buffer (50% glycerol, 
1 mM EDTA pH8.0, 0.25% bromophenol blue, 0.25% xylene cyanol) was added 
to the sample and loaded into the wells. Electrophoresis occurred at 50-100 V 
for 1-2 h in 1 x MOPS.
To visualise ribosomal RNA under UV light, the gel was immersed in distilled 
water for 10 min to wash out the formaldehyde and stained for 5 min in 5pg/ml 
solution of ethidium bromide. The gel was de-stained in water for 2 to 12 h and 
viewed under the UV light to check the integrity of ribosomal RNA bands.
2.12 Amplification of specific mRNA by reverse-transcription (RT)-PCR:
2.12.1 Reverse Transcription (RT) from RNA to cDNA:
To synthesise first strand cDNA from total RNA, the Superscript™ kit 
(18089-011 Gibco BRL) pre-amplification was utilised according to the 
manufacturer’s protocol. 5jig RNA (total RNA extracted from embryo or yolk sac
9.5 dpc) was combined with 1pil oligo(dT) (0.5ng/pl) to a total volume of 12pl 
DEPC treated H20, and incubated at 70°C for 10 min and quenched on ice for 
at least 1 min. 8jil of a solution containing; 1 x PCR buffer (10 x; 200mM Tris- 
HCI pH8.4, 500mM KCI), 2.5mM Mg2*, 0.5mM dNTPs, and 10mM DDT was
62
added to the tube and incubated at 42°C for 5 min, followed by addition of 200 
units Superscript II RT (200 units/pl). The RT reaction was initiated by 
incubation at 42°C for 50 min and terminated by heating at 70°C for 15 min. To 
remove RNA, 1 pi of RNase H was added to the tube, incubated at 37°C for 20 
min, and stored at -70°C until use.
2.12.2 Amplification of target cDNA (PCR):
PCR was initiated by addition of 1pl cDNA product from RT (2.12.1) to a 
fresh microeppendorf tube containing; 1 x PCR buffer (Cambio), 1.5mM Mg+2, 
0.2mM dNTPs, 0.5pM of each primer sets, and 2 units Taq DNA polymerase in 
a final volume of 50pl. The PCR solution was overlaid by 50pl mineral oil and 
the PCR was performed 25 cycles of: 94°C (denaturing) for 1 min, 53-61 °C 
(annealing) (Table 2.1) for 1-2 min, and 72°C (extension) for 2 min. The PCR 
reaction was terminated with 1 cycle 72°C extension for 5 min.
And the PCR products were detected on an agarose gel.
2.13 Northern analysis:
During this project, Northern blotting was utilised to study the expression 
of lgf2r gene in 9.5 dpc embryos bred onto either NIH/Ola or C57BI/6J/Ola 
strains. 9.5 dpc embryos were dissected and then snap-frozen in liquid 
Nitrogen. The total RNA was extracted as described before (2.11.3).
2.13.1 RNA gel electrophoresis:
8-1 Opg of the total RNA extracted from embryos was run alongside a 1 kb 
size marker in 0.8% denaturing agarose gel in circulating 1 x MOPS at 50-60V 
for 12 h as described before (2.11.5).
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2.13.2 Northern Blotting:
The gel was washed for 20-30 min in Milli-Q-water with 2-3 changes to 
wash out the formaldehyde. The marker lane was cut off and stained for 10 min 
in 1.5jig/ml ethidium bromide before de-staining in Milli-Q-water for 2-16 hours. 
The marker was then viewed on a UV transilluminator and photographed 
alongside a scale for reference. The rest of the gel was placed on a piece of 10 
x Standard Saline Citrate (SSC) (20 x SSC; 3M NaCI, 300mM Na citrate, 
pH7.4) soaked 3 MM Whatman paper, which was acting as a wick to a 
reservoir of 10 x SSC. Hybond N paper was cut to the size of the gel and 
placed on top, and any trapped air bubbles smoothed out. Two pieces of dry 3 
MM Whatman paper were placed on top of the Hybond N, and the area 
surrounding the gel was sealed with clingfilm. This was to prevent the 
evaporation of the 10 x SSC reservoir, and to ensure its passage only through 
the gel. A stack of paper towels were placed on top of the dry Whatman paper, 
followed by a small weight (1kg). The blot was left overnight, and the following 
day the RNA was fixed on to the filter by UV irradiation for 4 min. The filter was 
wrapped in clingfilm and stored at 4°C until use.
2.13.3 Probe labelling:
80-1 OOng of probe was labelled and cleaned by using Nick™ column as 
described before (2.6.4).
2.13.4 Northern Hybridisation:
The Hybond N filter and a fine mesh were soaked in 2 x SSC before 
rolling together and placing in a hybridisation bottle with 10-15mls of pre­
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hybridisation buffer [5 x SSC, 1 x Denharts [0.02% Ficoll, 0.02% 
polyvinylpyrrolidone, 0.02% BSA (Bovine Serum Albumin, RNase/DNase free, 
27-8914-02 Pharmacia Biotech)], 50% formamide, 0.5% SDS, 100jag/ml 
Salmon Sperm DNA] depending on the size of the filter. Incubation occured for 
3-5 hours at 42°C. The radioactive probe was denatured and added at 3 x 
107cmp to the hybridisation buffer (pre-hybridisation buffer with the addition of 
10% dextran sulphate). This replaced the pre-hybridisation buffer, and 
incubation at 42°C continued for a further 16 hours.
2.13.5 Washing and autoradiographing the filter after hybridisation:
The filter was washed and autoradiographed as described before (2.6.6-
8).
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3: Results
The aim of this project was to investigate factors modifying the 
phenotypic outcome of TGFB1(-/-) animals described in an earlier study 
(Dickson et al., 1995). To investigate the effects that genetic background might 
have on prenatal lethality, the Tgfbl null allele was to be bred through four 
generation onto C57BI/6J/Ola and NIH/Ola (by F.M. Cousins) to obtain mice 
which were «93% pure for each strain.
3.1 Genotyping animals for Tgfb l applying a single polymerase chain 
reaction (PCR) protocol:
A dual PCR approach was previously utilized to genotype animals for 
Tgfbl (Kulkarni et al., 1993). However, in this project a single combined PCR 
protocol was developed (figure 3.1). The advantages of this PCR protocol were 
as follows:
1) Half as many PCRs were required to screen animals for Tgfbl. The 
nature of this project required screening more than 1800 transgenic animals. 
Thus, decreasing the number of PCRs was important in terms of time and 
economical benefits.
2) In the dual reaction PCR approach, failure in either reaction could 
result in misgenotyping animals for Tgfbl. In the single combined PCR 
approach each reaction was an internal control for the other.
3.2 Phenotypic assessment:
In the previous study, using mixed genetic background animals (12.5% 
129/Sv, 50% NIH/Ola and 37.5% C57BI/6J/Ola), the phenotypes of TGFB1(-/-) 
embryos were classified into two groups; embryo lethality at 9.5 dpc (yolk sac 
phenotype) and survival to birth (Dickson et al., 1995). In this project survival to 
birth was utilized as the unambiguous criterion for animal classification to 
identify genetic and/or non-genetic modifying factors.
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Figure 3.1: Genotyping animals for Tgfb l gene by application of PCR.
a) Conventional PCR approach: In this approach, a dual reaction PCR was 
utilised to genotype animals. In one of the PCR reactions, the wild type allele 
(625 bp) for Tgfbl gene was amplified and in the other reaction, the 
knockout allele (375 bp) was amplified. Animal T2= wild type, Animal T3= 
heterozygous, Animal T4= heterozygous, Animal T5= heterozygous, Animal 
T6= heterozygous.
b) Single combined PCR approach: In this project, a single combined 
reaction PCR was developed to genotype animals for the Tgfbl gene. The 
wild type allele (625 bp) and the knockout allele (375 bp) were amplified 
simultaneously in a single PCR reaction. Animal No. 1 is heterozygous, No. 
2 is heterozygous, No. 3 is wild type, No. 4 is wild type, No. 5 is 
heterozygous, No 6 is null.
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3.3 Estimation of the percenfcge of TGFB1(-/-) neonate survivals:
In order to gemerate TCFB1(-/-) animals, crosses between TGFB1(-/+) 
animals were set up. Iff there w?s no prenatal loss of TGFB1 (+/-) and TGFB1(-/- 
), the Mendelian ratio of 1:2:' for TGFB1 (-/-), TGFB1(+/-) and TGFB1(+/+) 
animals would be expected. Tc avoid any interference by TGFB1(-/+) lethality 
which has been reported by previous researchers (Shull & Duchman., 1992, 
Dickson et al., 1995), the percentage survival (observed/expected) of TGFB1(-
/-) embryos to birth was estimated as N° (-/-) /  N° (+/+). The premise was that
any possible factor leading to prenatal loss of TGFB1(+/+) embryos would 
have an equal effect on TGFB1J-/-) embryos.
To estimate the percentage survival of TGFB1(-/-) neonates to birth, all 
neonates were culled prior to the stage of postnatal death 3 weeks post-partum 
(Shull et al., 1992) and were s:reened for Tgfbl genotype. The data obtained 
from this screening are shown in table 3.1. The percentage of TGFB1(-/-) born 
to NIH/Ola genetic background was estimated to be 82% whereas that of born 
to C57BI/6J/Ola was 0% which indicated that there were strain-specific 
modifying factor(s) determining survival versus pre-natal lethality of TGFB1(-/-) 
conceptuses.
To confirm strain-specific dependence of the TGFB1(-/-) phenotype, 2 x 
2 contingency statistical analysis was performed (Appendix l-A, Table 1) 
assuming the null hypothesis for involvement of strain-specific factors on the 
phenotype (Table 3.1). The P-value (« 1 0 '5), by excluding the possibility of the 
null hypothesis, confirms that different expressivity of the TGFB1(-/-) phenotype 
was due to strain specific factor(s).
3.4 Possible factors involved in different expressivity of TGFB1(-/-) 
phenotypes:
The possible factors involved in modifying the phenotypic outcome of 
TGFB1(-/-) conceptuses may be categorized into three classes:
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Table 3.1 The number of TGFB1 wild type and null neonates developing to 
term in two NIH X NIH and C57 X C57 crosses. To compare the number of 
TGFB1(-/-) neonates born to different strains, 2 X 2  contingency statistical 
analysis (Appendix I, Table 1) assuming the null hypothesis for involvement of 
strain-specific factors in the phenotype, was performed (Data extracted from 
table 3.2).
Group TGFB1(+/+)
neonates
TGFB1(-/-)
neonates
Total
NIH/Ola 89 73 162
C57BI/6J/Ola 68 0 68
Total 157 73 230
*2 42.83
P-value « 1 0 ‘s
1) Strain-specific role of TGFB1 in gametogenesis.
2) Strain-specific influence of maternal factors on the survival and development 
of TGFB1 (-/-) conceptuses.
3) Cardinal effect of the genetic background of TGFB1(-/-) conceptuses on the 
phenotypic outcomes.
To investigate the involvement of these possible factors in the differential 
expressivity of TGFB1(-/-) phenotype, various combinations of intercrosses 
between NIH/Ola and C57BI/6J/Ola were set up (Table 3.2). These results 
were analyzed in separate groups to evaluate the involvement of possible 
factors in the different expressivity of TGFB1(-/-) phenotype.
To investigate the possibility that there was selective failure or low 
transmission of the knockout allele (Tgfbl) through maternal gametes in 
C57BI/6J/Ola strain, statistical analysis on the results of various crosses using 
C57BI/6J/Ola females (Table 3.3.a) was performed. Assuming the involvement 
of Tgfbl gene in transmission of maternal gametes and/or gametogenesis, one 
would expect to observe no significant difference in percentage of TGFB1(-/-) 
neonates born to females from the same genetic background in various 
crosses. However, the calculated %2 of 19.49, 9.44 and 31.7 (Appendix l-B, 
Table 1,2,3) for the data from table 3.3a,b and c, with the relevant P-value of 
5.8 x 10'5 , 8 x 10'3 and 10'5,respectively,excluded this possibility.
The estimated %2 of 15.00 obtained from statistical analysis of various crosses 
using C57BI/6J/Ola males (Table 3.4) with the relevant P-value of 5.5 x 10"4 
also ruled out the possible involvement of Tgfbl gene in transmission of male 
gametes and/or male gametogenesis process.
To address the possible effect of maternal factors (such as maternal 
circulating TGFB1) on the phenotypic outcome of TGFB1(-/-) conceptuses, 
statistical analysis was carried out (Appendix l-B) on the results obtained from 
different breedings (Table 3.3, a,b,c). In this table, three different crosses were 
statistically analysed. In each group(a or b or c), three different crosses were 
compared with one another and despite the fact that all females were from the 
same genetic background, statistically significant deviation was observed in the
68
Table 3.2: Intercrosses between various combinations of NIH/Ola and 
C57BI/6J/Ola , and the number of TGFB1 transgenic animals born to each 
cross. These results were analyzed in separate groups to evaluate the 
involvement of possible factors in the different expressivity of TGFB1(-/-) 
phenotype.
Cross TGFB1(-/-) TGFB1(+/-) TGFB1(+/+)
NIH x NIH 73 129 89
NIH x F1 14 52 21
F1 x NIH 85 235 118
F1 x F1 80 530 190
NIH x C57 15 90 50
C57 x NIH 9 50 25
C57 x F1 3 50 29
F1 x C57 9 163 75
C57 x C57 0 122 68
Table 3.3: The number of TGFB1'7' embryos developing to term in different 
crosses using females from the same genetic background (Data extracted from 
table 3.2). The calculated % and the relevant P-values are shown (statistical 
analyses are demonstrated in Appendix l-B).
Cross TGFB1 (-/-) 
embryos
TGFB1 (+/+) 
embryos
Percentage of nulls 
survived
a) Females from 
C57B!/6J/Ola
C57X C57 0 68 0%
C57 X F1 3 29 10.3%
C57 X NIH 9 25 36%
2
X 19.49
P-value ; 5.8 x 10* ■
b) Females from 
NIH/Ola
NIH X NIH 73 89 82%
NIH X F1 14 21 66.66%
NIH X C57 15 50 30%
■ ■ 2,1:.:-;. 
X
P-value
c) Females from 
F1 (NIH X C57)
F1 x NIH 85 118 72%
F1 x F1 80 190 42%
F1 x C57 9 75 12%
31.7
P-value <<10* ■'
Table 3.4: The number of TGFB1(-/-) embryos developing to term in different 
crosses using males from C57BI/6J/Ola genetic background (Data extracted 
from table 3.2). The calculated % and the relevant P-value are shown.
Cross TGFB1 (-/-) 
embryos
TGFB1 (+/+) 
embryos
Percentage of 
nulls survived
males from 
C57BI/6J/Ola
C57 X C57 0 68 0%
F1 x C57 9 75 12%
NIH x C57 15 50 30%
15.00
P-value 5.5 x 10"
number of TGFB1(-/-) embryos developing to term. These results excluded the 
involvement of maternal factors in different expressivity of TGFB1 null 
phenotypes in two strains. However, the possible effect of maternal factors in 
the survival of TGFB1(-/+) to birth which could have a similar influence in both 
strains, remained to be elucidated.
3.5 Candidate gene approach:
Concurrently with the collection of DNA samples for a full genome 
search, the candidate gene approach was taken, to investigate possible 
genetic factors involved in determining different expressivity of TGFB1(-/-) 
phenotype. In a preliminary study, carried out on a small number of TGFB1(-/-) 
animals bred onto mixed genetic backgrounds, suggestive linkage of TGFB1(-/- 
) survival with markers tightly linked to Insulin like growth factor type II receptor 
(Igf2r) was shown (Bonyadi, Msc thesis, 1994). Therefore, further investigation 
of this gene was pursued to strengthen or exclude the linkage data, certain 
studies were carried out on Igf2r to investigate.
3.5.1 Insulin like growth factor type II receptor (Igf2r):
The following investigations were carried out on the Igf2r gene:
1) Igf2r gene expression study.
2) Investigation on 2.05kb of the cDNA of Igf2r gene.
1) /gf2r expression study:
Igf2r expression was investigate in 9.5 dpc embryos bred onto two 
genetic backgrounds, i.e. NIH/Ola and C57BI/6J/Ola strains. Embryos were 
dissected, total RNA was extracted, and checked for quality and quantity on a 
denaturing agarose gel (Figure 3.2). Applying Northern blotting, the gene 
expression level of Igf2r at 9.5 stage was compared between embryos from 
NIH/Ola and C57BI/6J/Ola strains (figure 3.3). As the results indicate, at 9.5 
dpc stage of embryo development there was no significant difference in the 
expression of Igf2r gene between two strains; NIH/Ola and C57BI/6J/Ola.
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Figure 3.2: Qualifying and quantifying RNAs extracted from 9.5 dpc 
embryos on a denaturing agarose gel: RNAs from whole embryos were 
extracted and run on a denaturing agarose gel. In each lane, 2pi of the RNA 
extracted from either 9.5 dpc embryos from NIH/Ola (lane I, II), or from 9.5 
dpc embryos from C57BI/6J/Ola strains were run on a denaturing agarose 
gel. The density of 28s rRNA and 18s rRNA was used to check the quantitiy 
and quality of RNAs.The concentration of RNAs in all lanes of denaturing 
agarose gel is the same.
Figure 3.3: Northern Blotting of Igf2r. The expression of Igf2r gene was 
examined at the 9.5 dpc stage in embryos of the mouse strains NIH/Ola 
(lane 1), C57BI/6J/Ola (lane 2) and 129/Sv (lane 3). No significant difference 
is observed in the expression of the Igf2r gene at the 9.5 dpc stage between 
embryos from NIH/Ola, C57BI/6J/Ola and 129/Sv strains. The full length of 
mRNA for Igf2r gene is 8877 bp (Embl access number is: MMU04710).
2) Investigation of the cDNA of Igf2r gene.
To investigate the possibility that strain specific polymorphisms are 
present in the protein encoded by Igf2r, 0.755 (6699^7453) + 1.3 
(1700-^2982) Kb of the mRNA were amplified by applying RT-PCR (Figures 
3.4 a,b) on RNA from the two strains, NIH/Ola and C57BI/6J/Ola. These 
regions were subjected to Chemical Mismatch Cleavage (CMC) analysis 
(figures 3.5 a,b). Since the sensitivity of CCM is about 90% (Cotton et al., 
1988), from figures 3.5a, and b, it could be concluded that the coding sequence 
for Igf2r in the regions under investigation is identical (with 90% certainty).
Prior to completion of the screening of the entire coding sequence of 
Igf2r, results obtained from new breedings dismissed the possible involvement 
of the Igf2r in the survival of homozygous Tgfbl null embryos, thus this aspect 
of the project was discontinued.
3.5.2 Evidence for exclusion of imprinted genes:
In this study, the possible involvement of imprinted genes in which 
expression of the genes dependent on parent-of-origin, was carefully 
examined. The data obtained from various reciprocal crosses (Table 3.7), 
excluded the possible involvement of any imprinted genes (e.g. Igf2r gene 
which is pateranally imprinted) in different expressivity of the TGFB1(-/-) 
phenotype.
3.6 Estimating the number of gene(s) involved in determining differential 
survival of TGFB1(-7-) neonates:
Before embarking on a detailed mapping project, it was useful to derive 
an estimate of the number of segregating genes involved in the expression of 
the trait under analysis. If we assume that a single codominant gene with two 
alleles explains the pattern of survival, then the maximum likelihood estimates
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Figure 3.4: RT-PCR products of the coding region of the Igf2r gene.
a) A 755 bp fragment from coding region of the Igf2r gene was amplified by 
applying RT-PCR. RNA was extracted from 9.5 dpc NIH/Ola embryos (lanes 
1, 2, 3) or C57BI/6J/Ola embryos (lanes 4, 5, 6). L; 1-kb ladder.
b) A 1.3 kb fragment from coding region of the Igf2r gene was amplified by 
applying RT-PCR. RNA was extracted from NIH/Ola embryos (lane 1) or 
C57BI/6J/Ola embryos (lane 2). L; 1-kb ladder.
Figure 3.5: Chemical Mismatch Cleavage analysis on the coding region of 
Igf2r gene.
a) RT-PCR products (755 bp) of Igf2r cDNAs from NIH/Ola and C57BI/6J/Ola 
strains were subjected to chemical mismatch cleavage analysis. No 
polymorphism in this region of Igf2r cDNA is observed between NIH/Ola and 
C57BI/6J/Ola strains. Lane 1; The hybrid (i.e. NIH / C57) was treated with 
hydroxylamine, Lane 2; The control treated with hydroxylamine (i.e. C57), 
Lane 3; The hybrid (i.e. NIH / C57) was treated with osmium tetroxide, Lane 
4; The control (i.e. C57) treated with osmium tetroxide, L; 1-kb ladder.
Figure 3.5: Chemical Mismatch Cleavage analysis on the coding region of 
Igf2r gene.
b) RT-PCR products (1.3 kb) of lgf2r cDNAs from NIH/Ola and C57BI/6J/Ola 
strains were subjected to chemical mismatch cleavage analysis. No 
polymorphism in this region of \gf2r cDNA is observed between NIH/Ola and 
C57BI/6J/Ola strains. Lanes 1, 2; The hybrid (i.e. NIH / C57) was treated 
with hydroxylamine, Lane 3; The control treated with hydroxylamine (i.e. 
C57), Lane 4, 5; The hybrid (i.e. NIH / C57) was treated with osmium 
tetroxide, Lane 6; The control (i.e. C57) treated with osmium tetroxide. L; 1- 
kb ladder.
for the survival rates for N/N, C/C, and N/C genotypes are 86%, 0%, and 32% 
respectively. These estimates take into account the varying numbers of pups 
as well as attempting to allow for the missing pups. The observed and 
predicted relative survival rates are shown in table 3.5. The relevant P-value is 
more than 0.05 (table 3.5), therefore we could conclude that the data were 
adequately modeled by a single codominant gene with two alleles (NIH, C57). 
In this model, F1 animals showed incomplete dominance (codominant trait) of 
the C57 allele, and mostly they were poised between lethality and survival.
3.6.1 Towards genetic mapping of loci modifying TGFB1 (-/-) phenotype:
An important choice upon beginning a new linkage study is whether to 
screen F1 backcross animals or F1 intercross. In this study, due to the 
codominant nature of the locus (loci), and to procure more informative animals 
and high-resolution mapping for the purpose of positional cloning, the 
intercross approach was applied for the linkage analysis.
3.7 Sex-linked genes:
The X Chromosome mostly comprises genes involved in sex-linked 
traits. The X chromosome constitutes at least 5% of the whole genome. To 
study the possible involvement of any sex-linked genes, further detailed 
analysis of the intercross data was required.
A): The percentage of TGFB1(-/-) male and female survivals:
The ratio of male to female TGFB1(-/-) survivals in different crosses 
(table 3.6) indicates that there was no significant difference between different 
crosses which excludes involvement of major X-linked genes in the different 
expressivity of TGFB1 null phenotypes.
B): The percentage of TGFB1(-/-) null neonates in reciprocal crosses:
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Table 3.5: Presentation of the observed and predicted relative survival rates in 
different crosses (Data extracted from table 3.2), assuming that a single gene 
with two alleles explains the pattern of survival.
Cross
(Number)
TGFB1
(-/-)
neonates
(Number)
TGFB1
(+/+)
neonates
(Percent.)
Observed
(-/-)
neonates
(Percent.)
predicted
(-/-)
neonates
(Number)
expected
(-/-)
neonates
C57 x C57 0 68 0% 0% 0
NIH x NIH 73 89 82% 86% 76.54
F1 x NIH 99 139 71.2% 59% 82.01
F1 x C57 12 104 11.5% 16% 16.64
F x F1 80 190 42% 37.5% 71.25
2
X 6.051
P 0.195
Table 3.6: Displaying the number of males and females born to different 
crosses (Data extracted from table 3.2) and the calculated Chis Square and the 
pertinent P-value.
Cross Number of TGFB1(-/-) 
Males
Number of TGFB1(-/-) 
Females
NIHxNIH 27 33
NIH x FI 47 37
NIHx C57 10 14
2
X 2.38
P-value 0.1
Table 3.7: Presentation of the number of TGFB1(-/-) born to reciprocal crosses 
(Data extracted from table 3.2) and the calculated % and the relevant P-value 
( 2X2  contingency table was applyed for statistical analysis, Appendix l-A).
Cross TGFB1(-/-) TGFB1(+/+) Percentage of 
TGFB1(-/-)
NIH x F1 14 21 66.6%
F1 x NIH 85 118 72%
2
X 0.04
P-value
NIH x C57 15 50 30%
C57 x NIH 9 25 36%
X
P-value
C57 x F1 3 29 10%
F1 x C57 9 75 12%
. 2 
X 0.03
P-value 0.85
Assuming the involvement of sex-linked loci in the phenotype, significant 
deviation between the percentage of TGFB1(-/-) neonates in reciprocal crosses 
would result. The results of reciprocal crosses between NIH/Ola and 
C57BI/6J/Ola presented in table 3.2 are analyzed statistically (table 3.7). As 
results in table 3.7 indicate there was no significant differences in the number 
of TGFB1(-/-) survivals between reciprocal crosses. Therefor, these results 
verified the exclusion of the involvement of major sex-linked gene in different 
expressivity of the TGFB1 (-/-) phenotype.
3.8 Genome screening (Autosomal chromosomes):
In this study, 150 microsatellites scattered throughout the genome were 
screened for polymorphisms between NIH/Ola and C57BI/6J/Ola strains 
(Appendix ll-C). In terms of the location and being polymorphic, only 55 
markers were informative for linkage analysis in this project. Moreover, two 
Restriction Fragment Length Polymorphism’s (RFLPs) for two important 
candidate genes, transforming growth factor type II receptor (Tgbr2) and 
plasminogen activator inhibitor type I (PlanHI), not previously mapped in the 
murine genome, were identified and utilised in this research (section). These 
RFLPs were also applied to map genes in the mouse genome.
3.8.1 Number of animals and markers required for preliminary study:
The first stage in the linkage approach was mapping to a sub- 
chromosomal interval. An optimal strategy to obtain high-resolution linkage 
mapping is to select animals with a specific phenotype, to choose an adequate 
number of affected animals, and to develop a framework map anchored by 
previously well-mapped loci spaced uniformly throughout the entire genome.
3.8.1.1 The phenotypic assessment taken in this project was previously 
discussed (3.2).
3.8.1.2 Number of animals and markers:
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To obtain a high-resolution map with both an average crossover 
resolution of 0.1 cM and an average marker density of one per cM, one would 
have to analyse 500 intercross animals for segregation at 1500 marker loci 
(spanning 1500 cM) which would require 750,000 independent typings. 
Therefore in this study a much more efficient approach was taken by dividing 
the protocol into two separate stages. The goal of the first stage was to link the 
locus (loci) to a defined sub-chromosomal interval. This approach was 
accomplished by typing a relatively small set of markers on a relatively small 
number of phenotypically typed animals. To develop a framework map which 
covers the entire genome, it was critical to calculate the minimum number of 
anchor loci sweeping the entire genome by screening a minimum number of 
phenotypically typed animals. This calculation was based on the length of the 
swept radius. The swept radius, the distance over which linkage can be 
detected between any marker and a test locus typed in a set number of animals 
was defined originally in terms of map distances (Carter & Falconer 1951).
With 100 backcross samples, the framework swept radius is at least 0.23 
recombinant fraction (rf) (Carter & Falconer 1951, Frankel et al., 1990). To a 
first approximation, each intercross sample is equivalent to two backcross 
samples. Thus, a swept radius of 0.23 rf can be obtained with 50 intercross 
samples. A further increase in the critical number of samples (45-50) provide 
only a marginal increase in the distance that is swept. In this study, as it is 
shown on table 3.8 and the figures presented in Appendix ll-B, by applying 54 
informative markers conducted on 50 intercross samples, about 90% of the 
genome was swept for a major modifying gene.
3.9 Statistical Methods applied in this project:
3.9.1 Null hypothesis:
In statistical analysis of data, it was important to predict the null 
hypothesis, which means that alleles at different genes would assort 
independently, leading to a 1:1 ratio of gametes with parental or recombinant 
combinations of alleles. In this study, by applying a null hypothesis in the 
analysis of each marker, it became possible to apply a statistical test to
73
Table 3.8: The number of markers per chromosome utilized to screen 48-80 F2 
(NIH/Ola X C57BI/6J) designed panel and the approximate percentage of the 
genome scanned in this research. Swept radius is taken 0.23 rf.
Chromosome Number of 
animals
Number of 
Markers
Length (cM) 
of the 
chromosome
Length (cM) 
of the 
chromosome 
not swept
Percentage 
of the 
chromosome 
swept.
1 48-50 4 116.61 OcM 100%
2 48-50 2 97.34 29 CM 70%
3 48-80 2 68.62 4 cM 93%
4 48-50 4 76 OcM 100%
5 80 10 87.32 OcM 100%
6 48-50 3 64.5 OcM 100%
7 48-50 1 70.9 3.98 cM 94%
8 48-50 3 76.4 OcM 100%
9 48-50 5 72.37 OcM 100%
10 48-50 2 74.74 OcM 100%
11 48-50 2 86. 14 cM 83%
12 48-80 4 62.75 OcM 100%
13 48-50 2 63.45 OcM 100%
14 48-50 4 62.27 OcM 100%
15 48-50 2 63.97 OcM 100%
16 48-50 3 55.76 OcM 100%
17 48-50 4 52 OcM 100%
18 48-50 1 40.6 OcM 100%
19 48-50 3 59.1 OcM 100%
determine whether the data actually observed were significantly different from 
the expected outcomes for no linkage. The expected outcome for each marker 
in this project in an F2 intercross was 25%, 50% and 25% for homozygosity for 
the NIH/Ola allele, heterozygosity (NIH/C57), and homozygosity for the 
C57BI/6J/Ola allele respectively.
3.9.2 The %2 test for intercross data:
The standard method to evaluate whether non-Mendelian recombination 
results are statistically significant is the method of x2- Upon calculating a value 
for x2 » it is possible to determine the likelihood that an observed set of data 
represents a chance deviation from the values predicted by a particular 
hypothesis. This determination provide information to reject or accept the 
hypothesis that is being tested.
The general form of the %2 statistic is defined as follows:
2
2 n lObserved - Expected)
1=1 Expected
Where n are potential outcome classes. Quick examination of the equation, 
shows that the x2 value is inversely related to the goodness-of-fit between the 
experimental results and the null hypothesis being tested. The size of the data 
set is important when the x2 test is applied. It can not be applied to very small 
data sets, which are defined as those in which 20% or more of the outcome 
classes have expected values that are less than five (Cochran, 1954).
3.10: Genome-wide search by applying microsatellites or restriction 
fragment length polymorphisms (RFLPs): 
3.10.1: Applying markers tightly linked to the candidate genes:
Prior to screening the whole genome using markers scattered randomly 
throughout the genome, several important candidate genes already mapped on 
the mouse genome were investigated for their possible implication in the
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different expressivity of the TGFB1(-/-) phenotype. To achieve this purpose, 
markers tightly linked to the candidate genes were utilized.
3.10.1.1: TGFB isoforms:
To investigate the possibility of functional redundancy with other TGFB 
isoforms in the two different strains; NIH/Ola and C57BI/6J/Ola, informative 
markers linked to TGFB2 and TGFB3 located on chromosomes 1 (101.5 cM) 
and 12 (41 cM) respectively, were selected (Appendix ll-B). Performing linkage 
studies conducted on 48-50 TGFB1(-/-) survivals by applying the linked 
markers (Appendix III), excluded any possible linkage of the TGFB isoforms 
with TGFB1(-/-) survivals.
3.10.1.2 Endoglin (Eng):
Due to histological similarities seen in HHT1 patients which have allelic 
variation in the ENG gene (McAllister et al., 1994) and the TGFB1(-/-) embryos 
dying due to yolk sac phenotype (Dickson et al., 1995), the Eng gene was 
chosen as a candidate gene in this study. The segregation of the gene was to 
be followed among TGFB1(-/-) neonates in F2 intercross. To achieve this 
purpose, a tightly-linked-marker (Qureshi et al.,1995) was selected (Appendix 
ll-B) and studied on 48-50 TGFB1(-/-) survivals. As the result indicates 
(Appendix III), there was no significant segregation distortion from 1:2:1 for 
homozygous NIH, heterozygous, and homozygous C57 alleles of the marker 
respectively. Thus, it excludes the involvement of Eng or any linked gene to the 
different experssivity of TGFB1 (-/-) phenotype.
3.10.2: Applying RFLPs for screening unmapped candidate genes:
3.10.2.1 Transforming growth factor beta type II receptor(Tgfbr2).
The TBR2 is a receptor for the ligands TGFB1, TGFB2 and TGFB3 
(Wrana et al., 1994). Its absence result in lethality of embryo in uterus at 9.5-
11.5 dpc due to deficiency in haematopoiesis and yolk sac vasculagenesis
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(Oshima et al., 1996). To investigate the possible involvement of Tgfbr2 in 
different expressivity of TGFB1 null phenotype, a 1.7-kb coding region cDNA 
probe was utilised to identify informative RFLPs between NIH/Ola and 
C57BI/6J/Ola strains. BamH1 digestion of genomic DNA revealed an RFLP that 
was 14 kb in NIH/Ola and 8 kb in C57BI/6J/Ola. A 317-nt Bglll-Sacl fragment 
hybridised with the BamH1 RFLP was designed (Figure. 3.6). Probe for Tgfbr2 
was used to probe DNA samples from 40 F2 (NIH x C57) TGFB1(-/-) null 
survivals, to study the segregation of RFLPs among survivals (table 3.9). 
Significant deviation from the expected distribution was not observed among 
TGFB1(-/-) survivals. Therefore, the possible implication of Tgfbr2 gene in 
different expressivity of the TGFB1(-/-) phenotype, was ruled out.
3.10.2.2 Plasminogen activator inhibitor type I (PlanHI):
It has been proposed that PlanHI involves in the activation of latent 
TGFB. And its implication in a number of vascular diseases has been reported 
(Grainger et al., 1993 and 1994). To investigate the possible implication of 
PlanHI in phenotypic outcomes of TGFB1 null conceptuses, a murine PlanHI 
coding region cDNA was utilized to identify informative RLFPs between 
NIH/Ola and C57BI/6J/Ola strains. Different enzyme-digested-DNAs from 
C57BI/6J/Ola and NIH/Ola were analyzed by Southern blot hybridization for 
informative RLFPs, using the full length murine PlanHI coding region cDNA 
(520 bp). Estimated fragments of 4 kb and 4.3 kb were detected in BamH1- 
digested NIH/Ola and C57BI/6J/Ola DNAs, respectively (figure 3.7).
Applying full length murine PlanHI cDNA, 48-50 TGFB1 null survivals were 
screened for distribution of PlanHI alleles (table 3.10). As analysis of the 
obtained data (table 3.10) indicates, no significant deviation from 1:2:1 for 
homozygous NIH, heterozyogus and homozyogus C57 alleles respectively was 
observed among TGFB1(-/-) neonates. Therefore, the possible involvement of 
PlanHI in different expressivity of TGFB1(-/-) phenotype, was excluded.
3.10.3 Genome- Wide search by applying random selected markers:
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Figure 3.6: Southern Blotting analysis of the Tgfbr2 gene from NIH/Ola 
and C57BI/6J/Ola strains. 317 bp Bglll-SacI fragment from the coding 
region of the gene was used as a probe. BamH1 digestion of genomic DNA 
revealed an RFLP that was 14 kb long in NIH/Ola and 8 kb in C57BI/6J/Ola, 
and 12 kb in 129/Sv strain.
Table 3.9: Presentation of the segregation of RFLPs for Tgfbr2 gene among 40 
F2 (NIH X C57) TGFB1(-/-) animals developing to term.
Probe Total TGFB1 
(-/-) neonates
N /N N /C C /C
Tgfbr2 40 12 14 14
2X 3.8
P-value 0.149
Table 3.10: Presentation of the segregation of RFLPs for PlanHI gene among 
48 F2 (NIH X C57) TGFB1 (-/-) animals.
Probe Total TGFB1 
(-/-) neonates
N /N N /C C /C
PlanHI 48 15 26 7
2X 3.2
P-value 0.2
Isl/c N/C NIH C57
4.3 kb 
4 kb
Figure 3.7: Southern Blotting analysis on PlanHI gene from NIH/Ola and 
C57BI/6J/Ola strains. Full length of the coding region of the gene was used 
as a probe. The fragments were approximately 4 kb and 4.3 kb in the 
BamHI-digested NIH/Ola and C57BI/6J/Ola DNAs, respectively.
Most of the markers used in this project were chosen on the basis of the 
previously published data that they were more informative between 
C57BI/6J/Ola intra-strain and other intra-strains such as Ob, Cast, C3h, Dba, 
Balb, Akr, Non, Nod, Lp. However, there was no information about the size of 
markers on NIH/Ola strain. 150 markers were screened between NIH/Ola and 
C57BI/6J/Ola. 55 informative markers in terms of being polymorphic and 
covering maximum space of genome were selected (Appendix ll-C, III). Most of 
the polymorphisms were small and detectable only by running on 8% 
polyacrylamide gel electrophoresis (Figures 3.8).
Genetic linkage analysis was conducted on 48-50 TGFB1(-/-) neonates 
born to F2 ( NIH/Ola X C57BI/6J/Ola) crosses by applying 54 informative 
markers. In the first screen conducted on 48-50 TGFB1(-/-) nulls, four regions 
of the genome (D3Mit6, D5Mit268, D5Mit188, D12Mit46) showing suggestive 
linkage (P> 0.05) were focused for further linkage analysis. Two of the regions 
(D5Mit268, D5Mit188) were located on the same chromosome. Thus, there was 
a possibility that linkage in one of the regions resulted in segregation distortion 
of the other region. To estimate the distance of these markers from each other, 
Kosambi’s formula (equation 3), or M A P m aker programme could be applied.
mk= 0.25 [ ln(1+2r) - ln(1-2r)] (equation 3)
By applying M A P m aker program, it was revealved that D5Mit188 was located in 
a region 41 cM distal to that of D5Mit268. In order to evaluate the independent 
support for the linked major modifier defined by D5Mit268 following formula 
(Martin Farral, Unpublished) was applied:
fcc= Qcc (1-r)2 + gCN (r-r2) + gNN r2 
fCN= 2gcc (r-r)2 + gCN (1-r)2 + 2gNN (r-r2) 
fNN = gccr2 + gcN (r-r2) +gNN (1‘ r)2
equations (4)
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Figure 3.8: Detecting polymorphism between microsatellites from NIH/Ola 
and C57BI/6J/Ola strains. Electrophoresis was carried out on an 8% 
polyacrylamide gel. Length polymorphism in D2Mit83 marker was less than 
8bp between NIH/Ola and C57BI/6J/Ola strains which was detectable on an 
8% polyacrylamide gel.
Where fCc, fcN. and fNN are the expected genotype frequencies at a linked locus 
and gcc, gcN and gNN are the observed genotype frequencies at the modifying 
genes ( when r=0, then fCc=gcc, fcN=gCN, and fNN=gNN )•
By solving the equations (4) for the observed frequencies (gcc, gcN, and gNN) of 
D5Mit268, the conditional genotype frequencies expected (fCc, fcN, and fNN ) at 
D5Mit188 were calculated. The expected genotype frequencies are fc c = 1 8 % ,  
fcN= 49%, and fNN 33 /o which are not significantly different from the observed 
frequencies (P>0.05). Therefore, segregation distortion of D5Mit188 was most 
likely due to the affect of the segregation distortion of D5Mit268 locus not due 
to the possible modifying gene(s) linked to D5Mit188.
With P-value 0.05 as providing evidence for linkage in this experiment, the 
expected proportion of false positive loci was 60%. Therefore, in the first 
screen only one marker out of three independent markers showing a P-value of 
0.05 was expected to be a truly linked locus. To confirm or dismiss linkage of 
each of four loci which appeared to show linkage, an additional 30 neonatal 
TGFB1(-/-) intercross DNA samples were analysed for markers on 
chromosomes 3, 5 and 12. P-values at the loci on chromosomes 3 and 12 
remained only suggestive (= 0.05). However, the support for linkage was 
strengthened at D5Mit268, surpassing the stringent linkage criteria (< 10*5) 
(Figure 3.9).
3.10.3.1 Screening control animals for D5Mit268 maker:
In this study only one group of animals [TGFB1 (-/-)] was available for 
linkage analysis i.e. those that survived to birth. Therefore, it was necessary to 
evaluate the observed linkage of chromosome 5 (D5Mit268) and provide 
evidence that the observed segregation distortion of the marker was genuinely 
due to a TGFB1 modifying gene(s) not due to any unknown possible factor. To 
address this possible problem, 50 wild type animals [TGFB1 (+/+)] from the 
same cross as the TGFB1(-/-) pups were screened for segregation of D5Mit268 
marker (Appendix IV). No segregation distortion (P>0.05) was observed among 
control animals, confirming that the linkage of the marker on TGFB1(-/-) 
animals must be due to a Tgfbl modifying gene.
78
,M it
49
cM
18.6
N/N
18
N/C
23
C/C
8
No. o f  A n im a ls  
49
251 17 27 49
116
Fin 13 
Fgfr3
76
268
75
267
80
233
197
188
161
8.0
3.3
1.3
3.3
3.0
7.4
5.2
8.6
15.2
2.5
34 39 7
37 35 8
35 37 8
33
21
20
20
21
39
23
21
22
21
31 37 12
26 28 9
80
80
80
80
49
49
49
49
80
63
17.3
PI anhi 15 26 48
Figure 3.9: Map of chromosome 5 showing the location of the major modifying gene and the 
proxim ity of candidate genes. The position of the informative M it markers used for mapping are 
shown to the right o f the chromosome, and the map distances (cM) are indicated between each 
pair o f markers (not drawn to scale). Map distances were calculated from the data using MAP- 
MAKER. Note that D5Mit268 was previously incorrectly mapped (Research Genetics), its true 
map location being between D5Mit76 and D5Mit267. The genotype numbers (CC:CN:NN) of 
the F2 neonates for each M it marker is shown to the right o f the figure. Note that 8/80 TGFB1 
(-/-) mice are homozygous CC over the region containing the major modifier gene.
3.10.3.2 Genotypic Risk Ratio (GRR):
GRR was initially defined by Risch et al (1993) as the ratio of disease 
risk in the backcross generation, compared with that in the high-risk parental 
strain. In this study, the formula of GRR for the backcross generation was 
modified for an intercross generation (Appendix ll-D) and it was defined to be 
the ratio of survival in the F2 generation, compared to the NIH/Ola (N/N) 
parental strain. From the data in table 3.2, the overall GRRf2 in the F2 
generation is therefore equal to 42% / 82% = 51.2%.
The GRRf2 contributed by a specific modifying gene can be estimated from the 
strength of linkage between a marker and the modifying gene (equations 2 and 
6, Appendix ll-D). By substituting the observed genotype frequencies for 
D5Mit268, the estimated GRRF 2 for the chromosome 5 major modifying gene 
was 54%. Risch et al (1993) proposed two multilocus genetic models, an 
additive model in which the effects at one modifying gene may substitute for 
another and a multiplicative, epistatic model of gene interaction. Under an 
additive model, where the overall GRRF2 {expressed as [(1 : GRRF2 ) -1 ] -  [(1 : 
GRRi ) - 1] + [(1 : GRR2 ) - 1] } is a sum of contributions from individual 
modifying genes, the chromosome 5 modifying gene explains 89% of the 
overall GRRF2 Under a multiplicative model, where the overall GRRF 2 is the 
product of contribution from modifying genes (expressed as: GRRF2 = GRRi x 
GRR2) the chromosome 5 modifier explains 92% of the overall GRRF2. 
Therefore, it could be concluded that the chromosome 5 modifying locus 
accounts for almost all of the genetic variability in the lethal embryonic 
phenotype.
3.11 Mapping order for the MIT markers on chromosome 5.
The mapping order and estimated map distance (cM), for the MIT 
markers located between centromere and D5Mit80 marker on mouse 
chromosome 5 was reported (Chromosome Commitee report 1996) as follow: 
D5MIT49 (8.6 cM)-D5MIT251 (6.7 cM)-D5MIT76 (0 cM)-D5MIT75 (1.3 cM)-
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D5MIT267 (0.4 cM)-D5MIT268 (1.3 cM)-D5MIT80, whereas, in our designed 
panel, for the same markers the following order and estimated map distance 
(cM) was found: D5MIT49 (18.6 cM)-D5MIT251 (8.0 cM)-D5MIT76 (3.3 cM)- 
D5MIT268 (1.3 cM)-D5MIT75 (3.3 cM)-D5MIT267 (3.0 cM)-D5MIT80. On the 
basis of these results, D5Mit76 maps to a region 1.9 cM proximal to that of 
D5Mit75, whereas these markers previously were not mapped separately. Also, 
in this designed panel, D5Mit268 previously mapped on a region 0.4 cM distal 
to that of D5Mit267, maps to a region 4.7 cM proximal to that of D5Mit267 
(figure 3.9).
3.12 The order of the candidate genes on the centromeric region of 
chromosome 5:
Three important candidate genes; Fibroblast growth factor receptor 3 
(Fgfr3), Interleukin 6 (II6), and Fibroblast growth factor inducible gene 13 (FIN 
13), map in the region showing definitive linkage. However, the positions of 
these genes on mouse chromosome 5 relative to that of MIT markers presently 
mapped has not been reported. Therefore, in an attempt to map the candidate 
genes relative to MIT markers utilised in the designed panel, the following 
investigations were carried out:
3.12.1 A tandom repeat on Fgfr3 intron:
A tandom repeat located in intron 4 (336....380nt) of Fgfr3 gene was 
already reported (Avivi et al., 1992). A primer set (Table 2.1,FGFR-C,D) was 
designed to screen the microsatellite for the possiblity of polymorphism 
between NIH/Ola and C57BI/6J/Ola strains. However, there was no size 
polymorphism between NIH/Ola and C57BI/6J/Ola strains.
3.12.2 RFLPs:
In an attempt to find any possible RFLP for Fgfr3 gene, the following 
restriction enzymes were utilized to digest DNA samples from NIH/Ola and
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C57BI/6J/Ola strains; Seal, Bgll, Bglll, Clal, EcoRI, EcoRV, Pstl, Xhol, Sail, 
Xbal, Kpnl, Apal, Hinfl, Hindlll. The digested-DNAs were hybridized with an 
Fgfr3 cDNA probe (full length). However, no informative RFLP was observed 
between NIH/Ola and C57BI/6J/Ola strains.
3.12.3 The microsatellites tightly linked to //6:
D5Nds8 maps to 17 cM of mouse chromosome 5, has been reported to 
be tightly linked to 116 (Breen et al., 1994). Amplified PCR of this marker 
between NIH/Ola and C57BI/6J/Ola strains did not show any size 
polymorphism.
A marker for 116 gene reported by Jacob et al (1993) was screened for 
polymorphism between NIH/Ola and C57BI/6J/Ola. The size of band was 
reported 125 bp in C57BI/6J/Ola strain. The same size was observed in 
NIH/Ola strain. Another marker for II6 reported by the same group, was 
screened between NIH/Ola and C57BI/6J/Ola. No size polymorphism between 
NIH/Ola and C57BI/6J/Ola strains was observed. The size of the marker on 
C57BI/6J/Ola strain is 80 bp.
3.13 Studies carried out on Candidate genes:
3.13.1 Expression Studies of candidate genes:
3.13.1.1 Fgfr3
Fgfr3 expression throughout the embryonic development (9.5-14.5 days 
pc) and into the early stages of fetal growth (14.5-16.5 dpc) has been reported. 
Its expression declined during late fetal development and then appeared to 
increase in the newborn (peters et al., 1993). However, there was no report 
about the expression of Fgfr3 in yolk sac. To investigate the possibility of strain 
specific expression of Fgfr3 at 9.5 dpc stage of embryo development, its 
expression was investigated by applying RT-PCR and utilizing designed primer 
set (Table 2.1, FGFR-A,B) from the coding sequence of Fgfr3 (Figure 3.10 a). 
To confirm that the fragment amplified by RT-PCR was complementary to Fgfr3 
gene, the PCR product was blotted onto a N hybond membrane and hybridized
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Figure 3.10: Expression studies on Fgfr3 by applying RT-PCR.
a) The expression of Fgfr3 in both yolk sac and embryo (9.5 dpc) of different 
strains. A single combined reaction PCR was developed to study the 
expression of Fgfr3. The 209 bp fragment is amplified from the coding region 
of the Fgfr3 gene and 72o bp fragment was amplified from GAPDFI gene 
which is used as a control. Fgfr3 is expressed at 9.5 dpc stage in both yolk 
sac and embryo from NIH/Ola and C57BI/6J/Ola strains. L; 100 bp ladder, N; 
NIH/Ola, C; C57BI/6J/Ola, E; Embryo, Y; Yolk sac.
b) Confirmation that the PCR product is from Fgfr3 gene. The PCR product was 
blotted onto a N hybond membrane and hybridised with a full length Fgfr3 
cDNA probe. The observation of the expected fragment size confirms that 
the PCR product is transcribed from the Fgfr3 gene.
with a full length Fgfr3 cDNA probe (Figure 3.10 b). The figure 3.10 b confirms 
that the PCR product was transcribed from Fgfr3 gene.
As it is illustrated on figure 3.10 a, Fgfr3 was expressed in 9.5 dpc embryos 
and yolk sacs in both strains.
3.13.1.2 Fin13:
To investigate the expression of Fin13 in 9.5 dpc embyos and yolk sac, 
in both strains, a RT-PCR was performed by utilising a designed set primers 
(table 2.1) from coding sequences of the gene (Figure 3.11).
The possibility that the expression of Fin13 was strain specific at 9.5 dpc 
embyo, is excluded. However, these results do not rule out the possiblity of 
different expression of FIN13 in TGFB1(-/-) embryos.
3.13.1.3 Tgfb l:
To investigate the expression of Tgfbl at 9.5 dpc embryos and yolk sacs 
in both strains, a set of primers was designed to perform RT-PCR from coding 
region of Tgfbl gene (Figure 3.12).
As it is illustrated in figure 3.12, Tgfbl expressed at 9.5 dpc stage in embryos 
and yolk sacs in both strains. Therefore, the possiblity of strain specific 
expression of Tgfbl was excluded.
3.13.2 Studies (heteroduplex and sequencing) on coding region of Fin13 
gene:
In an attempt to investigate the possiblity of polymorphism in Fin13 
cDNA between NIH/Ola and C57BI/6J/Ola strains, 1074 bp length (nt. 11-»563, 
nt. 959->1481) of the cDNA was amplified by utilising the designed primer sets 
(FN1A-B & FN3A-B, Table 2.2). The RT-PCR products were subjected to the 
heteroduplex anaylsis (HA) (figure 3.13). As it is illustrated in the figure there is 
no polymorphism detectable by HA in the regions under investigation between 
NIH/Ola and C57BI/6J/Ola strains.
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Figure 3.11: Expression studies on Fin13 gene by applying RT-PCR. The
expression of Fin13 in both yolk sac and embryo (9.5 dpc) of different 
strains. A single combined reaction PCR was developed to study the 
expression of Fin3. The 326 bp fragment is amplified from the coding region 
of the Fin13 gene and 209 bp fragment was amplified from Fgfr3 gene which 
is used as a control. Fin13 is expressed at 9.5 dpc stage in both yolk sac 
and embryo from NIH/Ola and C57BI/6J/Ola strains. L; 100 bp ladder, N; 
NIH/Ola, C; C57BI/6J/Ola, Y; Yolk sac, and E; Embryo.
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Figure 3.12: Expression studies on Tgfbl  gene by applying RT-PCR. The
expression of Tgfbl gene in both yolk sac and embryo (9.5 dpc) of different 
strains. A single combined reaction PCR was developed to study the 
expression of Tgfbl. The 326 bp fragment is amplified from the coding 
region of the gene and 209 bp fragment was amplified from Fgfr3 gene 
which is used as a control. Tgfbl is expressed at 9.5 dpc stage in both yolk 
sac and embryo from NIH/Ola and C57BI/6J/Ola strains. L; 100 bp ladder, N; 
NIH/Ola, and C; C57BI/6J/Ola. Y; Yolk sac. E; Embryo.
Figure 3.13: Heteroduplex analysis (HA) on Fin13 gene. In an attempt to 
investigate the possible polymorphism in the coding region of the Fin13 gene 
between NIH/Ola and C57BI/6J/Ola strains, the RT-PCR products (553bp + 
523 bp) from coding (and some untranslated) regions of the gene was 
amplified by utilising the designed primers (FN1A-B & FN3A-B, Table 2.2). 
The RT-PCR products were subjected to heteroduplex analysis. It can be 
seen that, there is no detectable polymorphism between the fragments from 
NIH/Ola and C57BI/6J/Ola. N; NIH/Ola, C; C57BI/6J/0!a, L; 1-kb ladder.
911 bp of the cDNA (table 3.11) (from coding and some non-coding sequence 
region of the gene) was sequenced (figure 3.14) to investigate possible 
polymorphism in the protein between NIH/Ola and C57BI/6J/Ola strains. No 
polymorphism was detected in the regions under investigation.
One of the RT-PCR products (nt. 959-»1481) from Fin13 gene amplified by 
utilising the designed primer set (FN3A-B, Table 2.2) was subcloned for further 
expression studies by other people in the group. The cloning was confirmed by 
utilising 2pl of the plasmid as a template. The expected size of the PCR 
product was observed (figure 3.15) confirming the insertion of the expected 
PCR product in the plasmid. Sequencing the insert (figure 3.14) verified the 
insertion of the expected PCR product.
3.14 TGFB1(+/-) embryo lethality:
TGFB1(+/-) lethality was suggested to be due to reduced TGFB1 levels 
(Dickson et al., 1995). During this project, to investigated the possibility of 
strain specific lethality of TGFB1(+/-) embryos, statistical analysis was 
performed on the data obtained from NIH/Ola and C57BI/6J/Ola crosses 
(Appendix IB, Table 4). As result indicate, there is no strain-specific factor 
responsible for TGFB1(+/-) embryo lethality in NIH/Ola and C57BI/6J/Ola 
strains.
3.15 Genomic mapping of Murine Transforming Growth factor beta type II 
receptor (Tgfbr2) gene.
Using somatic cell hybridisation and fluorescence in situ hybridisation, 
TBRII has been mapped to human chromosome 3p22 (Mathew et al., 1994) in 
a region syntenic with mouse chromosomes 6 (49-53 cM) and distal 9 (55-74 
cM) (Figure 3.16).
A 1.7-kb coding region cDNA probe was cloned by RT-PCR (Cui et al., 
1995). This full length cDNA was utilised to identify informative restriction 
fragment length polymorphism (RFLPs) among NIH/Ola, 129/Sv, and
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Table 3.11: The regions sequenced by applying different set primers of Fin13 
cDNA.
Regions sequenced (cDNA) bp sequenced(bp)
36 —>181 145
301 ->434 133
571 ->690 119
735 -> 940 205
955 —> 1075 120
1138 -> 1260 122
1375 -> 1442 67
Figure 3.14: Direct sequencing of cDNA of Fin13 gene from NIH/Ola and 
C57BI/6J/Ola strains.
d) 47 bp fragment sequenced between nucleotides 1017 - 1064. T;Thyamine, 
C; Cytosin, G; Guanin, and A; Adenosin.
T C G A  T C G A
Figure 3.14: Direct sequencing of cDNA of Fin13 gene from NIH/Ola and 
C57BI/6J/Ola strains.
c) 93 bp fragment sequenced between nucleotides 414 - 507. T;Thyamine, C; 
Cytosin, G; Guanin, and A; Adenosin.
Figure 3.14: Direct sequencing of cDNA of Fin13 gene from NIH/Ola and 
C57BI/6J/Ola strains.
b) 57 bp fragment sequenced between nucleotides 322 - 379. T;Thyamine, C; 
Cytosin, G; Guanin, A; Adenosin.
Figure 3.14: Direct sequencing of cDNA of Fin13 gene from NIH/Ola and 
C57BI/6J/Ola strains. Several regions of cDNA of Fin13 gene were 
amplified by utilising three primer sets and three nested primers (table 2.2). 
Afterward, the amplified regions were subjected to the sequencing 
technique.
a) 52 bp fragment sequenced between nucleotides 73 - 125. T;Thyamine, C; 
Cytosin, G; Guanin, and A; Adenosin.
L 1 2 3 4
I I I j I
Figure 3.15: Confirmation of subcloning (Fin13) by applying PCR. A 523 bp
RT-PCR product of Fin13 was cloned into a expression plasmid. Four 
different clones were picked up and the plasmid was extracted. Utilising 
these plasmids as templates in PCR revealed that two of the clones (lanes 
3, 4) contained the expected RT-PCR product (523 bp) whereas the other 
two clones (lanes 1, 2) contained longer RT-PCR products which could be 
due to recombination or insertion of non-specific RT-PCR products. L; 1 -kb 
ladder.
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Figure 3.16: Homologous regions of human chromosome 3p, on mouse 
chromosomes 6 and 9 (human-mouse homologue).
C57BI/6J/Ola. Genomic DNAs were digested with six different enzymes (Bell, 
Bglll, EcoRV, Xbal, Hindlll, BamHI) and subjected to Southern blot analysis. 
They were hybridised with full length 1.7-kb Tgfbr2 cDNA. Only BamHI- 
digested genomic DNA, revealed different bands among different strains (table 
3.12, Figure 3.17). There was a possibility that this RFLP among the strains 
was due to hybridisation of the probe (1.7-kb) with pseudogenes. To address 
this problem, the cDNA (Figure 3.18) was digested with different enzymes to 
obtain more specific fragments of the probe and also a 5’ Tgfbr2 probe (1-676) 
(Cui et al, 1995), represented as P1 in figure 3.18. These were utilised for 
detailed examination of RFLPs revealed in BamHI-digested DNAs. Using P1 as 
a probe for hybridisation of BamHI-digested DNA's, revealed the following DNA 
fragments; 4, 7.5, 14 kb for NIH/Ola, 4, 6, 8 kb for C57BI/6J/Ola, and 4, 7.5, 
and 12 kb for 129/Sv (Table 3.13, Figure 3.19).
BamHI-digested DNAs from different strains, was hybridised with P3, 3’ 557nt 
SacI-EcoRI probe (1160-1717). Different DNA fragments were revealed as 
shown in Table 3.14 and Figure 3.20. These fragments were; 8, 14 kb for 
NIH/Ola, 8 kb for C57BI/6J/Ola, and 4.5, 12 kb for 129/Sv.
Results presented in table 3.13, excluded the possibility that any of the bands 
were due to hybridisation of Tgfbr2 probe (1.7kb) with pseudogene(s).
In order to design a probe which could reveal RFLPs between different 
strains of NIH/Ola, C57BI/6J/Ola, and 129/Sv, a BamHI-restriction map of T0RII 
genomic structure between different strains of NIH/Ola, C57BI/6J, and 129/Sv 
was inferred by detailed examination of the DNA bands observed by applying 
different regions of the Tgfbr2 cDNA probe for hybridisation (Figure 3.21, Table 
3.15). On the basis of these results, a probe (P2) was designed which enabled 
an RFLP distinguished. Table 3.16 and figure 3.6 show DNA fragments 
revealed by applying P2 (843-1160) probe for hybridisation of BamHI-digested 
DNAs. This RFLP for the Tgfbr2 gene enabled the segregation of the gene in 
50 F2 (NIH/Ola x C57BI/6J/Ola) animals to be followed in order to localise the 
Tgfbr2.
As discussed before, TGFBR2 was mapped to human 3p22 in a region 
syntenic with mouse chromosomes 6 (49-53) and distal 9 (55-74). 12
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Figure 3.17: Southern Blotting analysis of the Tgfbr2 gene from NIH/Ola, 
C57BI/6J/Ola, and 129/Sv strains. Full length fragment (1.7 kb) from the 
coding region of the gene was used as a probe to reveal RFLPs between all 
strains under investigation; NIH/Ola, C57BI/6J/Ola, abd 129/Sv. BamH1 
digestion of genomic DNA revealed different size of fragments between the 
mouse strains as follows: NIH: 4, 7.5, 8, and 14 kb. C57: 4, 6, 8, and 12 kb. 
129: 4, 4.5, and 12 kb.
Table 3.12: Illustration of different size DNA fragments revealed when Bam HI- 
digested DNAs were hybridised with the full length (1.7-kb) Tgfbr2 probe.
Strain
▼
3 Kb 4 Kb 4.5 Kb 6 Kb 7.5 Kb 8 Kb 12 Kb 14 KbLength 
of Band
NIH/Ola - ++ - - d + - ++
C57BI/6J IIIIIII! - ++ - d - ++ d -
129/sV - ++ + - d - ++ -
Mus.
Spret.
d ++ “ d ++
“++” represents the presence of a very high density band whereas “+” stands 
for the presence of a band with weak density. stands for not observing any 
band, “d” stands for dubious band.
Figure 3.18: Restriction Enzyme map of mouse Tgfbr2 cDNA.
H,Sp,P,Sa Bg Sc Sa,X,BH,Sm,K,Sc,E
1 1 1 1
1 676 843 1160 1717
P1 P2
P3
H: Hindi 11, Sp: Sphl, P: Pstl, Sa: Sal I, Bg: Bgl II, Sc: Sacl, X: Xbal, BH: BamHI, 
Sm: Smal, K: Kpnl, E: EcoRI.
P1: Probe 1, P2: Probe 2, P3: Probe 3.
NIH NIH NIH C57 129
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Figure 3.19: Southern Blotting analysis of the Tgfbr2 gene from NIH/Ola, 
C57BI/6J/Ola, and 129/Sv. 676 bp (1-676 nt) fragment (P1) from the coding 
region of the gene was used as a probe. BamHI digestion of genomic DNA 
revealed the following fragments; NIH: 4, 7.5 and 14 kb. C57: 4, 6, and 8 kb. 
129: 4, 7.5, and 12 kb.
Table 3.13: Presentation of different size DNA fragments revealed when 
BamHI-digested DNAs were hybridised with the P1 probe (1-676 nt) Tgfbr2 
probe.
Strain
▼
3 Kb 4 Kb 4.5 Kb 6 Kb 7.5 Kb 8 Kb 12 Kb 14 KbLength 
of Band
NIH/Ola - ++ - - + - - +
C57BI/6J - ++ - + - + - -
129/sV ++ - - + - + -
Mus.
Spret. lillliilillll
+ ++ ~ “ +
“++” represents the presence of a very high density band whereas “+" stands for the presence 
of a band with weak density. stands for not observing any band.
NIH NIH NIH C57 129
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Figure 3.20: Southern Blotting analysis of the Tgfbr2 gene from NIH/Ola, 
C57BI/6J/Ola, and 129/Sv. 557 bp (1160-1717 nt) SacI-BamHI fragment 
(P3) from the coding region of the gene was used as a probe. BamHI 
digestion of genomic DNA revealed the following fragments; NIH: 8 and 14 
kb. C57: 8 kb. 129: 4.5 and 12 kb.
Table 3.14: Presentation of different size DNA fragments revealed when 
BamHI-digested DNAs were hybridised with the P3 probe (1160-1717 nt) 
Tgfbr2 probe.
Strain
▼
3 Kb 4 Kb 4.5 Kb 6 Kb 7.5 Kb 8 Kb 12 Kb 14 KbLength 
of Band
NIH/Ola - - - - - + - +
C57BI/6J - - - - - + - -
129/sV - - + - - - + -
Mus.
Spret. Ipp- '
“ ” +
' '
“
“++” represents the presence of a very high density band whereas “+” stands for the presence 
of a band with weak density. stands for not observing any band.
Figure 3.21: BamHI-restriction enzyme mapping of Tgfbr2 genome in different 
strains, (small arrows represent the restriction enzyme sites for BamHI enzyme)
+ A B C + D +
Table 3.15: Size of BamHI-restriction enzyme fragments of Tgfbr2 genome 
inferred from revealed DNA fragments in different Southern blotting by 
applying different parts of Tgfbr2 cDNA probe.
Strain A (Kb) B (Kb) C (Kb) D (Kb)
NIH/Ola 7.5 4 14 8
C57BI/6J 6 4 8 8
129/sV 7.5 4 12 4.5
Mus. Spr. 3 4 8 6
Table 3.16: Presentation of different size DNA fragments revealed when 
BamHI-digested DNAs were hybridised with the P2 probe (843-1160) Tgfbr2 
probe.
Strain i r 3 Kb 4 Kb 4.5 Kb 6 Kb 7.5 Kb 8 Kb 12 Kb 14 KbLength
NIH/Ola - - - - - - - +
C57BI/6J - - - - - + - -
129/sV - - - - - - + -
Mus.
Spret. iiiiiiiiii
“ “ “ “ “ +
“+”  represents the presence o f a band, whereas stands for not observing any band.
microsatellite markers from syntenic regions were screened between NIH/Ola 
and C57BI/6J/Ola strains. Four of the informative microsatellite markers 
(D6Mit25, D9Mit16, D9Mit150, D9Mit18) were selected from syntenic regions 
(table 3.17) and their segregation was followed in 50, F2 (NIH/Ola x C57BI/6J) 
animals.
Segregation of the microsatellite markers in 50 F2 intercross animals 
were compared to that of Tgfbr2 RFLPs. No linkage was found with D6Mit25, 
but linkage was found with markers on chromosome 9 (Figure 3.22)
By solving the equation (Standard Error, Appendix ll-E) for data obtained 
from mapping Tgfbr2, standard errors (SE) were calcualted as follow (cM ± 
SE): Centromere-D9Mit16 (2.1 ± 0.014)-D9Mit150 (3.1 ± 0.02)-Tgfbr2 (1 ± 0.0)- 
D9Mit18.
3.15.1 Uncloned mouse mutations:
Several uncloned mouse mutations map within the region of Tgfbr2, 
including ky ( kyphoscoliotic degenerative muscle; 56 cM), du (ducky; 59-60 
cM), tip (tippy; 63 cM), sr (spinner; 64 cM), fd (fur deficient; 48-54 cM), and sch 
(scant hair; 69-72 cM). In order to examine the possibility of a large deletion 
covering Tgfbr2 in any of these mutant mice, DNAs were obtained from 
Jackson labs. Southern blot analysis was performed using HindlH-digested 
DNAs from mice homozygous for du (Green 1989, Snell 1995) and 
homozygous for tip (Green 1989, Lane 1984) (Figure 3.23).
As illustrated in figure 3.23, the possibility of a large deletion covering the 
Tgfbr2 gene within either of these mutants was excluded. However, it is now 
known that nullizygous Tgfbr2 mice are not viable (Oshima et al., 1996), and 
any of the mutant mice listed above might involve more subtle molecular 
pathologies within the Tgfbr2 gene.
3.16 Genomic mapping of Murine Plasminogen activator inhibitor type I 
(PlanHI) gene.
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Table 3.17: Microsatellite markers located on mouse chromosomes 6 and 9, in 
a syntenic region with human 3p22.
Marker Chromosome cM Informative 
between NIH & C57
D6Mit13 6 49
—
D6Mit25 6 50 +
D6Mit197 6 50
—
D6Mit9 6 36.5
—
D6Mit19 6 33.5
—
D9Mit19 9 71
—
D9Mit152 9 70
—
D9Mit82 9 71
—
D9Mit151 9 72
—
D9Mit18 9 67 +
D9Mit16 9 57 +
D9Mit150 9 59 +
A2.1
3.1
D9Mit 16
D9Mit 150
1
Tgfbr2 
D9Mit 18
D9 Mit 16 □ ■ H 11 IS H
D9 Mit 150 n ■ II g 11 □ □ =N / N
Tgfbr2 n ■ II 11 □ □ ■  =N /C
D9 Mit 18 □ ■ ■ □ □ □ m C /C
7 17 20 1 3 2
Figure 3.22: Tgfbr2 maps to distal chromosome 9 (59-67 cM). (up)
Partial linkage map of chromosome 9, showing the position of Tgfbr2 relative to 
D9 Mit 16, D9 Mit 150, D9 Mit 18. Recombination distances between loci are 
shown to the left of the chromosome, (below) Allelic segregation of Tgfbr2 and 
D9 Mit 18 in the 50 ( NIH/Ola X C57BI/6J/Ola ) intercross mice, using the Bglll- 
Sacl Tgfbr2 probe. N, NIH allele; C, C57BI/6J/Ola allele. The number of 
animals exhibited each allelotype are shown below each column.
Figure 3.23: Southern Blotting analysis of the Tgfbr2 gene from 
himozygous tip and homozygous du mutant mice. 317 bp Bglll-SacI 
fragment from the coding region of the gene was used as a probe to 
investigate the possible large deletion of the Tgfbr2 gene in the mutant tip 
and du mice. Southern blot analysis was performed using Hindlll-digested 
DNA from mice homozygous for du (Line I), wild type (Line II), homozygous 
for tip (Line III), and wild type (Line IV). All lines are showing the same size 
which exclude the possible large deletion of the gene in these mutant mice
The PAH gene has been assigned to human 7 cen-q32 by Southern blot 
analysis of a panel of human/mouse somatic cell hybrids and utilising 
florescent in-situ hybridisation (FISH), it was further localised to 7q21.3-q22 
(Klinger et al., (a)1987;(b)1987 ). This region is syntenic with three regions of 
the mouse genome, the centromeric (1-20 cM) and distal (70-88 cM) region of 
chromosome 5 and the centromeric region of chromosome 6 ( cent.-15 cM) 
(figure 3.24). To map PlanHI on the mouse genome, a murine PlanHI coding 
region cDNA (Lund et al., 1996) was utilised to identify informative restriction 
fragment length polymorphism (RFLPs) between NIH/Ola and C57BI/6J. 
BamH1-digested DNAs hybridised with full length PlanHI probe (520 bp) 
revealed RFLPs among NIH/Ola, C57BI/6J/Ola, and 129/sV (Table 3.18, Figure 
3.7). DNAs from Mus. Spretus were either purchased from Jax. Lab. (USA) or 
given by Professor A. Balmain’s research group (Beatson Institute, UK). 
BamH1 -digested DNAs from two Mus. Spretus animals originated from USA 
and UK, hybridised with full length PlanHI cDNA revealed a RFLP between 
Mus. Spretus from USA and Mus. Spretus from UK ( Figure 3.25).
To localise the murine PlanHI gene, 48 progeny derived from matings of 
(C57BI/6J/Ola x NIH/Ola) F2 mice were utilised to examine the segregation of 
PlanHI RFLPs. Informative microsatellite markers from mouse chromosomes 5 
and 6 (Appendix ll-C) located in the syntenic region with human chromosome 
7q21.3-22, were selected (D6Mit74, D5Mit49, D5Mit251, D5Mit233, D5Mit7, 
D5Mit188, and D5Mit161) to screen the 48 progeny derived from matings of 
(C57BI/6J/Ola X NIH/Ola) F2.
The mapping of PlanHI gene was accomplished by searching for concordant 
segregation on designed panel of 48 F2 (NIH/Ola x C57BI/6J) animals between 
PlanHI RFLP’s and markers previously mapped on syntenic regions of human 
(7q21.3-22) on mouse chromosomes 5 and 6.
No linkage was observed with D6Mit74, which has already been mapped to the 
centromeric area (11 cM) of chromosome 6. However, linkage was obvious with 
some markers on chromosome 5 (Figure 3.26). Recombination fractions were 
calcualted by applying the computer program, MapMAKER vers. 3.0 b (Lander
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Figure 3.24: Syntenic regions of human chromosome 7q21, on mouse 
chromosomes ( human-mouse homologue).
Figure 3.25: Southern Blotting analysis on PlanHI gene between Mus 
Spretus strains origenated from the UK and USA. Full length of the 
coding region of the gene was used as a probe. The fragments were 
approximately 4 kb and 7.5 kb in the BamHI-digested DNAs from Mus 
Spretus (USA) (lane 1), and Mus Spretus (UK) (lane 2), respectively.
Table 3.18: Presentation of the size of RFLPs in different strains revealed by 
hybridisation of BamH1-digested-DNAs with full length PlanHI probe.
Strain Estimated Size of Band
NIH/Ola 4 Kb
C57BI/6J 4.3 Kb
129/sV 4 Kb
Mus. Spretus (UK) 7.5 Kb
Mus. Spretus (USA) 4 Kb
Recomb. cM SE Loci
14 19.2
D5Mit49
± 1.37
D5Mit251
15 20.6 ± 1.47
D5Mit233
13 15.3 ± 1.27
D5Mit7
13 17.1 ± 1.27
1.1 ± 0.0
D5Mit188
D5Mit161
13 17.1 ± 1.27
PlanH 1
Chromosome 5
Figure 3.26: The PlanHI RFLPs segregation in the 48 F2 (NIH/Ola x C57BI/6J) 
intercross mice compared with that of microsatellite markers (D5Mit49, 
D5Mit251, D5Mit233, D5Mit7, D5Mit188, D5Mit161, D6Mit74). These markers 
were selected from the regions of mouse chromosome 5 and 6 which show 
synteny with human 7q21,3-q22.
et al., 1987). Standard error was calculated by applying SE equation (Appendix 
ll-E).
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4: Discussion
4.1 TGFB1 knockout animals:
The observation of at least two different phenotypes of TGFB1(-/-) 
conceptuses bred onto the mixed genetic background (NIH/Ola, C57BI/6J/Ola, 
and 129/Sv), gave rise to the notion of the possible involvement of modifying 
factor(s). The presence of maternal TGFB1 in TGFB1(-/-) embryos has been 
demonstrated. It has been suggested that dichotomy in TGFB1(-/-) lethal 
phenotypes is due to maternal TGFB1 rescue of some, but not all, TGFB1(-/-) 
embryos (Letterio et al., 1994). Therefore, it was an absolute requirement to 
define the observed traits as strain-specific phenotypes and to then to attempt 
identify the modifying factors influencing in the expressivity of TGFB1(-/-) 
phenotype.
A previous study in which different expressivity of TGFB1(-/-) phenotype 
was observed, Tgfbl null allele was bred onto three different genetic 
backgrounds; 50% NIH/Ola, 37.5% C57BI/6J/Ola, and 12.5% 129/Sv. In this 
project, in order to study the possible influence of genetic background in the 
phenotype, the Tgfbl knockout allele was bred through four generations onto 
either NIH/Ola or C57BI/6J/Ola inbred strains. The selection of these two 
strains was on the basis of the following facts:
1) In independent studies carried out by Mr. Peter Kerr and Dr. Wei Cui, it was 
noticed that on a 75% NIH/Ola genetic background a high percentage of 
TGFB1(-/-) animals developed to term.
2) C. Biron and H. Su had bred null allele onto C57BI and found that out of 300 
animals no TGFB1(-/-) animal developed to term.
3) 129/Sv strain contributed 12.5% to the mixed genetic background animals 
showing different expressivity of TGFB1 (-/-), whereas that of NIH/Ola and 
C57BI/6J/Ola strains was 50% and 37.5% respectively. Therefore, due to less 
contribution of 129/Sv strain to the mixed genetic background, it was excluded 
from this study.
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4.2 Phenotypic assessments:
To understand the biology and pathological processes, and moreover to 
investigate the factors involved in any phenotype such as IDDM or NTD (neural 
tube defects), it has been necessary to carry out a full and objective phenotypic 
assessment to distinguish and classify animals into two or more classes. 
Therefore, according to conventional linkage analysis, animals had to be 
classified into at least two classes on the basis of their phenotypes. Upon 
starting this project two phenotypes; yolk sac phenotype and survival to birth, 
were identified on the mixed genetic background.
4.2.1 Yolk sac phenotype:
Ideally, DNA would have been analysed from both categories or 
phenotypes observed, by extracting DNA from embryos of known phenotype at
9.5 dpc i.e. normal and abnormal but prior to prenatal death. However, due to 
the difficulty of dissecting and accurately scoring very small 9.5 dpc embryos, 
the variable expressivity of the yolk sac phenotype, and the limiting quantities 
of DNA available, this did not seem like an ideal option. Furthermore, at the 
time, there was no information about the stage of TGFB1(-/-) embryo lethality 
bred onto C57BI/6J/Ola strain. Latest studies has shown that in C57BI/6J/Ola 
genetic background, a significant fraction of TGFB1(-/-) embryos tend to die 
before the midgestation stage (Rusholme PhD Thesis., 1997).
4.2.2 Survival to birth:
It was noticed that in NIH/Ola strain TGFB1(-/-) neonates tend to 
develop to term normally whereas in C57BI/6J/Ola strain all of the conceptuses 
were dying in utero. This implied that modifying factors in the NIH/Ola strain 
could rescue TGFB1(-/-) conceptuses from prenatal lethality but not in 
C57BI/6J/OIa strain. Therefore, utilising only animals which survived to birth 
would provide large quantities of DNA from an unambiguous phenotype. This 
would overcome the problems of different expressivity of the yolk sac
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phenotype and the availability of limiting quantity and quality of DNA. However, 
by taking survival to birth as the criterion for classification, only one group of 
animals could be accessible for the purpose of linkage analysis. The 
implication was that more matings needed to be set up to obtain sufficient 
TGFB1(-/-) neonates for analysis [only 42% survival of TGFB1 (-/-)] . In 
practise, the need to generate more TGFB1(-/-) neonates was not a problem 
since mating pairs produced new litters every three weeks, and each dam was 
capable of generating several litters. In contrast, if embryos had been 
harvested, each dam would only have provided one litter for analysis.
4.2.3 Control animals:
In conventional crosses set up for the purpose of identifying genetic 
factors involved in complex traits such as IDDM or NTD, affected versus 
unaffected animals have been studied as controls for each other. Therefore, 
the percentage of affected animals in various crosses between susceptible and 
resistance parental strains could be estimated to derive an approximate 
number of the loci involved in the phenotype. In this study, because of the 
constraints discussed above (4.2.2), only one group of TGFB1(-/-) animals was 
selected to study, therefore, it was necessary to choose an alternative group of 
animals as a control. To generate TGFB1(-/-) animals, intercrosses between 
TGFB1(+/-) animals were set up. The Mendelian ratio of 1:2:1 for TGFB1 (-/-), 
TGFB1(+/-) and TGFB1(+/+) animals respectively was expected. TGFB1(+/-) 
lethality was observed in both pure (93.7%) NIH/Ola and C57BI/6J/Ola strains 
without statistically significant differences between each other, indicating the 
involvement of non-strain specific factors in lethality of heterozygous embryos. 
Moreover, according to the previous study, the level of maternal circulating 
TGFB1 could be important in influencing prenatal survival of TGFB1(+/-) 
embryos (Dickson et al., 1995). Therefore, to avoid any interference by 
TGFB1(+/-) embryo lethality, the percentage of which is probably due to non- 
genetic factors, the percentage survival (observed/expected) of TGFB1(-/-) 
embryos to birth was estimated as N° (-/-) /  N° (+/+). The premise was that any
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possible factor leading to prenatal loss of TGFB1(+/+) embryos would have an 
equal effect on TGFB1(-/-) embryos.
4.3 Strain-dependent expressivity of TGFB1 (-/-) phenotype:
Observing 82% of TGFB1(-/-) embryos developing to term in NIH/Ola 
genetic background but non in C57BI/6J/Ola genetic background gave rise to 
the notion that different expressivity of TGFB1(-/-) phenotype was due to strain 
specific modifying factor(s). In NIH/Ola strain 18% of the TGFB1(-/-) embryos 
died in mid-gestation stage from defective yolk sac vasculogenesis and in 
C57BI/6J/Ola strain TGFB1(-/-) conceptuses tend to die prior to mid-gestation 
stage (Rusholme, PhD Thesis., 1997). The stage in which C57BI/6J/Ola 
TGFB1(-/-) conceptuses died yet remains to be revealed.
4.4 Possible factors involved in different expressivity of TGFB1(-/-) 
phenotypes:
In studies carried out to identify susceptible loci for a variety of 
genetically disorders such as IDDM or NTD, adult animals have been utilised. 
Therefore, in these investigations the major factor(s) involved in resistance or 
susceptibility of animals to the trait was solely due to the genetic background of 
animals and/or the respond of genetic factors toward environmental factors. 
However, in this project the major objective of the study was to study 
developmental outcome of TGFB1(-/-) embryos which could profoundly be 
influenced by maternal factors as well as embryonic factors. Therefore, despite 
the fact that different expressivity of the TGFB1(-/-) phenotype was strain- 
dependence, it was an absolute requirement for linkage analysis to differentiate 
between maternal strain specific (or non-embryonic) factors and embryonic 
strain-specific factors.
In the project, the possible strain-specific modifying factors involved in 
modifying the phenotypic outcome of TGFB1(-/-) conceptuses could be 
categorised into three classes as follows:
1) Strain-specific role of TGFB1 in gametogenesis.
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2) Strain-specific influence of maternal factors such as maternal source of 
TGFB1 or the maternal immune system on the survival and development of 
TGFB1(-/-) conceptuses.
3) Cardinal effect of the genetic background of TGFB1(-/-) conceptuses on the 
phenotypic outcome.
Also, there could be the possibility of additive or non-additive interactive effects 
of these factors in the different expressivity of TGFB1 (-/-) phenotype.
To accomplish the indirect investigation in clarifying the involvement of either of 
these possible factors in the different expressivity of TGFB1(-/-) phenotype, 
various combinations of inter-crosses between NIH/Ola and C57BI/6J/Ola were 
set up and statistically analysed.
4.4.1 Viability of gametes carrying null Tgfb l allele:
The selective failure or low transmission of mutant alleles is a rare 
event. The best model in the mouse is that of t-haplotypes that cause a low 
transmission of the homologous wild type (+) chromosome from male but not 
female. Sperm bearing complete t-haplotypes are preferentially transmitted 
during fertilisation from heterozygous t/+ males, often in excess of 95% relative 
to their (+) bearing meiotic partner. It has been reported that sperm from t- 
bearing males have an approximate two-to four fold increase in beta 1,4- 
galactosyltransferase (GlaTase) activity, a cell surface protein that mediates 
sperm binding to the egg zona pellucida (Shur & Scully, 1990).
There is much evidence indicating the role of TGFB1 in reproductive 
function, with effects ranging from an influence on germ cell migration during 
embryogenesis, to modulation of ovarian and testicular function in the adult 
(Godin and Wylie, 1991). TGFB1 has been localised in both sperm and ovum 
(Chu et al., 1996) and its expression in embryonic and adult testis and all 
ovarian cell types has been reported (Derynck et al., 1988; Miller et al., 1989 a, 
b; Watrin et al., 1991). Based on previously published data (Shull & 
Doetschman., 1994) and confirmed during this project, it is apparent that there 
is a loss of TGFB1(+/-) embryos. This could raise the possibility that TGFB1
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function may be important in haploid germ cell function such that in the 
absence of a functional Tgfbl gene, germ cell function or survival is impaired, 
leading to a reduction in the frequency of conceptions involving the mutant 
germ cells. This possibility could explain the reductions in both the 
heterozygous and homozygous mutant offspring relative to the wild type. 
However, in this study, the possibility of selective failure or low transmission of 
Tgfbl knockout allele through maternal and/or paternal gametes in 
C57BI/6J/Ola strain was ruled out by observing statistically significant 
differences in the number of TGFB1(-/-) survivals from various crosses using 
C57BI/6J/Ola either as females or males. Moreover, the possibility of failure or 
low transmission of the Tgfbl null allele should have changed the Mendelian 
ratio of 1:2 for TGFB1(+/+) and TGFB1(+/-) offsprings in C57BI/6J/Ola crosses 
but not in NIH/Ola crosses whereas there was no significant differences 
between these two strains in the percentage of TGFB1(+/-) neonates 
developing to term normally.
4.4.2 Maternal factors:
4.4.2.1 Maternal circulating TGFB1:
The main purpose of gene knockout technology is to remove a protein 
and examine the outcome in vivo. However, in the case of secreted proteins 
maternally-acquired protein could interfere with interpretations. It has been 
demonstrated that maternal TGFB1 can cross the placenta and its contribution 
to survival of TGFB1(-/-) embryos has been suggested (Letterio et al., 1994). 
Moreover, it has been shown that addition of TGFB1 to the culture medium 
significantly increases the percentage of embryos developing into blastocyst 
without increasing the number of cells per blastocysts (Paria & Dey., 1990) 
indicating the possible involvement of the environmental TGFB1 in 
development of embryos. Survival of more than 80% of the TGFB1(-/-) bred 
onto NIH/Ola strain but non in C57BI/6J/Ola strain, raised the possibility that 
the level of maternal circulating TGFB1 could differ and result in different 
expressivity of TGFB1(-/-) phenotype between two strains.
\
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4.4.2.2 The maternal immune system:
There is much evidence that pregnancy loss may be immunologically 
mediated. Failure of the maternal immune system to actively support the 
pregnancy may be responsible for its demise. Some mouse models have an 
unusual high rate of fetal resorption; 30% as compared to 5% in other matings. 
The first mouse model mentioned by Clark et al., (1980) includes CBA/J female 
mice mated to DBA/2J males. In the CBA/J x DBA/2J system, abortion occurs 
at four to six days after implantation and is followed by specific changes in the 
immune profile of CBA/J mothers. However, it is important to bear in mind that 
in inbred crosses, e.g. NIH/Ola or C57BI/6J/Ola strains, due to the fact that all 
animals are genetically identical, expressed antigens by embryos which belong 
to both maternal and paternal major histocompatibility complex (MHC) do not 
represent a potential target for the maternal immune system.
It has been shown that some cytokines produced by both T cells and 
non-T cells (IL-3, TGFB, IL-4, IL-10) favour fetal survival and growth whereas 
other cytokines such as IFN^y, TNF-p and TNF-a can rather compromise 
pregnancy (Piccinni & Romagnani., 1996). Therefore, it raised the notion that 
TGFB1(-/-) embryos could represents a potential target for the maternal 
immune system in C57BI/6J/Ola genetic background but not in NIH/Ola strain 
(polymorphism in the maternal immune systems between two strains).
The possible involvement of all maternal factors in different expressivity 
of the TGFB1(-/-) phenotype was studied indirectly by statistical analysis of the 
number of TGFB1(-/-) neonates developed to term in various reciprocal 
crosses between two strains; NIH/Ola and C57BI/6J/Ola. The lack of statistical 
significant difference in the number of TGFB1(-/>) survivals in reciprocal 
crosses, ruled out the involvement of any possible maternal factor in different 
expressivity of the TGFB1(-/-) phenotype.
4.4.3 Embryonic strain specific factor:
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The only major factor(s) contributed ~80% to the different expressivity of 
the TGFB1(-/-) phenotype has been clearly demonstrated to be embryonic 
strain specific factor(s). These genetic factor(s) in NIH/Ola but not in 
C57BI/6J/Ola could either compensate for the absence of TGFB1 function 
during early stage of embryogenesis or enable the embryo to respond to 
maternal source of TGFB1.
4.5 Estimating the number of gene(s) involved in the survival of TGFB1(-7-) 
neonates:
Before embarking on a detailed mapping project, it was useful to derive 
an estimate of the number of segregating genes involved in the expression of 
the trait under analysis. In complex cases of inheritance, the derivation of such 
an estimate is not possible. However, a crude estimate of the minimum number 
of genes involved can be made with a sufficient number of backcross animals if 
a discrete phenotype is evident which shows an absolute requirement for 
alleles at multiple unlinked loci from the affected parent. An estimation of gene 
number in this situation is trivial because the expression of the variant 
phenotype is absolutely correlated with the presence of a parental strain 
genotype at involved loci. The probability of this occurrence is (0.5)", where n is 
the total number of loci required for expression. Thus, if the observed 
proportion of affected animals is approximately 25%, this would imply the action 
of two required genes [i.e. (0.5)n=0.25 => n=2 ].
Sometimes a single polymorphic locus with a high degree of variable 
expressivity can give rise to phenotypic variation. However, if a single locus is 
responsible for the entire genetic contribution to different traits between two 
inbred strains, this would almost certainly become apparent in the second 
generation of either an F1 backcross or F1 intercross breeding protocol. The 
estimated number of loci involved depends critically on the assumed model of 
recessive epistasis. In fact, if the loci do not act in a purely recessive fashion 
(i.e. if heterozygotes can also be affected) then the above procedure can 
significantly underestimate the number of loci involved.
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To estimate the number of loci involved in the survival of TGFB1(-/-) 
neonates, analysis of data obtained from F1 (NIH x C57) crosses was required. 
Figure 4.1, shows idealised distributions for the expression of a discontinuous 
trait in two inbred strains and the F1 hybrid between them. In this example, the 
levels of expression for two inbred parental population (NIH , C57) are 
separated from each other according to the percentage of null pups bred onto 
NIH/Ola or C57BI/6J/Ola genetic backgrounds which developed to term 
normally. Three examples of F1 distribution are shown. The first F1 distribution 
would be expected with a trait controlled by a series of C57 alleles that all show 
complete dominance to their corresponding NIH alleles. The third F1 
distribution would be expected with a trait controlled by NIH and C57 alleles 
that all show strict semidominance. The second F1 distribution would be 
expected with more complex scenarios including incomplete dominance 
skewed toward one parent. Since each population is genetically homogenous, 
variation in expression must be due to environmental effects or chancel.
In this study, TGFB1(-/-) phenotype expressivity in F1 was 32%. This 
expression pattern follows the second F1 distribution in which incomplete 
dominance skewed towards the C57 parent. It could be interpreted to indicate 
that at least one codominant acting gene is involved or that several interacting 
genes with codominant outcome trait are involved, making it that 32% of the F1 
null embryos rescue from yolk sac phenotype (Rusholme PhD Thesis., 1997) 
while the rest die in utero. As mentioned above, the observed variation in 
expression in genetically homogenous TGFB1(-/-) embryos must be due to 
environmental factors. In this project the best candidate for environmental 
factor was the level of maternal circulating TGFB1.
To estimate the number of loci, several models could be proposed and 
the simplest model which fits the observed data obtained from different 
backcrosses and intercross could be suggested. The simplest model which fits 
the data, is a single gene model with two alleles. If we assume that a single 
gene with two alleles explains the pattern of survival, then the maximum 
likelihood estimates for the survival rates for N/N, C/C, and N/C genotypes are
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Figure 4.1: Illustration of distribution for the expressivity of TGFB1 
null conceptuses in two inbred strains and the three idealized 
distribution of F1 hybrids between them.
86%, 0%, and 32% respectively. These estimates take into account the varying 
numbers of pups as well as attempting to allow for the missing pups. In this 
model, F1 animals showed incomplete dominance of the C57 allele, and mostly 
they were poised between lethality and survival.
4.6 Screening the genome:
Due to the fact that TGFB1(+/-) parents bred onto either NIH/Ola or 
C57BI/6J/Ola strains were only ~93% pure, not all markers were informative in 
every animal. Therefore, uninformative animals for some of the markers were 
excluded from the statistical analysis.
During this project three approaches were utilised to perform linkage analysis 
on different loci:
1) Performing linkage analysis on candidate loci not mapped previously.
2) Linkage analysis carried out on candidate loci mapped previously.
3) Linkage analysis performed on unknown loci (genome-wide search).
4.6.1 F1 backcross or F1 intercross animals:
Upon beginning the linkage analysis in this study, either of crosses; F1 
intercross or F1 backcross, could be utilised based on the fact that F1 (NIH/Ola 
x C57BI/6J/Ola) males were fertile. However, it should be borne in mind the 
possibility that in some complex traits due to epistatic effects among the 
involved loci, some of the loci literally vanish between different crosses of the 
same parents. For example, in the epileptic EL mouse model, dominant alleles 
at EL1 and EL2 have major effects on seizure frequency in an (ABP x EL)F1 x 
ABP backcross, but negligible effects in the intercross (ABP x EL)F2 (Rise et 
al., 1991; Frankel et al., 1995). Conversely, EL5 had a large effect in an 
intercross (EL x DDY)F2 but none in the corresponding backcross to DDY 
(Frankel et al., 1995). A combination of backcross and intercross analysis 
would be ideal to check for the presence of all possible genes.
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In this study, due to the codominant nature of the locus (loci), and to 
procure more informative animals and high-resolution mapping for the purpose 
of positional cloning, the F1 intercross approach was applied for the linkage 
analysis.
4.6.2 Imprinted and sex-linked genes:
Genomic imprinting, inactivation of maternal (e.g. snrpn)(Letf et al., 
1992) or paternal (e.g. Igf2r)( Barlow et al., 1991) alleles of certain genes 
during gametogenesis, has been increasingly recognised as an important 
component of gene regulation (Surani et al., 1984; Barlow et al., 1991; Leff et 
al., 1992; DeChiara et al., 1991; Bartolome et al., 1991). During this study, the 
involvement of imprinted and/or sex-linked genes in the different expressivity of 
TGFB1(-/-) phenotype was investigated. The involvement of imprinted and/or 
sex-linked genes in any phenotype (trait) would result the observation of 
different percentages of animals developing the disease (or phenotype) in 
reciprocal crosses between different strains. The absence of significant 
difference in reciprocal crosses between NIH/Ola and C57BI/6J/Ola excluded 
this possibility. Also based on these results, the possible involvement of Igf2r in 
the survival of TGFB1(-/-) conceptuses which was suggested in a preliminary 
study carried out on a small number of TGFB1(-/-) animals from a mixed 
genetic background (Bonyadi, Msc Thesis, 1994), was ruled out. Moreover, the 
lack of any statistically significant difference in survival of male and female 
offsprings [ i.e. TGFB1(-/-) neonates] verified the exclusion of any major sex- 
linked gene involved in the different expressivity of TGFB1(-/-) phenotype. 
Therefore, the X chromosome constituting at least 5% of the whole genome 
was excluded from the genome-wide screening.
4.6.3 Candidate genes:
Prior to start genome-wide search and as part of the genome-wide 
search, the linkage of a few important candidate genes which were directly or 
indirectly involved in modifying TGFB1 functions, were investigated. The
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linkage of some candidate genes which had already been mapped to the 
mouse genome including Tgfb isoforms (Tgfb2 and 3) and endoglin was carried 
out by utilising tightly linked polymorphic markers (i.e. microsatellites). To study 
the linkage of the other candidate genes; Tgfbr2 and PlanHI, not previously 
mapped to the mouse genome, an informative RFLPs approach was applied. 
However, observing no linkage between either of these genes and the survival 
of TGFB1(-/-) in F2 intercrosses ruled out the possible involvement of these 
genes in the different expressivity of TGFB1(-/-) phenotype.
4.6.4 Genome-wide search:
As tools for genetic mapping, markers which can be typed in large 
numbers of animals with minimal amounts of sample material by PCR and 
referred to as microsatellites (Litt and Luty., 1989) are considerably more useful 
than standard RFLPs and minisatellites. These powerful new markers, 
microsatellites, and the availability of dense genetic linkage maps of them 
makes feasible to wide range of studies, including positional cloning of 
monogenic traits, genetic dissection of polygenic traits, construction of 
genome-wide physical maps, rapid marker-assisted construction of congenic 
strains, and evolutionary comparisons (Copeland et al., 1993).
During this project these highly polymorphic markers were utilised to reveal the 
genetic factor(s) involved in different expressivity of TGFB1(-/-) phenotype. 
Due to the fact that there was no information about the size of these markers in 
NIH/Ola strain, 150 microsatellites showing high polymorphism between other 
published intrastrains and C57BI/6J/Ola strain, were selected. These 
microsatellites scattered throughout the (autosomal) genome were screened for 
polymorphisms between NIH/Ola and C57BI/6J/0!a strains and in terms of the 
location and being polymorphic, only 55 markers were informative for linkage 
analysis in this project. In order to cover the entire genome during a genome- 
search the following factors are very critical:
1) The number and the location of markers.
2) The number of animals to be screened.
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3) The P-value accepted as an evidence for linkage especially for a whole 
genome search.
4.6.4.1 Number of animals and markers:
The first step in the first stage of the protocol was to develop a 
framework map that was “anchored” by previously well-mapped loci spaced 
uniformly throughout the entire genome. To accomplish this task most 
efficiently, it was critical to calculate the minimum number of anchor loci 
required to develop this low-resolution, but comprehensive, map. This 
calculation was based on the length of the “ swept radius “ which is the 
distance over which linkage can be detected between any marker and a test 
locus when both are typed in a set number of offspring generated with a 
defined breeding protocol (Carter & Falconer, 1951). The corresponding 
framework swept radius associated with 94 samples from backcross for each 
anchor locus is about 24 cM (Frankel et al., 1990; Lee M. Silver., 1995). To a 
first approximation, each intercross sample is equivalent to two backcross 
samples. Thus, a swept radius of -0.23 rf can be obtained with 50 intercross 
samples. A further increase in the critical number of samples (45-50) provide 
only a marginal increase in the distance that is swept.
4.6.4.2 The P-value for genome-wide search:
The P value is the probability that a statistic as large as or larger than 
the observed one would occur by chance. The P-value can be determined after
computing the %2 in the intercross approach. P-value taken as evidence for
linkage is very critical, especially for a whole genome search. Accepting a P- 
value of 0.05 as providing evidence for linkage means that 5% of the unlinked 
loci will show a false positive result. In this study, the experimental design was 
such that linkage was detectable out to 0.23 rf on both sides of an unmapped 
locus. As shown in equation (1), where 1500 (cM) is the total genome length, 
3.0 markers out of 100 distributed randomly across the genome should actually
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be in linkage with any particular test locus, in the whole genome search 
approach.
,.,2?.,t23. = o.03 PI
1500
Thus, in this example, 8 positive markers would be expected but only 3 would 
be genuinely linked. This means that a P-value 0.05 only provides a probability 
of linkage of 40% (Bayesion analysis). To increase this probability, it has been 
recommended to take a P-value of £p10'5 as criterion for definitive linkage and 
a P-value of 0.05 only as a suggestive linkage ( Lander & Kruglya, 1995).
54 informative markers scattered randomly throughout the genome were 
utilised to screen 48-50 TGFB1(-/-) neonates. Only three independent regions 
on chromosomes 3, 12, and 5 showed linkage with P value of less than 0.05. 
Another region on chromosome 5, located in =40 cM of the region showing 
linkage, also showed linkage with P value of less than 0.05. Statistical analysis 
performed on these two regions suggested that linkage in one of the regions 
could be due to the influence of the linkage in other region. As discussed 
above, in this study, P value of 0.05 provide a probability of linkage of 40%, 
therefore, only one of the three regions was expected to be a truly linked locus. 
To confirm or dismiss linkage of each of four loci which appeared to show 
linkage, an additional 30 neonatal TGFB1(-/-) intercross DNA samples were 
analysed for markers on chromosomes 3, 5 and 12. P-values at the loci on 
chromosomes 3 and 12 remained only suggestive (= 0.05). However, the 
support for linkage was strengthened at marker located on chromosome 5, 
D5Mit268, surpassing the stringent linkage criteria (< 10'5).
4.6.4.3 Control animals:
In conventional linkage studies, animals are classified into at least two 
phenotypic or physiologically distinctive groups. Linkage analysis is normally 
performed on both classes. Therefore, observing a linkage in one of the groups 
but not in the other group confirms that linkage is genuinely due to the 
interested phenotype (or trait) not due to other unknown strain specific factors. 
The segregation distortion of few markers in crosses between wild type strains 
has been observed (e.g. F1(B6 x D2) x D2 backcrosses (Corcus, unpublished
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1997). There are some possible explanations for this type of segregation 
distortion as follows:
1- Genotyping errors: One allele may be amplified preferentially, perhaps due 
to mismatches at the primer binding sites in one strain versus the other. A 
lower annealing temperature sometimes will enable both alleles to be amplified. 
In this case, several other closely linked markers would not show deviation 
from expected genotype frequencies.
2- Segregation distortion: The marker is linked to a gene that is subject to 
selection at the gamete or embryo level. If this is true, then several closely 
linked markers should also show similar distortion.
3- Chance (False positive): This depend on that which P-value taken as an 
evidence for linkage in a whole genome search.
In this study, 50 wild type [TGFB1 (+/+)] animals born from the same F2 
litters were genotyped by the marker showing linkage. Linkage at the marker 
was not observed in F2 wild type animals, excluding the possibility that linkage 
could be artefactual.
4.6.4.4 Genetic Risk Ratio (GRR) and proposed genetic models:
Insight into the contribution of the chromosome 5 modifier gene to the 
overall genetic variability segregating in the F1 intercross may be gained by 
adopting the approach of Risch and colleagues (1994). Genetic risk ratio 
(GRR) has been defined as the ratio of disease risk in the backcross 
generation, compared with that in the high-risk parental strain. In this study, the 
formula of GRR for the backcross generation was modified to that of an 
intercross generation. It is convenient to define the GRR to be the ratio of 
survival in the F2 generation, compared to the NIH/Ola parental strain. The 
overall GRRf2 in the F2 generation is estimated to be 51.2%.
An estimate of the GRRF 2 assuming that there is no recombination between the 
marker and the modifier gene is equal to 54%. Risch et al (1994) proposed two 
multilocus genetic models, an additive model in which the effects at one 
modifier gene may substitute for another and a multiplicative, epistatic model of 
gene interaction. Under an additive model, where the overall GRRF 2 expressed
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as [(1 : GRRF2) - 1] = [(1 : GRRi ) - 1] + [(1 : GRR2 ) - 1] } is a sum of 
contributions from individual modifier genes, the chromosome 5 modifier gene 
explains 89% of the overall GRRF2 - Under a multiplicative model, where the 
overall GRRF2 is the product of contribution from modifier genes expressed as: 
(GRRF2 = GRRi x GRR2) the chromosome 5 modifier explains 92% of the 
overall GRRF2. Therefore, it could be concluded that the chromosome 5 
modifier locus is a major modifier of embryonic lethality.
4.6.4.5 The stage of TGFB1(-/-) embryonic lethality in different genetic 
backgrounds:
An independent study carried out on the stages of TGFB1(-/-) embryo 
lethality on both NIH/Ola and C57BI/6J/Ola strains (Rusholme PhD Thesis., 
1997) revealed that null embryo lethality (18% of the total nulls) in NIH/Ola 
genetic background was due to yolk sac phenotype whereas in C57BI/6J/Ola 
strains almost all of the nulls die prior to this stage. According to that study, 
TGFB(-/-) embryos bred onto F1(NIH x C57) genetic background tend to 
survive up to 8.5 dpc, but only 32% of them develop to term normally and the 
rest die due to yolk sac phenotype. Those results verifies the results obtained 
during this project.
4.7 Candidate genes located in the region with definitive linkage:
Three important candidate genes; interleukin 6 (/Z_6), fibroblast growth 
factor receptor 3 (Fgfr3), and fibroblast growth factor inducible gene 13 (Fin13) 
map to the region showing linkage with TGFB1(-/-) survivals. 116 maps 2.2 cM 
proximal to Fgfr3 (Avraham et al., 1994). However, neither of the genes have 
been mapped in comparison to MIT markers. The data based on integration of 
independent studies (Jax lab.) and data produced during this project, the order 
of genes and markers could be inferred as follow:
D5Mit251-ll6-D5Mit76-D5Mit268-D5Mit75-D5Mit267. Fgfr3 and FIN13 genes 
map in a region very close to that of D5Mit76. Therefore, it could be inferred
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that the possible implication of Fgfr3 and Fin13 in different expressivity of 
TGFB1(-/-) phenotype is more than that of 116.
4.7.1 Fibroblast growth factor receptor 3 (Fgfr3):
The fibroblast growth factor receptors (FGFRs) are high affinity 
receptors for the large family of fibroblast growth factors (FGFs). FGFs are 
involved in a variety of activities including embryonic pattern formation, 
mitogenesis, angiogenesis, and wound healing. FGFRs contain an extracellular 
domain with 3 immunoglobin-like domains, a transmembrane domain, and a 
cytoplasmic tyrosine kinase domain (Givol & Yayon, 1992).
A complex pattern of binding specificities between FGFs and FGFRs is further 
complicated by the generation of multiple isoforms from a given receptor gene 
by alternative splicing and use of alternative start sites (Bottaro et al., 1990). 
Unlike FGFR1 and FGFR2 which bind both acidic FGF (FGF1) and basic FGF 
(FGF2), FGFR3 binds preferentially aFGF and showed approximately 20-fold 
lower affinity for bFGF (Ornitz & Leder., 1992). The immunoglobin III domain in 
the extracellular region of FGFR3 differs from those in FGFR1 and FGFR2 as a 
result of alternative splicing (Avivi et al., 1993). FGFR3 mRNA was abundant 
in the intestine, lung, kidney, and bone growth plates (Partanen et al., 1991). 
Fgfr3 was cloned from the K562, myeloid cell line, which suggests a possible 
role in hematopoietic development (Keegan et al., 1991).
The gene for achondroplasia (ACH), inherited as an autosomal dominant with 
essentially complete penetrance was assigned to 4p16.3 by linkage analysis 
(Le Merrer et al., 1994; Velinove et al., 1994; Francomano et al., 1994). 
Causative mutations were identified by the candidate gene approach in the 
gene for FGFR3 (Shiang et al., 1994; Rousseau et at., 1994; Bel I us et al., 
1995). Nucleotide 1138 of the FGFR3 gene is the most mutable nucleotide 
discovered to date. This mutation resulted in the substitution of an arginine 
residue for a glycine at position 380 of the mature protein, which is in the 
transmembrane domain of FGFR3. Mutations in the extracellular domains of 
FGFR3 have been reported in Thanatophoric displasia (TD). TD resembles 
homozygous achondroplasia in some respects (Tavormina et al., 1995; 
Rousseau et al., 1996). Naske et al (1996) studied the effect of the ACH and
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TD mutations on the activity and regulation of FGFR3 by transient transfection 
of NIH 3T3 and Baf3 pro-B cells with mutant FGFR3 cDNA. They showed that 
each of the mutations studied constitutively activates the receptor, as 
evidenced by ligand-independent receptor tyrosine phosphorylation and cell 
proliferation. Moreover, the mutations responsible for TD were more strongly 
activating than the mutation causing ACH, providing Naski et al (1996) with a 
biochemical explanation for the observation that the phenotype of TD is more 
severe than that of ACH.
Colvin et al (1996) reported studies in mice made FGFR3 deficient by targeted 
disruption in the Fgfr3 gene by knockout technique. Fgfr3(-/-) mice had 
phenotypic effects to bones that arise by endochondral ossification, i.e., 
increased length of the vertebral column and long bones had occurred. It has 
been proposed that one of the functions of FGFR3 is to limit osteogenesis. The 
recessive loss-of-function mutation in Fgfr3(-/-) mice produces a phenotype 
that is the opposite of that observed in ACH and TD.
Peter et al (1993) by applying In situ hybridisation studies have shown that 
Fgfr3 in common with Fgfrl and Fgfr2, was expressed prenatally in the 
germinal epithelium of the neural tube. The nature of the Fgfr3 gene as a 
growth factor receptor and its map location made it possible candidate for the 
different expressivity of TGFB1(-/-) phenotype. Therefore, during this project 
the expression of Fgfr3 was examined in both 9.5 dpc embryo and yolk sac. 
The possibility of strain specific expression of the gene between two mouse 
strains; NIH/Ola and C57BI/6J/Ola strains, was excluded by observing the 
expression of the gene in both wild type embryo and yolk sac in either of the 
strains. However, this study could not rule out the possibility of different 
expression of the gene in TGFB1(-/-) conceptuses bred onto different genetic 
background due to fact that in C57BI/6J/Ola strain null embryo were dying in 
very early stage of embryogenesis.
4.7.2 Fibroblast growth factor inducible gene 13 (Fin13):
Guthridge et al (1996) has shown that Fin13 is one of the 21 late- 
induced genes from an fibroblast growth factor-4 (FGF-4) transformed NIH3T3
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cell line. 6 fold Induction of mRNA for Fin13 was determined in NIH3T3 cells 
following FGF-4 stimulation. Sequencing of Fin13 and translation of a putative 
open reading frame revealed that it would encode a protein of 392 amino acids. 
The expression of Fin13 transcript was demonstrated in 10.5 dpc. embryos 
which became down-regulated thereafter. Due to map location of the gene and 
its nature to be highly induced by fibroblast growth factor-4, made it possible 
candidate in this study. This gene maps to a region 4.4 cM distal that of II6 
(proximal mouse chromosome 5). In this study, the expression of Fin13 
transcript in 9.5 dpc both embryo and yolk sac was examined. Studies on wild 
type 9.5 dpc embryos bred onto NIH/Ola and C57BI/6J/Ola excluded the 
possibility of strain specific expression of this gene in 9.5 dpc embryo and yolk 
sacs. However, comparative studies on TGFB1(-/-) embryos bred onto two 
different strains due to the fact that null embryos bred onto C57BI/6J/Ola strain 
die prior to 9.5 dpc stage, was not practical.
To study the possibility of polymorphism in the protein encoded by Fin13 gene 
from NIH/Ola and C57BI/6J/Ola strains, the coding sequence of the gene was 
subjected to heteroduplex and direct sequence analysis. The examined regions 
between two mouse strains are shown to be identical.
4.8 TGFB1(-/-) embryonic lethality in 129/Sv genetic background:
During this project it has been demonstrated that genetic factors clearly 
influence the frequency of prenatal lethality of TGFB1(-/-) neonates with the 
C57BI/6J/Ola allele of chromosome 5 predisposing to prenatal lethality. 
However the NIH/Ola allele of this chromosome tends to rescue null embryos 
from prenatal lethality. It could be interesting to study the effect of a 129/Sv 
genetic background in expressivity of the TGFB1(-/-) phenotype.
When Shull et al (1992) generated TGFB1 (-/-), one copy of the Tgfbl gene 
was disrupted in mouse embryonic stem (ES) cells derived from the 129/Sv 
strain. ES cells containing the disrupted Tgfbl allele were then injected into 
C57BI/6J mouse blastocysts. TGFB1(+/-) animals that transmitted the ES cell- 
derived dominant agouti coat colour and the disrupted Tgfbl allele to their 
progeny were intercrossed to generate TGFB1(-/-) animals (shull et al., 1992).
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From intercrosses of these animals, which were a mixture of 129/Sv and 
C57BI/6J genetic backgrounds, a total number of 806 live offspring were 
yielded (Shull & Doetschman., 1992). Of these, 280 were homozygous wild- 
type, 413 were heterozygous, and 113 were homozygous for the disrupted 
Tgfbl allele (Shull & Doetschman, 1992). Significant deviation from the 
Mendelian ratio of 1:2:1 was clearly observed among these numbers. These 
numbers revealed that only 40% of TGFB1(-/-) and 73.7% of TGFB1(+/-) 
neonates developed to term normally whereas the rest died in utero. On the 
basis of this data, the percentage of 129 /Sv strain contributed to the TGFB1(-/- 
) animals is not clear. However, observing 40% survival of TGFB1(-/-) 
conceptuses bred onto a mixture of 129/Sv and C57BI/6J strains give rise to 
the notion that the modifying gene originated from 129/Sv strain, despite that 
from C57BI/6J, could rescue TGFB1(-/-) conceptuses from embryo lethality. To 
find out the penetrance of modifying gene originated from 129/Sv strain, it is 
required further experiments.
4.9 TGFB1(+/-) embryo lethality in different crosses:
~20% of TGFB1(+/-) embryo lethality on a mixed genetic background 
was already reported (Shull & Doetschman, 1992; Dickson et al., 1995). 
Further investigation by Dickson et al (1995), showed that 20% loss of 
TGFB1(+/-) conceptuses was rectified when 2 cell-stage preimplantation 
embryos from TGFB1(+/-) cross underwent gestation in the recipient 
TGFB1(+/+) mother. They also noticed that in a TGFB1(+/-) mother and 
TGFB1(+/+) father cross the frequency of TGFB1(+/-) survival was less 
compared to that of a reciprocal cross; TGFB1(+/+) mother and TGFB1(+/-) 
father. The only difference in these reciprocal crosses was whether female was 
TGFB1(+/-) or TGFB1 (+/+). These results indicate that TGFB1(+/-) 
conceptuses which have the reduced level of endogenous TGFB1 are 
dependent to the maternal source of TGFB1 and there is a connection between 
the maternal level of TGFB1 and the percentage of TGFB1(+/-) survivals. In the 
TGFB1(+/-) cross when mother is TGFB1(+/-) and has the reduced level of 
TGFB1, the maternal TGFB1 is not adequate to compensate the reduced level
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of endogenous TGFB1 in all TGFB1(+/-) embryos. This may be the reason for 
the high frequency of TGFB1(+/-) embryo lethality in the TGFB1(+/-) mother 
and TGFB1(+/+) father cross.
During the present project, it has been demonstrated that the TGFB1(+/- 
) embryo lethality occurs in both NIH/Ola and C57BI/6J/Ola strains with no 
significant difference. Therefore, it could indicate the similar level of maternal 
TGFB1 in both C57BI/6J/Ola and NIH/Ola strains. Unpublished data from Dr, 
Akhursfs Lab suggesting that C57BI/6J/Ola and NIH/Ola have similar TGFB1 
circulation levels verifies this suggestion.
4.10 Genetic mapping:
A genetic map is simply a representation of the distribution of a set of 
loci within the genome. There are three distinct types of genetic maps that can 
be derived for each chromosome in the genome. The three types of maps; 
linkage, chromosomal, and physical are distinguished both by the methods 
used for their derivation and the metric used for measuring distances within 
them.
4.10.1 Linkage maps:
“Linkage maps” referred to as a “recombination map”, can only be 
constructed for loci that occur in two or more heritable forms or alleles. These 
maps are generated by counting the number of offspring that receive either 
parental or recombinant allele combinations from a parent that carries two 
different alleles at two or more loci. Analysis of this type of data allows one to 
determine whether loci are linked to each other and if they are, their relative 
order and the relative distances that separate them. Distances are measured in 
centiMorgans, with one centiMorgan equivalent to a crossover rate of 1%. 
Therefore, the linkage map is based on classical breeding analysis.
4.10.2 Chromosome maps:
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The chromosome (cytogenetic) map is based on the karyotype of the 
genome. All mouse chromosomes are defined at the cytogenetic level 
according to their size and banding pattern. In this map, positions are indicated 
with the use of band names. Several different approaches are utilised to 
generate chromosome maps.
1-Somatic cell hybrid lines contain only portions of the mouse karyotype 
within the milieu of another species’ genome. By correlating the presence or 
expression of a particular mouse gene with the presence of a mouse 
chromosome or subchromosomal region in these cells, one can obtain a 
chromosomal or subchromosomal assignment.
2-The second approach can be used in those special cases where 
karyotypic abnormalities appear in conjunction with particular mutant 
phenotypes. When the chromosomal lesion and the phenotype assort together, 
from one generation to the next, it is likely that the former causes the latter. 
When the lesion is a deletion, translocation, inversion, or duplication, one can 
assign the mutant locus to the chromosomal band that has been disrupted.
3-In situ hybridisation: This method enables to visualise the location of 
the corresponding sequence within a particular chromosomal band directly.
4.10.3 Physical maps:
All physical maps are based on direct analysis of DNA, and distances 
between and within loci are measured in basepairs (bp), kilobasepairs (kb), or 
megabasepairs (mb).
During this project a linkage map approach was utilised to map two important 
candidate genes; Tgfbr2 and PlanHI on mouse chromosomes,.
4.10.4 Transforming growth factor beta type II receptor (Tgfbr2):
4.10.4.1 RFLPs:
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Utilising 1.7 kb cDNA of Tgfbr2 as a probe, variety of different bands 
were revealed between BamH1 digested DNAs from NIH/Ola, C57BI/6J/Ola, 
129/Sv, and Mus Spretus strains. RFLPs observed between these strains could 
have been due to hybridisation of the probe with pseudo genes. To address 
this problem, the full length cDNA was digested into small fragments which 
were then used as probes. Utilising small digested fragments of cDNA as 
probes, resulted only selective hybridisation of bands. Therefore, it was 
confirmed all RFLPs observed between different strains belonged to Tgfbr2 
gene and the possible interference of any pseudo gene was ruled out.
Detailed examination of the DNA bands observed when applying different 
regional Tgfbr2 cDNA probes for hybridisation enabled the design of a probe 
which distinguished RFLPs of Tgfbr2 gene among different strains of NIH/Ola, 
C57BI/6J, 129/sV, and Mus. Spretus.
4.10.4.2 Human-mouse homology:
Mathew et al (1994) used somatic cell hybrids and fluorescence in situ 
hybridisation to map TGFBRII to human chromosome 3p22 in a region syntenic 
with mouse chromosomes 6 ( 49-53) and distal 9 (55-74). During this project by 
utilising the designed probe, this gene was mapped on distal end of mouse 
chromosome 9. The order of the mapped gene in compare to MIT markers 
mapped previously was calculated as follow (cM ± SE): Cenrtromere-D9Mit16 
(2.1 ± 0.014)-D9Mit150 (3.1 ± 0.02)-Tgfbr2 (1 ± 0.0)-D9Mit18.
4.10.4.3 Mutant mice.
Several uncloned mutations map to the region of Tgfbr2 gene including 
Ky (kyphoscoliotic degenerative muscle), due (ducky), pcy (polycystic kidney 
disease), tip (tippy), sr (spinner), fd (fur deficient), and sc/?(scant hair). During 
this project, two uncloned mutants; ducky and tippy, were examined for the 
possibility of large deletion of Tgfbr2 gene within them.
4.10.4.3.1 Ducky:
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The ducky mutation arose spontaneously in a non-inbred stock. 
Homozygous show a waddling or reeling gait and tendency to fall to one side. 
They are slightly smaller than normal and may occasionally have seizures. 
Viability is somewhat less than normal. Males living to maturity may be fertile, 
but are poor breeders. Females rarely breed (Snell 1955). This mutation which 
shows recessive pattern of inheritance maps to distal end of chromosome 9 
(Kingsley et al., 1989). Southern blot analysis, performed using Hindlll- 
digested DNA from mice homozygous for due has excluded the possibility of a 
large deletion of Tgfbr2 within this mutant.
4.10.4.3.2 Tippy:
This mutation arose in a linkage cross in 1977. Mice homozygous for tip 
are small, cannot stand or walk without falling over, and generally die by a bout 
3 weeks postpartum (Green 1989; Kingsley 1992). The gene is on chromosome 
9 near ducky and shows recessive pattern of inheritance (Lane 1984). 
Southern blot analysis, performed using Hindi 11-digested DNA from mice 
homozygous for tip has excluded the possibility of a large deletion of Tgfbr2 
within this mutant.
However, it has been recently shown that Tgfbr2 null embryos die by
13.5 dpc. due to yolk sac hematopoiesis and vasculogenesis deficiency 
(Oshima et al., 1996) and any of the mutant mice listed above might involve 
more subtle molecular pathologies within the Tgfbr2 gene.
4.10.4.4 Tgfbr2 gene as a candidate gene for cancer:
Studies carried out in susceptibility to skin carcinogenesis has revealed 
that there are two different stages of initiation and promotion. Linkage studies 
on a genetic model developed for the study of promotion susceptibility utilising 
relatively sensitive DBA/2 and relatively resistant C57BI/6 mice has suggested 
the involvement of genes mapping to chromosomes 2, 9, and 11 in promotion
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susceptibility. Further study supported the linkage of a promotion susceptibility 
locus to mouse chromosome 9 (D9Mit53) (Angel et al., 1996). This marker 
maps close to a region in which Tgfbr2 gene maps. Therefore, Tgfbr2 gene 
could be a good candidate gene for the skin carcinogenesis promotion 
susceptibility.
4.10.5 Plasminogen activator inhibitor type I (PlanHI)
In an attempt to map the PlanHI gene on mouse genome, polymorphic 
RFLPs was observed between two mouse strains by applying the PlanHI cDNA 
as a probe. The PAI1 gene has already been mapped to human chromosome 
7q21.3-»q22 (Klinger et al., 1987). Therefore, markers from the syntenic region 
were selected and the segregation of markers and the RFLP were followed 
among 48 F2 intercross animals. The murine PlanHI has been mapped in the 
distal region of chromosome 5, which is syntenic with human chromosome 
7q21-q22.
4.11 Conclusion:
During this project it has been shown that the TGFB1(-/-) phenotype 
depends on the genetic background of the conceptus. In NIH/Ola strain, null 
conceptuses tend to develop to term normally whereas in C57/6J/Ola strain 
almost all of the nulls die In utero. A major codominant modifying gene of 
embryo lethality was mapped to proximal mouse chromosome 5, using a 
genome scan for non-Mendelian distribution of alleles in TGFB1(-/-) neonatal 
animals which survive prenatal lethality. This gene accounts for around three 
quarters of the genetic effect between mouse strains.
Expression studies of three candidate genes; Tgfbl, Fin13, and Fgfr3 carried 
out on 9.5 dpc wild type embryos and yolk sacs bred onto either NIH/Ola or 
C57/6J/Ola strains, excluded the possibility of strain specific expressivity of the 
genes in a specific stage of embryogenesis.
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Applying heteroduplex and direct sequencing approaches, excluded the 
possibility of polymorphism in the protein encoded by Fin13 gene between 
NIH/Ola and C57BI/6J/Ola strains.
During this project also Transforming Growth Factor Beta type II receptor 
(Tgfbr2) and Plasminogen activator inhibitor type I (PlanHI) genes were 
mapped on the proximal ends of mouse chromosomes 9 and 5, respectively. 
Following the mapping Tgfbr2 on the mouse genome, two uncloned mutant 
mice; Tippy and Ducky, which map in the vicinity of the Tgfbr2 location were 
examined by application of Southern blotting for the possibility of a large 
deletion in Tgfbr2 gene in either of these mutants. Observing no differences in 
the size of Southern blot bands between wild type and homozygous mice (in 
both Tippy and Ducky mice) the possibility of large deletion of Tgfbr2 in these 
mutants has been excluded.
4.12 From Linkage to Locus for Polygenic Traits:
Putting aside speculation about possible candidate genes, it is important 
to consider the general issue of how to proceed from the initial detection of 
linkage to the definitive identification of a gene contributing to a polygenic trait. 
Cloning mammalian genes based solely on position remains a daunting task 
even for genes controlling simple Mendelian traits; it has been accomplished in 
very few cases to date. Nonetheless, genomic mapping tools are improving and 
the task may well became more tractable. In anticipation of continued 
improvement, an approach to cloning the modifier gene based on position is 
outlined:
1- It is important to confirm the linkage, by repeating the precise cross used 
initially.
2- If linkage can be confirmed, a small region containing the modifier locus 
(ML) allele from C57 strain could be moved genetically into NIH strain by 
successive backcrosses to create congenic strains differing only in the region 
of the ML. To ensure the introgression of the ML allele from C57 strain, 
progeny that have inherited alleles from C57 strain at a pair of genetic markers 
flanking the ML should be selected. To accelerate the removal of C57 strain 
elsewhere in the genome, individuals who have fortuitously lost more than the
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expected 50% proportion of C57 strain alleles per generation could be 
selected. In practice, such selection can roughly halve the number of backcross 
generations required of introgression (Paterson et al., 1988). Once congenic 
strains have been established, the percentage of TGFB1 nulls developing to 
term in intercrosses of these congenic animals could be compared to that of 
C57 cross to find out if there is any other loci involved in different expressivity 
of the TGFB1(-/-) phenotype.
3- Using the congenic strains, the ML could be mapped more closely by 
arranging a backcross to collect individuals recombinant for a pair of flanking 
markers. Using a denser map of genetic markers, the recombination 
breakpoints could be identified and the ML could be mapped relative to these 
by testing the recombinant progeny.
4- when the region has been adequately narrowed, a physical map could be 
constructed to identify genes in the region. Because MLs seem likely to involve 
subtle mutations rather than gross gene disruption, the mutations themselves 
may be difficult to find. Instead, one may need to select and test plausible 
candidate genes in the region.
5- To prove that a candidate gene corresponds to the trait, homologous 
recombination could be utilised to construct gene knockouts in strains carrying 
a dominant allele (which can then be tested for loss of dominance at the ML) or 
to substitute the allele in C57 strain into NIH strain and demonstrate that the 
ML effect has been transferred as well.
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Appendix:
Appendix I-A
Table 1: The format of 2 X 2 contingency table by the use of symbols 
(Wardlaw, 1992).
G roup TG FB1 (+/+ ) 
neonates
TG FB1 (-/-) 
neonates
T o ta l
A a b (a + b)
B c d (c + d)
T o ta l (a + c) ( b +d) N
The formula ( 1 ) to calculate Chis Square:
2 N{|ad-bc|-i^N}2 
T = ----------------------------------  (equation 1)
(a+b) x (c+d) x (a+c) x (b + d )
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Appendix I-B
Table 1: Observed and expected numbers for the TGFB1(-/-) and TGFB1(+/+) 
embryos born to C57BI/6J females mated to males with different genetic backgrounds 
(Data extracted from table 3.2), and calculation of %2.
Cross Observed 
numbers (0)
Expected 
numbers (E)
(0  - E ) 2 
E
TGFB1(-/-) 
embryos born to 
(C57 X C57)
0
{ (0+3+9)/134 }x  
{(68 + 0)} = 6.089 6.089
TGFB1(+/+) 
embryos born to 
(C57 X C57)
68
{(68+29+25)/134} 
x (68+0)=61.91 0.599
TGFB1(-/-) 
embryos born to 
(C 57X F 1)
3
{ (0+3+9)/134 }x  
{( 3+29)} = 2.865 0.006
TGFB1(+/+) 
embryos born to 
(C 57X F 1)
29
{(68+29+25)/134} 
X (29+3)=29.13 0.0005
TGFB1(-/-) 
embryos born to 
(C 57X N IH )
9
{(0+3+9)/134 }X  
{(9+25)} = 3.044 11.653
TGFB1(+/+) 
embryos born to 
(C57 X NIH)
25
{(68+29+25)/134} 
X (25+9)= 30.95 1.143
Total 134 133.993 %2u 19.49
Chis Square test was performed (discussed in section 3.10.2) on each group of nulls and 
wild types separately. To calculate the expected numbers for each group of wild types, 
the total number of wild types (68+29+25), was divided by the total number of animals 
under statistical analysis [i.e. (68+29+25) : 134 ]. This ratio was multiplied to the total 
number of animals (nulls and wild types) in each cross, to find the estimated number of 
wild types in that cross [e.g. in C57 x C57 cross, this ratio was multiplied to (68+0)]. 
The same approach was utilised to find the estimated number of nulls in each cross. The 
total %2 is 19.49. Assuming the null hypothesis, the relevant P-value with 2 d.f. is equal 
to 5.8 x 10'5.
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Table 2: Observed and expected numbers for the TGFB1(-/-) and TGFB1(+/+) 
embryos born to NIH/Olac females mated to males with different genetic 
backgrounds (Data extracted from table 3.2), and calculation of %2.
Cross Observed 
numbers (0)
Expected 
numbers (E)
( 0 - E ) 2
E
TGFB1(-/-) 
embryos born to 
(NIH X NIH)
73 63.05 1.57
TGFB1(+/+) 
embryos born to 
(NIH X NIH)
89 98.93 0.99
TGFB1(-/-) 
embryos born to 
(NIHXF1)
14 13.62 0.01
TGFB1(+/+) 
embryos bom to 
(NIHXF1)
21 21.37 0.006
TGFB1(-/-) 
embryos born to 
(NIH X C57)
15 25.30 4.19
TGFB1 (+/+) 
embryos born to 
(NIHXC57)
50 39.69 2.67
Total 262 261.96 X2,9.44
Chis Square test was performed (discussed in section 3.10.2) on each group of 
nulls and wild types separately. To calculate the expected numbers for each 
group (i.e. nulls and wild types), the same approach as table 1 (appendix l-B) 
was taken. The %2 is 9.44. Assuming the null hypothesis, the relevant P-value 
with 2 d.f. is equal to 0.008 (<0.05).
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Table 3: Observed and expected numbers for the TGFB1(-/-) and TGFB1(+/+) 
embryos born to F1 (NIH x C57) females mated to males with different genetic 
backgrounds (Data extracted from table 3.2), and calculation of %.
Cross Observed 
numbers (0)
Expected 
numbers (E)
(0 - E) 2 
E
TGFB1(-/-) 
embryos born to 
(F1 X NIH)
85 63.41 7.35
TGFB1(+/+) 
embryos bom to 
(F1 X NIH)
118 139.5 3.31
TGFB1(-/-) 
embryos born to 
(F1 XF1)
80 84.34 0.22
TGFB1(+/+) 
embryos bom to 
(F1 XF1)
190 185.65 4.35
TGFB1(-/-) 
embryos born to 
(F1 X C57)
9 26.24 11.32
TGFB1(+/+) 
embryos born to 
(F1 X C57)
75 57.75 5.15
Total 557 556.899 X2* 31.70
Chis Square test (c iscussed in section 3.10.2) was performed on each group of
nulls and wild types separately. To calculate the expected numbers for each 
group (i.e. nulls and wild types), the same approach as table 1 (appendix l-B) 
was taken. The sum of %2 was equal to 31.70. Assuming the null hypothesis, 
the relevant P-value with 2 d.f. is less than 10'5.
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Table 4: Observed and expected numbers for the TGFB1(+/-)and TGFB1(+/+) 
embryos born to either NIH/Ola or C57BI/6J/Ola strains (Data extracted from table 
3.2), and calculation of %2.
Cross
Observed 
numbers (0)
Expected 
numbers (E)
( 0 - E ) 2
E
NIH/Ola 
TGFB1(+/+ )
89 83.8
NIH/Ola 
TGFBK+/-)
129 134
C57Bl/6J/01a
TGFB1(+/+)
68 73.1
C57BI/6J/OIa
TGFB1(+/-)
122 116.8
Total 408 407.9 X2=1.0966
Chis Square test (discussed in section 3.10.2) was performed on each group of 
nulls and wild types separately. To calculate the expected numbers for each 
group (i.e. hets and wild types), the same approach as table 1 (appendix l-B) 
was taken. The sum of % was equal to 1.0966. Assuming the null hypothesis, 
the relevant P-value with 1 d.f. is 0.2950.
119
Appendix ll-B
Location of the markers utilised to screen the whole mouse genome. The 
position of some candidate genes screened during this project are shown. 
Continous lines show the regions of the chromosomes swept by the markers.
-■ M1 
-■ M2
- M3
- M4 ( TGF/32 )
Chrom. 1
M1; MIT318, M2; MIT76. 
M3; MIT387, M4; MIT403.
M1 ( Eng )
- M2
M1; MIT83, 
M2; MIT38.
M1
-  M2
M1; MIT 6, 
M2; MIT106,
- M1
- M2
-  M1 -M3
- M4
-  M2
- M5
-  M3
- M6
-M7
-  M4 - PlanHI
M1; MIT192, 
M2; MIT178, 
M3; MIT175, 
M4; MIT170.
M1; MIT49, 
M5; MIT80 
M7; MIT188
; ( TG F-pi) « 1  «
- M1
-  M1 - M1
- M2
- M1 -  M2
- M3
- M2
( Fgf3) - M3 - Tgfbr2
M1
M2
Chrom. 8 10
M1; MIT74, 
M2; MIT213, 
M3; MIT25.
M1; MIT284, M1; MIT190. 
M2; MIT9, 
M3; MIT166.
M1; MIT268 
M2; MIT16
M1; MIT20 
M2; MIT95
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• • -1
- M1 - M1 -  M1
- M1 -
(  TGF-J33)
-M2 -M2 -  M2
- M2
Chromos: 11 12 13 14 15
M1; MIT5, M1; MIT46, M1;MIT63, M1; MIT141, M1;MIT220
M2; MIT258. M2; MIT8. M2; MIT290. M2; MIT35. M2; MIT159.
- M1 * M1 ( LTBP2)
-M2 - M2 (1 gf2r) • ■ M1
-  M3 M2
I-M1
-M3 - M4 I -M3
Chrom: 16 17 18 19
M1; MIT181, 
M3; MIT114.
M1; MIT43, 
M3; MIT21, 
M4; MIT93.
M1; MIT150. M1
M2
M3
MIT31, 
MIT19, 
MIT103.
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Appendix IIC:
Table showing markers used to screen NIH/Ola and C57BI/6J/Ola strains for 
polymorphism.
Chromosome: Marker: Polymorphism: Location:
Chromosome 1 D1 Mit 318 129=NIH<C57 17 cM
Chromosome 1 D1 Mit 403 NIH<C57 98 cM
Chromosome 1 D1 Mit 387 NIH<C57 66 cM
Chromosome 1 D1 Mit 60 ? 60 cM
Chromosome 1 D1 Mit 451 129<=NIH=C57 82 cM
Chromosome 1 D1 Mit 76 NIH »  C57 33 cM
Chromosome 1 D1 Mit 236 NIH «  C57 25.9 cM
Chromosome 1 D1 Mit 446 75.7 cM
Chromosome 1 D1 Mit 102 77.9 cM
Chromosome 2 D2 Mit 98 129=NIH=C57 52 cM
Chromosome 2 D2 Mit 7 129=NIH<C57 28 cM
Chromosome 2 D2 Mit 83 129<NIH<C57 17 cM
Chromosome 2 D2 Mit 368 129=C57>NIH ? 28 cM
Chromosome 2 D2 Mit 38 NIH»C57 45 cM
Chromosome 2 D2 Mit 244 34.2 cM
Chromosome 2 D2 Mit 243 34.2 cM
Chromosome 3 D3 Mit 38 NIH=?129»C57 50 cM
Chromosome 3 D3 Mit 6 NIH<C57 18 cM
Chromosome 3 D3 Mit 106 129=NIH«C57 41 cM
Chromosome 4 D4 Mit 192 129=NIH>C57 9 cM
Chromosome 4 D4 Mit 175 NIH»C57 42 cM
Chromosome 4 D4 Mit 9 NIH=C57>129 33 cM
Chromosome 4 D4 Mit 129 129<NIH<C57 64 cM
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Chromosome 4 D4 Mit 192 129?NIH»C57 9 cM
Chromosome 4 D4 Mit 170 NIH»C57=?129 63 cM
Chromosome 4 D4 Mit 178 NIH »  C57 27 cM
Chromosome 4 D4 Mit 80 28 cM
Chromosome 5 D5 Mit 147 129<C57=NIH 5.6 cM
Chromosome 5 D5 Mit 135 129>C57=NIH 29.4 cM
Chromosome 5 D5 Mit 25 129=C57=NIH 47.4 cM
Chromosome 5 D5 Mit 66 129=NIH>C57 13.5 cM
Chromosome 5 D5 Mit 234 129<C57=NIH 28.3 cM
Chromosome 5 D5 Mit 83 129>NIH=C57 28 cM
Chromosome 5 D5 Mit 250 129=C57=NIH 5.6 cM
Chromosome 5 D5 Mit 7 129=NIH<C57 33.9 cM
Chromosome 5 D5 Mit 251 129=C57>NIH 9 cM
Chromosome 5 D5 Mit 23 129=C57>NIH 38.4 cM
Chromosome 5 D5 Mit 103 NIH=C57=129 3 cM
Chromosome 5 D5 Mit 233 129=C57<NIH 20 cM
Chromosome 5 D5 Mit 265 NIH=C57 68 cM
Chromosome 5 D5 Mit 188 129=?NIH«C57 53 cM
Chromosome 5 D5 Mit 24 C57<129<NIH 47 cM
Chromosome 5 D5 Mit 6 129=C57=NIH 23.9 cM
Chromosome 5 D5 Mit 73 129<C57=NIH 9 cM
Chromosome 5 D5 Mit 10 129=C57=NIH 38.4 cM
Chromosome 5 D5 Mit 76 129=C57<NIH 15.8 cM
Chromosome 5 D5 Mit 49 129=C57<NIH OcM
Chromosome 5 D5 Mit 109 129=C57=NIH 26 cM
Chromosome 5 D5 Mit 268 NIH«C57=129 18 cM
Chromosome 5 D5 Mit 4 129=C57=NIH 15.8 cM
Chromosome 5 D5 Mit 44 129=C57<NIH 13.5 cM
Chromosome 5 D5 Mit 1 NIH=C57>129 3 cM
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Chromosome 5 D5 Mit 82 129>C57=NIH 27.2 cM
Chromosome 5 D5 Mit 80 129=C57<NIH 18 cM
Chromosome 5 D5 Mit 197 129=C57«NIH 27.2 cM
Chromosome 5 D5 Mit 5 129=C57=NIH 27.2 cM
Chromosome 5 D5 Mit 77 129=C57=NIH 16 cM
Chromosome 5 D5 Mit 267 129<<C57<<NIH *******
Chromosome 5 D5 Mit 180 129=C57=NIH 5 cM
Chromosome 5 D5 Mit 251 129=C57>NIH 9 cM
Chromosome 5 D5 Mit 34 129=C57=NIH 84 cM
Chromosome 5 D5 Mit 126 NIH > C57 16 cM
Chromosome 5 D5 Mit 75 NIH «  C57 16 cM
Chromosome 5 D5 Mit 182 NIH = C 57 17 cM
Chromosome 5 D5 Mit 354 NIH = C 57 17 cM
Chromosome 6 D6 Mit 9 NIH=C57>129 36 cM
Chromosome 6 D6 Mit 74 NIH«C57=?129 11 cM
Chromosome 6 D6 Mit 19 NIH<C57»129 33 cM
Chromosome 6 D6 Mit 13 NIH=C57=129 63 cM
Chromosome 6 D6 Mit 25 129<NIH<C57 50 cM
Chromosome 6 D6 Mit 70 NIH«C57=?129 34 cM
Chromosome 6 D6 Mit 69 NIH=?129«C57 35 cM
Chromosome 6 D6 Mit 324 30 cM
Chromosome 6 D6 Mit 213 NIH «  C57 30 cM
Chromosome 7 D7 Mit 109 NIH=C57=129 64 cM
Chromosome 7 D7 Mit 284 NIH=129»C57 44 cM
Chromosome 8 D8 Mit 16 NIH=C57 7 cM
Chromosome 8 D8 Mit 3 NIH=C57«129 7 cM
Chromosome 8 D8 Mit 13 NIH<<C57<<129 69 cM
Chromosome 8 D8 Mit 166 NIH=129»C57 57 cM
Chromosome 8 D8 Mit 9 NIH<C57 36 cM
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Chromosome 8 D8 Mit 8 NIH=C57 35 cM
Chromosome 8 D8 Mit 63 NIH#C57 14 cM
Chromosome 8 D8 Mit 226 23 cM
Chromosome 8 D8 Mit 190 NIH «  C57 23 cM
Chromosome 9 D9 Mit 286 129=NIH«C57 ? 17 cM
Chromosome 9 D9 Mit 150 NIH<<C57<129 59 cM
Chromosome 9 D9 Mit 18 NIH>C57=129 67 cM
Chromosome 9 D9 Mit 286 NIH=?129«C57 23 cM
Chromosome 9 D9 Mit 82 NIH=C57 74 cM
Chromosome 9 D9 Mit 16 NIH«C57=129 57 cM
Chromosome 9 D9 Mit 19 NIH=C57=129 71 cM
Chromosome 9 D9 Mit 17 C57=129 62 cM
Chromosome 9 D9 Mit 9 C57<129 48 cM
Chromosome 9 D9 Mit 4 C57<129 29 cM
Chromosome 9 D9 Mit 2 C57=129 17 cM
Chromosome 9 D9 Mit 104 34 cM
Chromosome 9 D9 Mit 174 32 cM
Chromosome 10 DIOMit 20 NIH<C57 23 cM
Chromosome 10 D10 Mit 21 NIH=C57 39 cM
Chromosome 10 DIOMit 95 NIH=?129«C57 50 CM
Chromosome 10 DIOMit 32 NIH=C57 32 cM
Chromosome 10 DIOMit 95 C57»NIH=?129 50 cM
Chromosome 10 DIOMit 15 NIH<C57 23 cM
Chromosome 10 DIOMit 21 NIH=C57 39 cM
Chromosome 10 DIOMit 15 NIH<C57 23 cM
Chromosome 10 DIOMit 20 NIH<C57 23 cM
Chromosome 10 DIOMit 30 NIH=C57 21 cM
Chromosome 10 DIOMit 42 NIH > C57 40.5 cM
Chromosome 10 DIOMit 117 43.9 cM
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Chromosome 11 D11 Mit 258 N IH »129»C 57 67 cM
Chromosome 11 D11 Mit 5 NIH=129«C57 37 cM
Chromosome 11 D11 Mit 151 NIH<C57<<129 10 cM
Chromosome 11 D11 Mit 110 17.9 cM
Chromosome 11 D11 Mit 308 19 cM
Chromosome 12 D12 NDS 2 NIH>C57 62 cM
Chromosome 12 D12 Mit 8 129>NIH>C57 60 cM
Chromosome 12 D12 Mit 46 C57»NIH 17 cM
Chromosome 12 D12 Mit 77 NIH>C57 44 cM
Chromosome 12 D12 Mit 101 NIH=129=C57 47 cM
Chromosome 12 D12 Mit 154 NIH#C57 18 cM
Chromosome 12 D12 Mit 46 NIH=?129«C57 15 cM
Chromosome 12 D12 NDS 11 NIH=129>C57 7 cM
Chromosome 12 D12 Mit 101 NIH=129=C57 47 cM
Chromosome 12 D12 Mit 5 NIH>129 33.9 cM
Chromosome 12 D12 Mit 68 NIH<C57 23 cM
Chromosome 13 D13 Mit 290 C57.1>C57.2>NIH 46 cM
Chromosome 13 D13 Mit 63 NIH>C57 20 cM
Chromosome 13 D13 Mit 119 NIH=129=C57 20 cM
Chromosome 14 D14 Mit 141 NIH=?129«C57 19.2 cM
Chromosome 14 D14 Mit 140 NIH=?129«C57 16.9 cM
Chromosome 14 D14 Mit 239 NIH<C57 46.5 cM
Chromosome 14 D14 Mit 61 NIH=C57 21.4 cM
Chromosome 14 D14 Mit 35 NIH<?C57 48.8 cM
Chromosome 15 D15 Mit 159 NIH«C57 46 cM
Chromosome 16 D16 Mit 114 NIH«C57 35 cM
Chromosome 16 D16 Mit 181 NIH>C57 3.3 cM
Chromosome 16 D16 Mit 146 NIH=C57>129 19 cM
Chromosome 16 D16 Mit 57 NIH=C57 23 cM
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Chromosome 16 D16 Mit 181 NIH>C57 3 cM
Chromosome 16 D16 Mit 58 25.8 cM
Chromosome 16 D16 Mit 59 NIH »  C57 26.9 cM
Chromosome 17 D17 Mit 16 NIH<C57=129 8 cM
Chromosome 17 D17 Mit 93 NIH>C57 41 cM
Chromosome 17 D17 Mit 43 NIH>129>C57 1 cM
Chromosome 17 D17 Mit 47 12 cM
Chromosome 17 D17 Mit 13 10 cM
Chromosome 17 D17 Mit 48 1 cM
Chromosome 17 D17 Mit 21 10 cM
Chromosome 18 D18 Mit 209 NIH=C57>129 27 cM
Chromosome 18 D18 Mit 150 NIH>C57>129 17 cM
Chromosome 18 D18 Mit 66 0 cM
Chromosome 18 D18 Mit 4 38 cM
Chromosome 19 D19 Mit 92 NIH=C57 60 cM
Chromosome 19 D19 Mit 22 NIH=C57=129 13 cM
Chromosome 19 D19 Mit 28 NIH<C57=129 14 cM
Chromosome 19 D19 Mit 103 NIH»C57 40 cM
Chromosome 19 D19 Mit 31 NIH>C57=129 13 cM
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Appendix II-D:
Modification of GRR for backcross (Risch et al., 1993) to GRR for intercross.
GRR was defined as the ratio of disease risk in the backcross generation with that in the 
high-risk parental strain.
F1 +
GRR =
-F2 + — F3 
4
F3
( 1 )
1 + F1 . 2F2
GRR =
F3 F3 ( 2 )
Where in this research, F1 denotes the penetrance (proportion of animals 
affected) of the CC genotype, F2 denotes the penetrance (proportion of 
animals affected) of the NC genotype, and F3 denotes the penetrance 
(proportion of animals affected) of the NN genotype.
The GRR for a given locus can be estimated from the observed 
genotypes (e.g. at the closest linked marker) among affected animals. If a total 
of A affected animals is observed in the intercross generation, It would be 
expected that the proportion (formula 3) would be homozygous CC, the 
proportion (formula 4) would be heterozygous NC, and the proportion (formula 
5) would be homozygous NN.
F1
F1 + F2 + F3
2F2 
F1 + F2 + F3
F3
F1 + F2 + F3
( 3 )
( 4 )
( 5 )
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By solving the equation (2) for the number of animals ( equations 3, 4, 5 ) the 
following formula ( 6 ) was obtained.
1 +
GRR =
A1_
A3
A2
A3
( 6 )
Where A1 = the number of ( C/C ) animals, A2 = the number of ( C/N ) animals, 
and A3 is the number of (N/N) animals.
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Appendix II-E
SE =
X (  1 - X  )
Where SE is “ standard error”, “n” is the number of meiosis, and “X” is the 
recombination fraction. This formula was applyed to find standard error in estimation of 
distance of the markers and genes utilised in the designed panel.
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Appendix III
Performing linkage studies conducted on 48-50 TGFB1(-/-) survivals by 
applying the linked markers to some candidate genes.
candidate gene linked marker Chromosome x2 P-Value 
(2 d.f)
Tqfb2 D1Mit403 1 0.45 >0.05
Eng D2Mit83 2 2.59 >0.05
fgf3 D7Mit284 7 1.79 >0.05
Tgfb3 D12Mit8 12 4.49 >0.05
lgf2r D17Mit16 17 1.0 >0.05
Ltbp2 D19Mit31 19 2.79 >0.05
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Appendix IV
In order to evaluate the observed linkage of chromosome 5 (D5Mit268) and 
provide evidence that the observed segregation distortion of the marker was 
only due to TGFB1 modifying gene(s) not due to any unknown possible factor, 
50 wild type animals [TGFB1 (+/+)] from the same cross as TGFB1(-/-) were 
screened for D5Mit268 marker.
Animal Marker N/N N/C C/C 2X P-Value
TGFB1(+/+) D5Mit268 14 24 12 0.24 >0.05
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